KOL | Charles L LoprinziMayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN ... |
kolの履歴書 Charles L Loprinzi
| Year | |
|---|---|
| 2022 | Mayo Clinic, Rochester, MN; |
| 2021 | Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Mayo Clinic, Rochester, MN, USA |
| 2020 | Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, United States of America Division of Medical Oncology, Mayo Clinic, Rochester, USA North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota Mayo Clinic, Rochester, MN, United States. |
| 2019 | Department of Oncology; Mayo Clinic; Rochester, Minnesota Mayo Clinic Rochester, Florida, USA Medical Oncology |
| 2018 | Department of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA Division of Medical Oncology, Mayo Clinic, Rochester, MN |
| 2017 | Division of Medical Oncology, Mayo Clinic, Rochester, MN. Timothy Gilligan, Cleveland Clinic, Cleveland, OH ; Nessa Coyle, Memorial Sloan Kettering Cancer Center, New York; Ronald M. Epstein, University of Rochester School of Medicine, Rochester, NY; Richard M. Frankel, Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN; Donna L. Berry and Christopher S. Lathan, Dana-Farber Cancer Institute, Harvard Medical School; Vicki A. Jackson, Massachusetts General Hospital, Harvard Medical School, Boston; Carole Seigel, Patient/Advocacy Representative, Brookline, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Esme Finlay, University of New Mexico School of Medicine, Albuquerque, NM; Charles L. Loprinzi, Mayo Clinic, Rochester, MN; and Lynne H. Nguyen and Walter F. Baile, The University of Texas MD Anderson Cancer Center, Houston, TX. Mayo Clinic Minnesota Department of Oncology Rochester Minnesota The Cancer Center |
| 2016 | Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN Mayo Clinic Cancer Center, Rochester, Minnesota |
| 2015 | Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA Mayo Clinic Division of Medical Oncology Rochester Minnesota |
| 2014 | Mayo Clinic Cancer Center Rochester MN |
| 2013 | From the Department of Oncology and Cancer Center Statistics, Mayo Clinic, Rochester, MN. Mayo Clinic Rochester, 200 First Street, SW, 55905, Rochester, MN, USA |
| 2012 | Department of Oncology, Mayo Clinic, 55905, Rochester, MN, USA Mayo Clinic, Rochester, MN, United States |
Charles L Loprinzi：統計に影響を与えます
レポートを実行します
| Concept | World rank |
|---|---|
| acetate dexamethasone | #1 |
| symptoms hormone deprivation | #1 |
| points diphenhydramine | #1 |
| arhgef10 cipn | #1 |
| or1 year patients | #1 |
| doxepin mouthwash | #1 |
| ru221408i | #1 |
| agents humans clinicians | #1 |
| cipn20 data | #1 |
| attribution percentage | #1 |
| leap 12 months | #1 |
| survivors genitourinary syndrome | #1 |
| cipnmethodspatients | #1 |
| patients gabapentin | #1 |
| induced cipn | #1 |
| cipn trials | #1 |
| flashes treatment | #1 |
| qolconclusionsthe | #1 |
| hot flash frequency | #1 |
| patientreported nasal symptoms | #1 |
| diphenhydraminelidocaineantacid | #1 |
| cipn nervous diseases | #1 |
| decrease hot | #1 |
| isaes | #1 |
| cipn phase iii | #1 |
| doxepin mouthwash patients | #1 |
| cachexia megestrol | #1 |
| duloxetine response | #1 |
| patients paclitaxel polyneuropathy | #1 |
| enoxaparin cvte | #1 |
| phase iii evaluation | #1 |
| treatment cipn | #1 |
| authors 30 minutes | #1 |
| favor placebo | #1 |
| individuals cipn | #1 |
| ocular ice | #1 |
| lymphedemafree rates groups | #1 |
| neoplasms climacteric | #1 |
| tools hypothetical scenarios | #1 |
| rs17683288 | #1 |
| cipn data | #1 |
| gsm fsfi | #1 |
| aes relatedness | #1 |
| ctcae grade | #1 |
| alliance n08ca | #1 |
| week hot | #1 |
| isae patients | #1 |
| cyclohexanecarboxylic acids gamma | #1 |
| skin dermatitis trials | #1 |
| neuronal uptake transporters | #1 |
| hot flashes day | #1 |
| illness neuropathic symptoms | #1 |
| backgrounddehydroepiandrosterone | #1 |
| alliance study a221102 | #1 |
| isae data | #1 |
| therapy hot | #1 |
| peripheral neuropathy paclitaxel | #1 |
| 2007 guidelines guideline | #1 |
| toxicity anecdotal observations | #1 |
| women 65 day | #1 |
| treating institution intervention | #1 |
| ulabtka hfs | #1 |
| routine feces sensitivity | #1 |
| prtmethodsdata | #1 |
| ssc device prototype | #1 |
| physical consequences cipn | #1 |
| small cell continuity | #1 |
| severe stomatitis | #1 |
| mouthwash diphenhydramine | #1 |
| flashes venlafaxine | #1 |
| oestrogen survivors | #1 |
| education lymphedema education | #1 |
| chemotherapy treatment chemotherapy | #1 |
| cancer anorexia cachexia | #1 |
| bupropion nicotine dependence | #1 |
| pharmacological targeting oct2 | #1 |
| papsmethodspatients | #1 |
| attribution clinical trials | #1 |
| leucovorin breast cancer | #1 |
| shooting burning | #1 |
| tingling numbness | #1 |
| background hot | #1 |
| ganglion surveys humans | #1 |
| established cipn | #1 |
| rom leap | #1 |
| tools oncologists | #1 |
| study stool samples | #1 |
| 2007 guidelines suggestion | #1 |
| anorexia antineoplastic agents | #1 |
| active nonhormonal | #1 |
| newer antidepressants gabapentin | #1 |
| topical cannabinoids patients | #1 |
| cipn postural control | #1 |
| amines antidepressive | #1 |
| paclitaxel favor | #1 |
| cachexia cancer anorexia | #1 |
| isae anthracycline | #1 |
| median δ qs | #1 |
| fosaprepitant isae | #1 |
| gabapentin baseline week | #1 |
| oxybutynin doses | #1 |
| neuropathic symptoms breast | #1 |
| drowsiness unpleasant taste | #1 |
| recurrences clinical histories | #1 |
| increased difficulty patients | #1 |
| toxicity ocular | #1 |
| hormone deprivation cancer | #1 |
| minocycline cipn | #1 |
| feet oxaliplatin | #1 |
| benefit fluoxetine | #1 |
| 1 month appetite | #1 |
| revisitation doc | #1 |
| bellergal | #1 |
| hormone deprivation symptoms | #1 |
| education lymphedema prevention | #1 |
| lidocaine antacid | #1 |
| hormone deprivation | #1 |
| chamomile mouthwash | #1 |
| aminobutyric acid adt | #1 |
| historical placebo response | #1 |
| therapeutic targets cipn | #1 |
| induced neurotoxicity oct2 | #1 |
| postural instability chemotherapy | #1 |
| 5fuinduced stomatitis | #1 |
| hfs trial | #1 |
| cisplatin therapy cinv | #1 |
| nasal vestibulitis | #1 |
| n00cb | #1 |
| underdescribers | #1 |
| weeks hot flashes | #1 |
| patients 10 range | #1 |
| suggestion pregabalin | #1 |
| oral cryotherapy prevention | #1 |
| cipn20 | #1 |
| peripheral neuropathy | #1 |
| regional hypothermia burden | #1 |
| cryotherapy auc | #1 |
| difficulty neuropathic pain | #1 |
| hfs symptoms patients | #1 |
| burden alopecia | #1 |
| flash score | #1 |
| pilot trials efficacy | #1 |
| patient followup studies | #1 |
| n01c9 | #1 |
| authors 115 patients | #1 |
| overview oncology providers | #1 |
| acetate appetite | #1 |
| nonestrogenic management | #1 |
| baseline neuropathic pain | #1 |
| 8week observation period | #1 |
| cytotoxic chemotherapy supportive | #1 |
| placebo oral mucositis | #1 |
| leucovorin breast | #1 |
| gene arhgef10 | #1 |
| n08cb | #1 |
| stellate ganglion block | #1 |
| treatment symptom intervention | #1 |
| developed mucositis | #1 |
| 22 nonestrogenic management | #1 |
| nsclc response rate | #1 |
| nonhormonal therapies paroxetine | #1 |
| hfs ulabtka | #1 |
| nonhormonal | #1 |
| fourth treatment week | #1 |
| complete response authors | #1 |
| patients nasal vestibulitis | #1 |
| cipn adult | #1 |
| understanding potential benefits | #1 |
| rs9657362 | #1 |
| dmc mutations | #1 |
| oral mucositis alopecia | #1 |
| adjuvant numeracy calculators | #1 |
| adt cyclohexanecarboxylic acids | #1 |
| trust oncologists competence | #1 |
| antidepressant gabapentin | #1 |
| treatment attribution | #1 |
| subcutaneous testosterone improvements | #1 |
| compounded topical gel | #1 |
| 137 patients cycle | #1 |
| efficacy agent | #1 |
| management genital symptoms | #1 |
| 81 patients patients | #1 |
| fsfi 95 | #1 |
| women megestrol acetate | #1 |
| based chemotherapy isae | #1 |
| joints syndrome | #1 |
| attribution treatment | #1 |
| prestudy hypothesis | #1 |
| extreme phenotyping | #1 |
| aimss life | #1 |
| neoplasms placebos | #1 |
| 2 study arms | #1 |
| score baseline values | #1 |
| deprivation symptoms | #1 |
| antiemetic prescribing practices | #1 |
| nonhormonal agents | #1 |
| acute symptoms cycle | #1 |
| paps fatigue | #1 |
| compliance institutional guideline | #1 |
| purposehot | #1 |
| therapy numbness | #1 |
| bortezomib alters | #1 |
| rose geranium | #1 |
| placebo 30 points | #1 |
| suggestion oral cryotherapy | #1 |
| crc patients 95 | #1 |
| compassionate honesty | #1 |
| fluorouracilinduced stomatitis | #1 |
| infliximab cancer | #1 |
| aps paclitaxel | #1 |
| 12 months anticoagulation | #1 |
| tpn initiation death | #1 |
| δ − 95 | #1 |
| oncologists prognostic | #1 |
| antidepressive agents gamma | #1 |
| n08c1 | #1 |
| venous toxicity fosaprepitant | #1 |
| longitudinal continuation | #1 |
| association arhgef10 | #1 |
| iii double | #1 |
| taxane infusion | #1 |
| 5fuinduced ocular toxicity | #1 |
| life qlqcipn20 | #1 |
| neuropathy randomized | #1 |
| hot flashes women | #1 |
| pilot study minocycline | #1 |
| nonhormonal agent | #1 |
| numbness hands | #1 |
| bridging editorial | #1 |
| management hot | #1 |
| recommended colorectal | #1 |
| nonfluid weight gain | #1 |
| patients placebo pellet | #1 |
| numeracy benefit | #1 |
| male megestrol megestrol | #1 |
| toxicity gabapentin | #1 |
| auc cryotherapy | #1 |
| baseline week gabapentin | #1 |
| life leap | #1 |
| neuropathy data | #1 |
| doubleblinded manner | #1 |
| paclitaxel weekly cryotherapy | #1 |
| patientreported outcomes balance | #1 |
| pilot trials venlafaxine | #1 |
| loe prevention | #1 |
| pilot trial hands | #1 |
| prevention oral cryotherapy | #1 |
| drug humans interferons | #1 |
| n08ca | #1 |
| patients cancer anorexia | #1 |
| hot flashes acceptability | #1 |
| treatment alteration | #1 |
| acetate versus | #1 |
| placebo arms percentage | #1 |
| pregenplus | #1 |
| reducing hot | #1 |
| toxicity prospective trial | #1 |
| flashes objective | #1 |
| gabapentin hot | #1 |
| placebo mouthwash | #1 |
| daily questionnaires | #1 |
| mascc isoo evidence | #1 |
| snv rs9657362 | #1 |
| qol reported difficulty | #1 |
| receiving fluorouracil | #1 |
| diseases pilot | #1 |
| single snv rs9657362 | #1 |
| numbness tingling | #1 |
| megestrol acetate nausea | #1 |
| patients spray product | #1 |
| cachexia cyproheptadine | #1 |
| oncologists competence 95ci | #1 |
| oral cryotherapy patients | #1 |
| rs9657362 previous study | #1 |
| flashes quality | #1 |
| oxybutynin hot flashes | #1 |
| fluoxetine hot | #1 |
| purposepaclitaxel | #1 |
| megestrol acetate weeks | #1 |
| breakthrough nausea patients | #1 |
| cyclohexanols female | #1 |
| chemotherapy response rates | #1 |
| flashes prostate | #1 |
| 95 doxepin mouthwash | #1 |
| symptoms feet | #1 |
| hot flash control | #1 |
| tpn death | #1 |
| olanzapine arm emesis | #1 |
| n08cb alliance | #1 |
| bothersome hot | #1 |
| vte recurrence enoxaparin | #1 |
| qolresultsfrom | #1 |
| placebo anecdotal observations | #1 |
| day cisplatin therapy | #1 |
| treatment hot flashes | #1 |
| sensory neuropathy symptoms | #1 |
| mascc isoo guidelines | #1 |
| differences neuropathy syndromes | #1 |
| oral cryotherapy | #1 |
| altered sensory organization | #1 |
| cancer hot | #1 |
| numeracy adjuvant | #1 |
| managing hot flashes | #1 |
| lymphedemafree rates | #1 |
| cipn paps | #1 |
| flashes week | #1 |
| acetate doses | #1 |
| alliance n08c1 | #1 |
| acetate hot | #1 |
| randomized study lymphedema | #1 |
| tested interventions lymphedema | #1 |
| dmc assay | #1 |
| gabapentin antidepressant | #1 |
| subsequent chemotherapy cycles | #1 |
| dronabinol megestrol acetate | #1 |
| flashes patients | #1 |
| data clinical histories | #1 |
| cachexia trial | #1 |
| mouthwash placebo | #1 |
| replacement testosterone andropause | #1 |
| chemotherapy regimen type | #1 |
| patients ulabtka | #1 |
| neuropathic pain difficulty | #1 |
| rs2294039 | #1 |
| efficacy gabapentin | #1 |
| flashes breast | #1 |
| glutathione cipn | #1 |
| cipn common | #1 |
| tingling | #1 |
| effects limited efficacy | #1 |
| safety progestational agents | #1 |
| cancerassociated anorexia cachexia | #1 |
| prominent clinical problem | #1 |
| baseline week followup | #1 |
| flashes gabapentin | #1 |
| leap lymphedema | #1 |
| 1year survival trials | #1 |
| balance impairments patients | #1 |
| paclitaxel study arms | #1 |
| treatment hot | #1 |
| progestational agents patients | #1 |
| flashes prospective | #1 |
| uncertain gbu | #1 |
| sham acupuncture participants | #1 |
| lymphedema prevention education | #1 |
| items uncertain gbu | #1 |
| n08c3 | #1 |
| numbness scores | #1 |
| dfs 5fu | #1 |
| darbepoetin alfa head | #1 |
| resected cutaneous melanomas | #1 |
| stomatitis scores | #1 |
| gabapentin hot flashes | #1 |
| nonhormonal agents treatment | #1 |
| neoplasm recurrence apixaban | #1 |
| agents cipn | #1 |
| flashes common | #1 |
| oil nasal | #1 |
| udi δ − | #1 |
| suggested gabapentin | #1 |
| daily hot | #1 |
| baseline prognosis values | #1 |
| cryotherapy hands | #1 |
| uniscale qol baseline | #1 |
| hot flash activity | #1 |
| flashes stellate | #1 |
| cipn clinical trial | #1 |
| positive indication prognosis | #1 |
| stomatitis administration | #1 |
| modalities cancer patients | #1 |
| symptoms cipn | #1 |
| gait testing patients | #1 |
| trial n00cb | #1 |
| cachexia carcinoma life | #1 |
| flash scores | #1 |
| extensive animal data | #1 |
| udi scores baseline | #1 |
| disease patient factors | #1 |
| judicious tpn | #1 |
| outcomes study points | #1 |
| relatedness treatment | #1 |
| life megestrol acetate | #1 |
| pharmacologic therapeutics | #1 |
| patients 25 micrograms | #1 |
| residual hot flashes | #1 |
| gabapentin arm | #1 |
| supportive nsclc | #1 |
| ulabtka placebo cream | #1 |
| cancerrelated fatigue interventions | #1 |
| cvte rivaroxaban | #1 |
| balance gait testing | #1 |
| topical keratolytic | #1 |
| flaxseed bar lignans | #1 |
| acceptability ssc device | #1 |
| methylphenidate cancer patients | #1 |
| 20 data patients | #1 |
| current trial | #1 |
| adam vte | #1 |
| cryotherapy mucositis | #1 |
| patientcompleted questionnaires | #1 |
| hot flashes | #1 |
| taxane treatment development | #1 |
| initiation tpn | #1 |
| polyneuropathy allelic variability | #1 |
| underdescribers weeks | #1 |
| pregabalin paclitaxel | #1 |
| cachexia studies | #1 |
| highdose melphalan intervention | #1 |
| underdescribing | #1 |
| digital melt curve | #1 |
| recommendation prevention | #1 |
| incurable cancer records | #1 |
| infliximab lung | #1 |
| rest psychostimulants | #1 |
| cipn topical gel | #1 |
| fractures infertility | #1 |
| neuropathy 20 | #1 |
| qlq cipn20 | #1 |
| hot flashes treatment | #1 |
| tpn female services | #1 |
| conducted studies hrt | #1 |
| middle aged minocycline | #1 |
| patients physical examinations | #1 |
| cipn function | #1 |
| overview crci | #1 |
| hot flash scores | #1 |
| purpose hot | #1 |
| cipn development severity | #1 |
| week tamoxifen | #1 |
| magnesium oxaliplatininduced neurotoxicity | #1 |
| patients dosing guidelines | #1 |
| nonhormonal hot | #1 |
| device 5 weeks | #1 |
| symptoms hands | #1 |
| bakplo | #1 |
| safety oestrogen | #1 |
| nonfluid bodyweights | #1 |
| testosterone improvements | #1 |
| coasting phenomenon | #1 |
| oncology providers crci | #1 |
| placebo 15 points | #1 |
| response relationship odc | #1 |
| newer antidepressants | #1 |
| painful oxaliplatininduced cipn | #1 |
| aes placebo arm | #1 |
| 5 weeks device | #1 |
| patients underdescribers | #1 |
| deprivation therapy patients | #1 |
| cipn20 sensory | #1 |
| patients hot flashes | #1 |
| hec cisplatin therapy | #1 |
| alleviate hot | #1 |
| vaginal cytology women | #1 |
| motor subscales | #1 |
| antibiotic lozenge placebo | #1 |
| cancers prevalence | #1 |
| duloxetine response patients | #1 |
| antiserotonergic drug | #1 |
| flash therapies | #1 |
| time publication attitude | #1 |
| fsfi udi | #1 |
| weeks hot | #1 |
| n08ca patients | #1 |
| anthracycline data | #1 |
| adjuvant numeracy | #1 |
| natural postural instability | #1 |
| accru study ru221408i | #1 |
| benefit 5fu | #1 |
| 5fu adjuvant | #1 |
| placebos pregabalin quality | #1 |
| oral mucosa study | #1 |
| anorexia appetite | #1 |
| postsurgical neuropathic pain | #1 |
| anecdotal observations gabapentin | #1 |
| gabapentin aminobutyric acid | #1 |
| phytotherapy vitamin | #1 |
| antibiotic lozenge | #1 |
| pregabalin paps | #1 |
| acute pain syndrome | #1 |
| control hot flashes | #1 |
| sae δ − | #1 |
| ulabtka arm | #1 |
| toxicities opioids | #1 |
| cipn agents | #1 |
| prominent toxicity | #1 |
| lymphedema incidence intervention | #1 |
| − fsfi | #1 |
| individual patients understanding | #1 |
| metastatic disease initiation | #1 |
| cinv day | #1 |
| supportive cytotoxic chemotherapy | #1 |
| a151408 | #1 |
| preliminary promising data | #1 |
| bakplo placebo | #1 |
| weight loss investigation | #1 |
| sensory subscale | #1 |
| cachexia dexamethasone | #1 |
| uncertain gbu gbu | #1 |
| hot flashes quality | #1 |
| compliance institutional guidelines | #1 |
| glutamine toxicity | #1 |
| ncctg n08c3 | #1 |
| 43 oral complications | #1 |
| ncctg n08c1 | #1 |
| ganglion surveys | #1 |
| slight appetite stimulation | #1 |
| a151408 study data | #1 |
| improvements hot flashes | #1 |
| ambulatory patients opioids | #1 |
| appetite stimulation patients | #1 |
| reduction hot | #1 |
| estimated benefit dfs | #1 |
| placebo arm gabapentin | #1 |
| populations neurologic humans | #1 |
| megestrol acetate patients | #1 |
| male megestrol life | #1 |
| placebo 15 glutathione | #1 |
| cinv neoplasms vomiting | #1 |
| patients subcutaneous testosterone | #1 |
| female services tpn | #1 |
| myalgias arthralgias | #1 |
| accru study | #1 |
| lymphedema hrqol outcomes | #1 |
| oral mucositisrelated pain | #1 |
| dmc samples | #1 |
| hot flash data | #1 |
| cyproheptadine appetite | #1 |
| records adult patients | #1 |
| magnesium camg | #1 |
| creatine placebo groups | #1 |
| hot flashes patients | #1 |
| inadequate hot | #1 |
| megestrol acetate | #1 |
| women male megestrol | #1 |
| n08ca association | #1 |
| preceding 2 months | #1 |
| toxicity agent | #1 |
| acetate anorexia | #1 |
| paclitaxel acute | #1 |
| alliance trial | #1 |
| placebo pilot trials | #1 |
| inadequate control antidepressant | #1 |
| agents antihypertensive agents | #1 |
| humans ganglion surveys | #1 |
| baseline fsfi score | #1 |
| anecdotal observations | #1 |
| points doxepin | #1 |
| eortc cipn | #1 |
| management hot flashes | #1 |
| patients dfs predictions | #1 |
| oestrogen hot flashes | #1 |
| balance patientreported outcomes | #1 |
| hot flashes weeks | #1 |
| dfs predictions adjuvant | #1 |
| neuropathy prevention | #1 |
| doxepin mouthwash placebo | #1 |
| olanzapine projects vomiting | #1 |
| paresthesia peripheral | #1 |
| supportive cryotherapy | #1 |
| prevention paps | #1 |
| antiemetic prescribing | #1 |
| data hot | #1 |
| alopecia ocular toxicity | #1 |
| oncologists competence | #1 |
| hot flash relief | #1 |
| head therapeutic equivalency | #1 |
| institutional guidelines patients | #1 |
| managing hot | #1 |
| antacid mouthwash | #1 |
| hormonal ablation andropause | #1 |
| prevention cipn | #1 |
| nonfluid weight | #1 |
| chemotherapy neuropathy | #1 |
| preliminary evidence improvement | #1 |
| prevent oxaliplatin | #1 |
| purposehot flashes | #1 |
| 5 methylphenidate | #1 |
| bothersome hot flashes | #1 |
| topical cannabinoids | #1 |
| cipn methods | #1 |
| lenolidamide | #1 |
| arthralgia breast life | #1 |
| ulabtka | #1 |
| nonfluid | #1 |
| pilot evaluation | #1 |
| vitamin cipn | #1 |
| dronabinol combination | #1 |
| treating hot | #1 |
| nociceptors putative mechanism | #1 |
| difference cipn20 scores | #1 |
| individuals impaired balance | #1 |
| premenopause radiotherapy | #1 |
| 65 day | #1 |
| paclitaxel coasting phenomenon | #1 |
| prognosis items | #1 |
| eortc qlqcipn20 instrument | #1 |
| hot flashes gabapentin | #1 |
| adam vte trial | #1 |
| topic rectum surveys | #1 |
| flashes women | #1 |
| symptom intervention | #1 |
| vaginal dehydroepiandrosterone | #1 |
| agents cyclohexanecarboxylic | #1 |
| topic peripheral neuropathy | #1 |
| paclitaxel polyneuropathy | #1 |
| oral cryotherapy management | #1 |
| vaginal dehydroepiandrosterone dhea | #1 |
| baseline prognosis | #1 |
| effects hot flashes | #1 |
| cipn20 questionnaire | #1 |
| baseline assessment week | #1 |
| pilot trials citalopram | #1 |
| combination chemotherapy hec | #1 |
| pain chemotherapy | #1 |
| n06ca | #1 |
| tpn longterm survival | #1 |
| suggestion toxicity | #1 |
| antidepressants gabapentin | #1 |
| survival tpn initiation | #1 |
| alleviating hot | #1 |
| flaxseed hot flashes | #1 |
| hot flash mechanism | #1 |
| guidelineendorsed treatment | #1 |
| antineoplastic agents nrs | #1 |
| bakplo symptoms | #1 |
| alliance a151724 | #1 |
| 95 increased difficulty | #1 |
| intervention leap | #1 |
| women inadequate control | #1 |
| 30 points 95 | #1 |
| numerical analogue scale | #1 |
| hot flash | #1 |
| prevention induced cipn | #1 |
| discrepancies clinicians assessment | #1 |
| discrepancies women | #1 |
| lignans 6 weeks | #1 |
| patients highdose interferon | #1 |
| items positive indication | #1 |
| eortc cipn20 | #1 |
| accru trial | #1 |
| aminobutyric acid hec | #1 |
| hours nighttime sleep | #1 |
| life study arms | #1 |
| evidence cipn | #1 |
| flashes pilot | #1 |
| flaxseed bar | #1 |
| studies cyproheptadine | #1 |
| chamomile mouthwash toxicity | #1 |
| burning pain | #1 |
| patients megestrol acetate | #1 |
| relatedness treatment arms | #1 |
| leap rom | #1 |
| hot flash score | #1 |
| weight megestrol acetate | #1 |
| flashes androgen | #1 |
| 95 neuropathic pain | #1 |
| gas menopause patient | #1 |
| centrally active agent | #1 |
| ocular ice packs | #1 |
| cipnsummarythere | #1 |
| treatments modalities | #1 |
| isae | #1 |
| life cipn | #1 |
| grade peripheral neuropathy | #1 |
| placebo drowsiness | #1 |
| effects cipn | #1 |
| drowsiness doxepin mouthwash | #1 |
| impaired postural control | #1 |
| ncctg trial n06ca | #1 |
| study dmc assay | #1 |
| oral iron 46 | #2 |
| improvement hot | #2 |
| duloxetine hydrochloride humans | #2 |
| cipn cohort | #2 |
| historic controls npy | #2 |
| scrambler | #2 |
| glutamine placebo preparation | #2 |
| 40000 40k arm | #2 |
| females cessation treatment | #2 |
| fsfi score baseline | #2 |
| 150 groups patients | #2 |
| design considerations recommendations | #2 |
| lmwh arms 7 | #2 |
| 4 treatment weeks | #2 |
| months randomized | #2 |
| participants 3 stools | #2 |
| n03cb | #2 |
| central cancer | #2 |
| women hot flashes | #2 |
| life venlafaxine hydrochloride | #2 |
| pregabalin treatments placebo | #2 |
| 16 sdt2 | #2 |
| gabapentin symptoms | #2 |
| treatment breakthrough cinv | #2 |
| versus megestrol | #2 |
| placebo bar | #2 |
| oxybutynin doses placebo | #2 |
| fosaprepitant patients | #2 |
| dermatitis symptom evolution | #2 |
| 7 control arms | #2 |
| qol crc | #2 |
| lessons cipn | #2 |
| 49 venlafaxine | #2 |
| patients adjuvant 5fu | #2 |
| megestrol acetate dexamethasone | #2 |
| arms conclusions | #2 |
| palliative communications | #2 |
| placebo vaginal dryness | #2 |
| leucovorin women | #2 |
| 46 screenrelevant neoplasms | #2 |
| predictors disagreement | #2 |
| hemoccultsensa detection | #2 |
| placebo hf frequency | #2 |
| intermediate term efficacy | #2 |
| mometasone surveys | #2 |
| treatment week placebo | #2 |
| neuropathy caused | #2 |
| acknowledged loss | #2 |
| flashes placebo | #2 |
| infertility ovarian failure | #2 |
| daily mmf radiotherapy | #2 |
| tamoxifenassociated hot flashes | #2 |
| cipn20 factor analysis | #2 |
| time ncctg alliance | #2 |
| patients shark cartilage | #2 |
| n06c4 | #2 |
| pilot citalopram | #2 |
| 3 months bupropion | #2 |
| placebo combination therapy | #2 |
| life venlafaxine | #2 |
| sunscreen arms | #2 |
| trial baseline week | #2 |
| 800 liquid suspension | #2 |
| standard arm rate | #2 |
| feet 18 months | #2 |
| treating chemotherapy | #2 |
| older age bupropion | #2 |
| ncctg n10c1 | #2 |
| citalopram hot flashes | #2 |
| cohosh treatment | #2 |
| stomatitis women | #2 |
| positive doseresponse | #2 |
| study arms conclusions | #2 |
| n01c4 | #2 |
| weight concerns 26 | #2 |
| cck8 anorexia severity | #2 |
| receive parenteral | #2 |
| symptoms surveys | #2 |
| venlafaxine treatment 75 | #2 |
| kps nutrition score | #2 |
| alliance folfox | #2 |
| citalopram cyclohexanols humans | #2 |
| preventive therapies cipn | #2 |
| tamoxifen medications | #2 |
| neuropathy cipn | #2 |
| adjuvant 5fu models | #2 |
| product hot flashes | #2 |
| anabolic corticosteroid | #2 |
| sdt2 hemoccult | #2 |
| hf frequency placebo | #2 |
| pregabalin arms | #2 |
| folfox alliance | #2 |
| study arms quality | #2 |
| humans citalopram cyclohexanols | #2 |
| worse survivorship | #2 |
| scrambler therapy treatment | #2 |
| stat erythema | #2 |
| 979254 | #2 |
| placebo oxybutynin doses | #2 |
| aprepitan | #2 |
| 120000 epoetin alfa | #2 |
| sdt2 sdt1 | #2 |
| anabolic corticosteroid treatment | #2 |
| peripheral neuropathy cipn | #2 |
| rash incidence severity | #2 |
| cold items 71 | #2 |
| average stomatitis sex | #2 |
| study arms tetracycline | #2 |
| life aimss | #2 |
| hot flash frequencies | #2 |
| numeracy prognosis | #2 |
| hot flash trials | #2 |
| 432 smokers treatment | #2 |
| decreasing stomatitis | #2 |
| cpmp scrambler therapy | #2 |
| 80 anorexia | #2 |
| disagreement patients | #2 |
| vte recurrence doacs | #2 |
| 34—vitamin | #2 |
| target doses placebo | #2 |
| guidelines recommendation | #2 |
| cipn prevention trials | #2 |
| increased risk cipn | #2 |
| advancedstage cancer | #2 |
| dexamethasone fluoxymesterone | #2 |
| doses megestrol | #2 |
| cipn paclitaxel | #2 |
| usual breathing | #2 |
| venlafaxine gabapentin | #2 |
| 120k arm | #2 |
| real patients treatment | #2 |
| dalteparin lowest risk | #2 |
| tens global impression | #2 |
| differences mometasone | #2 |
| life cipn20 | #2 |
| pilocarpine arms | #2 |
| failure prior chemotherapy | #2 |
| folfox auc p0·0001 | #2 |
| global impression life | #2 |
| venlafaxine oxaliplatin neurotoxicity | #2 |
| cisplatin polymerase inhibitors | #2 |
| patients 40k arm | #2 |
| appearing pilot data | #2 |
| 01 mmf | #2 |
| cipn | #2 |
| study n08cb alliance | #2 |
| anorexia severity | #2 |
| survival 3915 patients | #2 |
| fatigue improvement methylphenidate | #2 |
| surveys repeated measures | #2 |
| flash diary | #2 |
| pa outcomes pros | #2 |
| 120 arm | #2 |
| coumarin placebo | #2 |
| illness tetracycline egfr | #2 |
| mucositis 5fubased chemotherapy | #2 |
| 135±19 | #2 |
| alternative treatment regimen | #2 |
| tamoxifen percentage reduction | #2 |
| patients treating institution | #2 |
| aprepitant 4 weeks | #2 |
| week baseline week | #2 |
| prevent radiation | #2 |
| trials suggested | #2 |
| trials newer antidepressants | #2 |
| humans postmenopause pregabalin | #2 |
| randomized receive | #2 |
| cycle chronic neurotoxicity | #2 |
| ncctg trial | #2 |
| screenrelevant neoplasms | #2 |
| glutathione prevention | #2 |
| 14 hot flashes | #2 |
| dosing zoledronic | #2 |
| substantial hot flashes | #2 |
| folfox auc analysis | #2 |
| flash studies | #2 |
| ctcae pruritus | #2 |
| kps nutrition scores | #2 |
| mometasone time | #2 |
| vte recurrence dalteparin | #2 |
| day study week | #2 |
| folfox symptoms | #2 |
| cachexia acetate | #2 |
| dhea 4 weeks | #2 |
| week breast cancer | #2 |
| manuscript “use | #2 |
| hot flashes humans | #2 |
| pregabalin hot flashes | #2 |
| lamotrigine neuropathic symptoms | #2 |
| treatment target doses | #2 |
| therapy hot flashes | #2 |
| tingling shooting | #2 |
| oxaliplatin doses trends | #2 |
| topical aged antimetabolites | #2 |
| hot flashes data | #2 |
| pain ≥4 10 | #2 |
| disagreement increased risk | #2 |
| 40k arm 120000 | #2 |
| longitudinal studies postmenopause | #2 |
| piroxantrone women | #2 |
| treatment arm mmf | #2 |
| locoregional event | #2 |
| levetiracetam 4 weeks | #2 |
| methylphenidate cancer | #2 |
| induced peripheral | #2 |
| woman quality | #2 |
| 95 oral placebo | #2 |
| paclitaxel induced | #2 |
| cancerassociated wasting | #2 |
| postmenopausal women previous | #2 |
| previous hot flashes | #2 |
| trial acetate doses | #2 |
| type chemotherapy drug | #2 |
| time randomized study | #2 |
| infliximab docetaxel | #2 |
| questionnaires antineoplastic agents | #2 |
| life treatment weeks | #2 |
| dna markers participants | #2 |
| hot flashes citalopram | #2 |
| acttionconsortium | #2 |
| qol hb increment | #2 |
| week black cohosh | #2 |
| experience hot flashes | #2 |
| physicians kps | #2 |
| circulating concentrations npy | #2 |
| patients olanzapine arm | #2 |
| screenrelevant neoplasms 16 | #2 |
| anthraquinones agents breast | #2 |
| vitamin hot | #2 |
| npy levels groups | #2 |
| data relative benefits | #2 |
| subject global impression | #2 |
| oxaliplatin hands | #2 |
| day average pain | #2 |
| patients chemotherapyassociated anemia | #2 |
| appetite dissent | #2 |
| declining qol | #2 |
| scrambler therapy | #2 |
| treatment smoking abstinence | #2 |
| cipn20 scores | #2 |
| patients receiving fluorouracil | #2 |
| induced arthralgias | #2 |
| women rom | #2 |
| hemoccultsensa sdt2 | #2 |
| life cancerrelated fatigue | #2 |
| 15 points 95 | #2 |
| placebo situ carcinoma | #2 |
| monthly intervals appetite | #2 |
| sdt2 | #2 |
| epoetin alfa 40000 | #2 |
| phytogenic female humans | #2 |
| placebo arms women | #2 |
| allopurinol mouthwash | #2 |
| iii randomized | #2 |
| sensitivity cold items | #2 |
| hot flash diary | #2 |
| indirect comparison apixaban | #2 |
| time toxt approach | #2 |
| ≤ moderate correlations | #2 |
| oral megestrol | #2 |
| oxybutynin women | #2 |
| nutrition score disagreement | #2 |
| starting tamoxifen | #2 |
| depomedroxyprogesterone | #2 |
| nonhormonal management | #2 |
| hemoccultsensa sdt1 | #2 |
| treatment minority smokers | #2 |
| patients oxybutynin doses | #2 |
| smokers nicotine inhaler | #2 |
| real real patients | #2 |
| ductal mometasone furoate | #2 |
| autonomic scales | #2 |
| 1 oral megestrol | #2 |
| nutrition scores 95 | #2 |
| advanced cancer anorexia | #2 |
| scrambler therapy management | #2 |
| fluoxymesterone treatment | #2 |
| tens 2 weeks | #2 |
| symptomatic cipn | #2 |
| chronic chemotherapy | #2 |
| natural paps | #2 |
| injections hot flashes | #2 |
| pilocarpine vaginal dryness | #2 |
| placebo breast radiotherapy | #2 |
| irox folfox auc | #2 |
| reduce hot | #2 |
| coriat | #2 |
| patients cipn | #2 |
| clinical trials n9741 | #2 |
| colonoscopically normal patients | #2 |
| nonestrogenic hot | #2 |
| cachexia pentoxifylline | #2 |
| study arms | #2 |
| chemotherapyassociated anemia caa | #2 |
| hot flashes pregabalin | #2 |
| women stomatitis | #2 |
| singleagent megestrol acetate | #2 |
| weekly hf score | #2 |
| breast cancer venlafaxine | #2 |
| hot flash management | #2 |
| paclitaxel chronic neuropathy | #2 |
| poor qol 95 | #2 |
| lvef 1000 | #2 |
| conclusions sunscreen | #2 |
| guaninemethyltransferase | #2 |
| suggested agents | #2 |
| cipn cancer survivors | #2 |
| hemoccultsensa sensitivity | #2 |
| nutrition scores physicians | #2 |
| weekly epoetin | #2 |
| control arms rate | #2 |
| supplementary n03cb | #2 |
| mometasone cream | #2 |
| chemotherapy peripheral neuropathy | #2 |
| dronabinol versus | #2 |
| scrambler therapy tens | #2 |
| pruritus pros | #2 |
| inadequate benefit | #2 |
| life scrambler therapy | #2 |
| intervention 18 months | #2 |
| ferric gluconate darbepoetin | #2 |
| symptoms skin toxicity | #2 |
| treatment alterations | #2 |
| cipn clinical | #2 |
| neoplasms double | #2 |
| single snv | #2 |
| 95 indirect estimates | #2 |
| ctcae differences | #2 |
| day baseline week | #2 |
| receiving megestrol | #2 |
| efficacy scrambler therapy | #2 |
| nicotine inhaler bupropion | #2 |
| “use vitamin | #2 |
| cipn primary outcomes | #2 |
| induced peripheral neuropathy | #2 |
| 5fuinduced mucositis | #2 |
| anorexia antineoplastic | #2 |
| trial suggestion | #2 |
| skindex16 ctcae | #2 |
| hot flashes bupropion | #2 |
| middle aged survivors | #2 |
| breakthrough cinv | #2 |
| cycle folfox | #2 |
| mmf itching | #2 |
| evaluating venlafaxine | #2 |
| appetite cachexia | #2 |
| venlafaxine control | #2 |
| patients 120k arm | #2 |
| life illness tetracycline | #2 |
| tamoxifen metabolism evidence | #2 |
| clinically deficient fatigue | #2 |
| nonestrogenic therapies | #2 |
| original report time | #2 |
| anthrapyrazoles piroxantrone | #2 |
| original report mometasone | #2 |
| bupropion nicotine inhaler | #2 |
| randomized study mometasone | #2 |
| 5fubased chemotherapy mucositis | #2 |
| appetite improvement | #2 |
| patients black cohosh | #2 |
| npy anorexia cholecystokinin | #2 |
| stomatitis sex | #2 |
| subsequent mucositis | #2 |
| dronabinoltreated patients | #2 |
| newer antidepressants trials | #2 |
| tingling patients | #2 |
| neuropathy paclitaxel | #2 |
| placebo pregabalin treatments | #2 |
| descriptive manner | #2 |
| incidence severity stomatitis | #2 |
| detection dna markers | #2 |
| n0993 | #2 |
| antidepressants hot | #2 |
| patients monthly intervals | #2 |
| eortc qlqcipn20 | #2 |
| stat itching | #2 |
| tetracycline rash incidence | #2 |
| cachexia decision | #2 |
| appetite dissent disputes | #2 |
| hot flashes aprepitant | #2 |
| cipn antineoplastic agents | #2 |
| time toxt analysis | #2 |
| detection screenrelevant neoplasms | #2 |
| thiophenes treatment life | #2 |
| moderate correlations ≤ | #2 |
| egfr inhibitor tetracycline | #2 |
| patients difluoromethylornithine | #2 |
| hot flashes efficacy | #2 |
| evaluate weight | #2 |
| 46 adenomas 1 | #2 |
| shark cartilage patients | #2 |
| oxaliplatin induced neurotoxicity | #2 |
| cipn cancer treatment | #2 |
| skindex16 itching | #2 |
| reducing chemotherapy | #2 |
| treatment cycles cycle | #2 |
| established chemotherapy | #2 |
| docetaxel serum concentrations | #2 |
| sulfate prevent | #2 |
| hemoccultsensa hemoccult | #2 |
| hot flashes dehydroepiandrosterone | #2 |
| hot flash studies | #2 |
| prevalence weight concerns | #2 |
| conclusions original report | #2 |
| cipn cases | #2 |
| hot flash quality | #2 |
| 16 hemoccult | #2 |
| antidepressant hot flashes | #2 |
| treatment baseline week | #2 |
| sensitivity screenrelevant neoplasms | #2 |
| ecog nutrition score | #2 |
| outcome measures ctcae | #2 |
| cancerassociated anorexia | #2 |
| conceppt | #2 |
| cipn interventions | #2 |
| rcts preventive therapies | #2 |
| infliximab 5 day | #2 |
| postural instability individuals | #2 |
| desipramine hot flashes | #2 |
| study treatment citalopram | #2 |
| 120k arm patients | #2 |
| data gabapentin | #2 |
| provider assessed | #2 |
| prevent paclitaxel | #2 |
| 75 49 venlafaxine | #2 |
| improvement hot flashes | #2 |
| anabolic corticosteroid appetite | #2 |
| stage disease 5fu | #2 |
| toxicity profiles time | #2 |
| 40k arm | #2 |
| shark cartilage product | #2 |
| dronabinol combination therapy | #2 |
| baseline week day | #2 |
| flashes citalopram | #2 |
| cdf score | #2 |
| gabapentin 4 weeks | #2 |
| local antineoplastic agents | #2 |
| cipn peripheral neuropathy | #2 |
| lmwh arms | #2 |
| vitamin hot flashes | #2 |
| pilocarpine vaginal | #2 |
| sdt1 hemoccult | #2 |
| topic estrogen | #2 |
| postchemotherapy rheumatism | #2 |
| life 4week intervention | #2 |
| 108±11 | #2 |
| magnesium oxaliplatin | #2 |
| management genitourinary symptoms | #2 |
| patients daily mmf | #2 |
| shark cartilage placebo | #2 |
| starting tamoxifen women | #2 |
| gabapentin venlafaxine hydrochloride | #2 |
| dhea vaginal symptoms | #2 |
| treatment aprepitant | #2 |
| anemia caa | #2 |
| patient‐physician disagreement | #2 |
| evaluating gabapentin | #2 |
| combinationtreated arms survival | #3 |
| qol hgb | #3 |
| study antidepressive agents | #3 |
| study population mcbdr | #3 |
| hemoccult hemoccultsensa | #3 |
| aminobutyric acid gabapentin | #3 |
| etanercept current trial | #3 |
| ctcae grades patients | #3 |
| burning pain patients | #3 |
| mastectomy rates | #3 |
| cmt gene | #3 |
| mfsisf 4 weeks | #3 |
| chemotherapy induced | #3 |
| neuropathy trials | #3 |
| bacterial agents life | #3 |
| cancer patients drugs | #3 |
| baseline treatment day | #3 |
| paps dose | #3 |
| average severity | #3 |
| controls singleton snv | #3 |
| undergoing androgen ablation | #3 |
| pros differences | #3 |
| iii controlled | #3 |
| trials n9741 | #3 |
| frequency hot | #3 |
| asco guideline management | #3 |
| trial bmd | #3 |
| qlqcipn20 | #3 |
| life antineoplastic agents | #3 |
| survivors gsm | #3 |
| neoplasms vomiting | #3 |
| physiologic pilot | #3 |
| osteoporosis osteopenia letrozole | #3 |
| hot flashes placebo | #3 |
| cipn evidence | #3 |
| cumulative neurotoxicity oxaliplatin | #3 |
| treatment bother | #3 |
| oxaliplatinbased therapy | #3 |
| oxaliplatininduced neuropathy | #3 |
| rash prevention | #3 |
| male megestrol | #3 |
| measures peripheral | #3 |
| hgpin chemoprevention trial | #3 |
| cipn n08cx population | #3 |
| toxicities selfreport | #3 |
| patients baseline week | #3 |
| topic mayo clinic | #3 |
| subcutaneous weekly | #3 |
| preventing peripheral | #3 |
| placebo preparation | #3 |
| ginseng arm | #3 |
| carboplatin gwas | #3 |
| chlorhexidine mouthwash | #3 |
| oxaliplatin primary endpoint | #3 |
| paps scores dose | #3 |
| neurotoxic chemotherapy cipn | #3 |
| median δ | #3 |
| n08ca n08cb study | #3 |
| snv cmtassociated genes | #3 |
| patients cancerassociated wasting | #3 |
| ctcae grading arms | #3 |
| recommendations dietary counseling | #3 |
| patient completed | #3 |
| crossover methodology | #3 |
| epoetin alfa hgb | #3 |
| general subscale mfsisf | #3 |
| epoetintreated patients study | #3 |
| blind trial | #3 |
| qol placebotreated patients | #3 |
| primary endpoint gwas | #3 |
| oxaliplatin cipn | #3 |
| ginseng crf | #3 |
| longitudinal adverse | #3 |
| placebo breast | #3 |
| “use | #3 |
| cipn snv | #3 |
| middle aged pilot | #3 |
| prevent epidermal | #3 |
| incurable cancers | #3 |
| sham acupuncture week | #3 |
| feet 15 | #3 |
| egfr inhibitor patients | #3 |
| canada collaborative effort | #3 |
| relationship numbness | #3 |
| cyproheptadine patients | #3 |
| n03cc | #3 |
| pts stage iii | #3 |
| centrally active agents | #3 |
| intravenous calcium magnesium | #3 |
| upfront arm | #3 |
| epa combinationtreated arms | #3 |
| fluoxetine arm | #3 |
| mucositis scores | #3 |
| epoetintreated patients | #3 |
| topical ceramides | #3 |
| projects prospective | #3 |
| placebo prostate adenocarcinoma | #3 |
| survival epa | #3 |
| dalteparin vte | #3 |
| data pilot trials | #3 |
| drug toxicity patients | #3 |
| tamoxifen fluoxetine | #3 |
| chemotherapy increases | #3 |
| chemotherapy gabapentin | #3 |
| thromboembolism secondary | #3 |
| classic sums | #3 |
| toxicity agents | #3 |
| cyclohexanecarboxylic acids | #3 |
| 1 month cytokines | #3 |
| hormonal ablation | #3 |
| female gabapentin | #3 |
| hgb rbc transfusions | #3 |
| neuropathy chemotherapy | #3 |
| anorexia anorexia appetite | #3 |
| cmt genes oxaliplatin | #3 |
| follow fsfi | #3 |
| shooting burning pain | #3 |
| receive placebo | #3 |
| genetic predictors cipn | #3 |
| neurotoxic chemotherapies | #3 |
| completed diaries | #3 |
| egfr inhibitorinduced rash | #3 |
| chemotherapyassociated anemia | #3 |
| hot flashes trial | #3 |
| 95 udi | #3 |
| starting letrozole | #3 |
| patients lidocaine patch | #3 |
| corticosteroid medications | #3 |
| n08ca paclitaxel | #3 |
| week venlafaxine therapy | #3 |
| depression somnolence | #3 |
| 51 female age | #3 |
| ” numbness | #3 |
| gwas mayo clinic | #3 |
| patients scrambler therapy | #3 |
| pilot evaluation gabapentin | #3 |
| mouthwash patients | #3 |
| prophylactic tetracycline | #3 |
| eventual sensory patients | #3 |
| controlled double | #3 |
| cartilage shark | #3 |
| cipn cmtassociated genes | #3 |
| oral megestrol acetate | #3 |
| bit hands | #3 |
| hemoccultsensa | #3 |
| flutamide hgpin | #3 |
| iii evaluation | #3 |
| advanced cancer standard | #3 |
| real day | #3 |
| asco surveillance | #3 |
| rash symptoms | #3 |
| upfront treatment arm | #3 |
| cold items | #3 |
| patients antiemetic | #3 |
| months bupropion | #3 |
| relationship response rate | #3 |
| weekly arm differences | #3 |
| minocycline prevention | #3 |
| mcbdr | #3 |
| fasting chemotherapy | #3 |
| hands burning pain | #3 |
| methylphenidate patients | #3 |
| stomatitis sucralfate | #3 |
| ≤−20 | #3 |
| interventions cancerrelated fatigue | #3 |
| centric decision | #3 |
| mcbdr primary endpoint | #3 |
| thirdline hormonal therapy | #3 |
| additional 4 weeks | #3 |
| eightyone randomized women | #3 |
| cmtassociated genes | #3 |
| vitamin prevention | #3 |
| cipn mcbdr population | #3 |
| patients cyproheptadine | #3 |
| ssc device | #3 |
| ctpm experts | #3 |
| cachexia decision humans | #3 |
| methodologic lessons | #3 |
| oncology colorectal | #3 |
| chronic neuropathy patients | #3 |
| delayed treatment arm | #3 |
| apixaban lowest risk | #3 |
| data ginseng | #3 |
| qlqcipn20 scores | #3 |
| clonidine randomized trials | #3 |
| acute neuropathy | #3 |
| genetic factors patients | #3 |
| survival cancerassociated wasting | #3 |
| purposeoxaliplatin | #3 |
| cipn biological targets | #3 |
| gabapentin management | #3 |
| 3 weeks 80k | #3 |
| n05c4 | #3 |
| n08cx | #3 |
| selfreport ctcae grading | #3 |
| 95 40 points | #3 |
| evidence prostate adenocarcinoma | #3 |
| patients paps scores | #3 |
| repeated measures analyses | #3 |
| pilot trial pregabalin | #3 |
| tingling burning pain | #3 |
| baseline general subscale | #3 |
| baseline hot | #3 |
| mpa single dose | #3 |
| week chemotherapy dose | #3 |
| genetic predictors paclitaxel | #3 |
| dhea hot flashes | #3 |
| patients chemotherapy cycle | #3 |
| chemotherapy‐associated anemia | #3 |
| paps scores | #3 |
| snv charcotmarietooth disease | #3 |
| bivariate construct | #3 |
| acetate treated | #3 |
| qlqcipn20 traditional ctcae | #3 |
| cvte | #3 |
| life hospice patients | #3 |
| radiation‐induced mucositis | #3 |
| numeracy patients | #3 |
| reported rash | #3 |
| questionnaires syndrome paclitaxel | #3 |
| rash conclusions | #3 |
| experience greater | #3 |
| 40000 units | #3 |
| rash study arms | #3 |
| traditional ctcae | #3 |
| management cancer cachexia | #3 |
| 20 calories | #3 |
| ctcae pros | #3 |
| 10 weeks therapy | #3 |
| combinationtreated arms | #3 |
| epoetintreated patients incidence | #3 |
| alfa compared | #3 |
| experts cipn | #3 |
| purposefosaprepitant | #3 |
| trials newer | #3 |
| life dronabinol | #3 |
| patients upfront arm | #3 |
| delayed zoledronic | #3 |
| cipn ctpm | #3 |
| vaginal dhea | #3 |
| inhibitorinduced rash | #3 |
| life eortc qlq | #3 |
| benefits adjuvant | #4 |
| breast medical oncologists | #4 |
| or1 year | #4 |
| appetite stimulation | #4 |
| additional meta analysis | #4 |
| 3915 patients | #4 |
| major doselimiting toxicity | #4 |
| administration parp inhibitor | #4 |
| paced breathing | #4 |
| baseline fatigue survival | #4 |
| logistic regression incidence | #4 |
| chemotherapy‐induced peripheral | #4 |
| hot flashes week | #4 |
| flaxseed placebo | #4 |
| oral cryotherapy mucositis | #4 |
| receive oral | #4 |
| recommended endorsement | #4 |
| placebo hot | #4 |
| achievements ncctg | #4 |
| oral cavity mucosa | #4 |
| anorexia cholecystokinin | #4 |
| recommendation ctx | #4 |
| dietician | #4 |
| intrapatient difference | #4 |
| controls imbalance | #4 |
| survivors hot | #4 |
| odx ctx | #4 |
| loss syndrome | #4 |
| mastectomy rates patients | #4 |
| doubleblind manner | #4 |
| egfr inhibitor rash | #4 |
| toxt analysis | #4 |
| trpa1 cisplatin | #4 |
| colorectal cancer asco | #4 |
| therapy aimss | #4 |
| severity sexes | #4 |
| symptoms individual patients | #4 |
| apr dex | #4 |
| bupropion 3 months | #4 |
| prominent problem | #4 |
| hfs quality | #4 |
| cipn20 ctcae | #4 |
| numbness toes | #4 |
| nonabsorbable antibiotic | #4 |
| nsclc trials | #4 |
| hgpin antineoplastic agents | #4 |
| cachexia purpose | #4 |
| doac dalteparin | #4 |
| control hot | #4 |
| therapy oncologists | #4 |
| parenteral iron | #4 |
| severe stomatitis leukopenia | #4 |
| hec cisplatin | #4 |
| treatment ncctg | #4 |
| predictors duloxetine response | #4 |
| oxybutynin placebo | #4 |
| guidelines oral | #4 |
| inhibitor induced | #4 |
| vaginal assessment scale | #4 |
| treatment cancer anorexia | #4 |
| suggested efficacy | #4 |
| day paroxetine | #4 |
| hemoccult | #4 |
| nonestrogenic | #4 |
| daily baseline | #4 |
| tpn initiation | #4 |
| bupropion 3 | #4 |
| single dose venlafaxine | #4 |
| doxepin female head | #4 |
| fluorouracilbased chemotherapy | #4 |
| placebo arms | #4 |
| backgroundhistorically | #4 |
| arm breast neoplasms | #4 |
| anorexia weight | #4 |
| weekly toxicity | #4 |
| 1093 women | #4 |
| topic survivors | #4 |
| endorsed treatment | #4 |
| secondary vte prevention | #4 |
| publication antiemetics humans | #4 |
| aged mouthwashes | #4 |
| chronic neuropathy | #4 |
| cancer acute vte | #4 |
| weight loss syndrome | #4 |
| to100 | #4 |
| cutaneous electrostimulation | #4 |
| outcomes olanzapine | #4 |
| 900 dose | #4 |
| qol baseline fatigue | #4 |
| anorectic cancer patients | #4 |
| rash study | #4 |
| gabapentin day | #4 |
| women greater toxicity | #4 |
| based chemotherapy women | #4 |
| flash frequency | #4 |
| aimss | #4 |
| calgb 70305 | #4 |
| rash incidence | #4 |
| general subscale | #4 |
| measurable metastatic disease | #4 |
| based chemotherapy severity | #4 |
| surgery lymphedema | #4 |
| appetite quality | #4 |
| ctx odx | #4 |
| 95 oral iron | #4 |
| addition letrozole | #4 |
| cco guideline followup | #4 |
| risk reduction therapy | #4 |
| odc odc activity | #4 |
| qol performance score | #4 |
| hot flashes therapy | #4 |
| ais biomarkers | #4 |
| odc activity mice | #4 |
| 40000 | #4 |
| followup surveillance protocol | #4 |
| iron arm | #4 |
| 6 months bupropion | #4 |
| appetite enhancement | #5 |
| neuropathic pain qol | #5 |
| mucositis caused | #5 |
| disputes female humans | #5 |
| libido | #5 |
| crc cancers | #5 |
| acetate placebo | #5 |
| ttr cindices | #5 |
| vasomotor hot flashes | #5 |
| cipn participants | #5 |
| centrally active | #5 |
| questionnaires pregabalin | #5 |
| groups leptin concentrations | #5 |
| trial gabapentin | #5 |
| postsurgical neuropathic | #5 |
| olanzapine arm | #5 |
| race ttr | #5 |
| 3 stools | #5 |
| sham real | #5 |
| crc cancer types | #5 |
| genetic quality life | #5 |
| ajcc external validation | #5 |
| ttr ajcc | #5 |
| reduce chemotherapy | #5 |
| neoplasms compared | #5 |
| reported hot | #5 |
| cancerrelated fatigue patients | #5 |
| aapro | #5 |
| progestational agent | #5 |
| nodal status stage | #5 |
| cipnrelated symptoms | #5 |
| pain scores dose | #5 |
| death communication humans | #5 |
| ongoing clinical trial | #5 |
| cyclohexanecarboxylic | #5 |
| fluoxymesterone patients | #5 |
| women 5fu | #5 |
| trial developed | #5 |
| rectal cancer surveillance | #5 |
| cachexia anorexia | #5 |
| digital melt | #5 |
| cisplatin ganglia | #5 |
| subsets treatment benefits | #5 |
| combination electroacupuncture | #5 |
| trial hot | #5 |
| 3 patients 4 | #5 |
| epa supplement | #5 |
| gabapentin patients | #5 |
| tools numeracy | #5 |
| physicians predictive ttr | #5 |
| fosaprepitant prevention | #5 |
| models ttr | #5 |
| colorectal cancer society | #5 |
| induced stomatitis | #5 |
| intravenous calcium | #5 |
| discontinuation aimss | #5 |
| cumulative neurotoxicity | #5 |
| acetate neoplasms | #5 |
| patient outcomes numeracy | #5 |
| hb increment | #5 |
| nodal status grade | #5 |
| medical oncology outpatients | #5 |
| agents basis | #5 |
| oxantrazole | #5 |
| higher drug doses | #5 |
| receiving paclitaxel | #5 |
| trials cytotoxic chemotherapy | #5 |
| numeracy tools | #5 |
| fiftynine percent | #5 |
| cipn effects | #5 |
| trials lessons | #5 |
| iron oral | #5 |
| physicianreported | #5 |
| mucositis allopurinol | #5 |
| cindices ajcc | #5 |
| bone loss osteopenia | #5 |
| difference control arm | #5 |
| kps ecog | #5 |
| nutrition scores | #5 |
| gabapentin trial | #5 |
| current trial patients | #5 |
| ajcc version staging | #5 |
| neuropeptide leptin | #5 |
| patients lmwh injections | #5 |
| colorectal cancer surveillance | #5 |
| odx | #5 |
| neoplasm diagnostic tests | #5 |
| life epa | #5 |
| treatment benefits sex | #5 |
| ajcc tools | #5 |
| acetate neoplasms quality | #5 |
| cancer survivors symptoms | #5 |
| life lmwh | #5 |
| treating postmenopausal | #5 |
| numeracy online clinical | #5 |
| flashes data | #5 |
| grade model estimates | #5 |
| study dmc | #5 |
| neuropathy acute | #5 |
| placebo exposed | #5 |
| additional 8 weeks | #5 |
| major outcome measure | #5 |
| impaired postural | #5 |
| editor manuscript | #5 |
| cancer anorexia | #5 |
| 5fu trials | #5 |
| cipn numbness | #5 |
| ttr variables | #5 |
| background chemotherapy | #6 |
| versus combination | #6 |
| hrqol breast neoplasms | #6 |
| agents breast | #6 |
| rs11572080 | #6 |
| north central | #6 |
| megestrol | #6 |
| daily diary questionnaires | #6 |
| studies vomiting | #6 |
| mri trends | #6 |
| loe guidelines | #6 |
| her2directed therapy | #6 |
| severity data | #6 |
| induced sensory | #6 |
| cipn treatment | #6 |
| selective poly | #6 |
| bf qol | #6 |
| olanzapine prevention | #6 |
| flashes humans | #6 |
| death kps | #6 |
| pharmaceutic aged aged | #6 |
| 5fubased chemotherapy | #6 |
| fatigue pilot study | #6 |
| 71 sensitivity | #6 |
| cancerrelated fatigue life | #6 |
| smoking abstinence rates | #6 |
| participants sham acupuncture | #6 |
| 4week intervention | #6 |
| neurological safety | #6 |
| nci ctcae | #6 |
| apixaban cancer patients | #6 |
| highly emetogenic chemotherapy | #6 |
| staging patient outcomes | #6 |
| 500 mcg | #6 |
| life toxicity | #6 |
| breakthrough nausea | #6 |
| wisconsin ginseng | #6 |
| placebo hfs | #6 |
| depomedroxyprogesterone acetate | #6 |
| data supporting | #6 |
| severity neuropathic symptoms | #6 |
| placebo arm patients | #6 |
| sensory scale | #6 |
| proportion aes | #6 |
| sadenosyllmethionine treatment | #6 |
| active malignancy | #6 |
| alliance clinical | #6 |
| medical acupuncture | #6 |
| inhaler bupropion | #6 |
| therapy 10 weeks | #6 |
| methylo | #6 |
| paclitaxel peripheral neuropathy | #6 |
| nonanthracycline chemotherapy | #6 |
| placebo hot flashes | #6 |
| predictive illness surveys | #6 |
| nicotine inhaler | #6 |
| intervention lymphedema | #6 |
| imidazoles letrozole | #6 |
| hospitalized oncology patients | #6 |
| longacting methylphenidate | #6 |
| 5fu folfox | #6 |
| induced rash | #7 |
| intervention lymphedema status | #7 |
| throat discomfort | #7 |
| 1week baseline period | #7 |
| serum concentrations cytokines | #7 |
| sensitivity fecal | #7 |
| uniscale | #7 |
| neuropathy oxaliplatin | #7 |
| intermediate odx | #7 |
| appetites | #7 |
| hemoccult hemoquant | #7 |
| cmt genes | #7 |
| incidence rbc transfusion | #7 |
| bupropion relapse | #7 |
| citalopram cyclohexanols | #7 |
| lymphedema education | #7 |
| 20 percent placebo | #7 |
| chronic postmastectomy pain | #7 |
| cancer patients anorexia | #7 |
| lower extremity symptoms | #7 |
| mpa arm | #7 |
| cryotherapy arm | #7 |
| accru | #7 |
| nutrition score | #7 |
| patients oral cryotherapy | #7 |
| venlafaxine therapy | #7 |
| transdermal clonidine | #7 |
| rs10509681 | #7 |
| fuinduced | #7 |
| adjuvant interferon patients | #7 |
| scheduled receive | #7 |
| menopause hot | #7 |
| follow year | #7 |
| weekly epoetin alfa | #7 |
| patients product | #7 |
| weight concerns smokers | #7 |
| pain cipn | #7 |
| mucositis placebo | #7 |
| prevalence moderatetosevere | #7 |
| hemoquant | #7 |
| study arms difference | #7 |
| cyclophosphamidedoxorubicin | #7 |
| smoking 3 | #7 |
| toxic polyneuropathy | #7 |
| model estimates survival | #7 |
| fluoxetine clinical trials | #7 |
| patient anthracycline | #7 |
| paclitaxel peripheral | #7 |
| 5fu based chemotherapy | #7 |
| vte recurrence doac | #7 |
| blind study | #7 |
| cream versus | #7 |
| week followup | #7 |
| patients hb response | #7 |
| stage nodal status | #7 |
| skindex16 | #7 |
| placebocontrolled trial | #7 |
| illness antimetabolites | #7 |
| nausea cancer patients | #7 |
| symptom subscale | #7 |
| study drug trial | #7 |
| venlafaxine day | #7 |
| letrozole differences | #7 |
| venlafaxine versus | #7 |
| induced neuropathy | #7 |
| pregabalin prevention | #7 |
| 12 treatment arms | #7 |
| uniscale qol | #7 |
| odx score | #7 |
| minority smokers | #7 |
| outcomes primary outcomes | #7 |
| tamoxifeninduced hot flashes | #8 |
| 18 months symptoms | #8 |
| odx risk | #8 |
| administered systemically | #8 |
| neuropathy scale | #8 |
| libido women | #8 |
| oxaliplatin neuropathy | #8 |
| nonhormonal treatments | #8 |
| induced painful | #8 |
| mouth sores | #8 |
| series clinical trials | #8 |
| topic antineoplastic | #8 |
| opioids moderate pain | #8 |
| 70305 | #8 |
| life antibodies | #8 |
| severe hot flashes | #8 |
| cpmp | #8 |
| stomatitis patients | #8 |
| epa survival | #8 |
| evidence pharmacologic interventions | #8 |
| oral placebo | #8 |
| symptoms neuropathy | #8 |
| folfox dfs | #8 |
| venlafaxine hot flashes | #8 |
| flutamide placebo | #8 |
| 1355 | #8 |
| smokers weight concerns | #8 |
| neuropathy pain | #8 |
| sdt1 | #8 |
| neuropathic symptoms | #8 |
| treatment cinv | #8 |
| direct oral factor | #8 |
| placebo pilot study | #8 |
| recurrence colon cancer | #8 |
| greater toxicity | #8 |
| women hfs | #8 |
| paclitaxel severity | #8 |
| efficacy newer antidepressants | #8 |
| antidepressant patients | #8 |
| progestational | #8 |
| oral iron placebo | #8 |
| factors cipn | #8 |
| chronic neurotoxicity | #8 |
| cycle capecitabine | #8 |
| fecal blood | #8 |
| oxaliplatin paclitaxel | #8 |
| placebo suggestion | #8 |
| cancer survivors cipn | #8 |
| pros aes | #8 |
| anecdotal | #8 |
| venous toxicity | #8 |
| prior chemotherapy exposure | #8 |
| agents newer | #8 |
| raw data trials | #8 |
| paclitaxel pain | #8 |
| dose dfmo | #9 |
| prevention vomiting | #9 |
| trial paroxetine | #9 |
| study treatment arm | #9 |
| mucositis pain | #9 |
| hot flashes tamoxifen | #9 |
| ambulatory analgesics | #9 |
| baseline week week | #9 |
| cancer patients cipn | #9 |
| fatigue methylphenidate | #9 |
| appetite weight | #9 |
| apixaban lower rate | #9 |
| neuropathic symptoms patients | #9 |
| questionnaires syndrome | #9 |
| sensory axonopathy | #9 |
| surgical year | #9 |
| disease receive | #9 |
| incurable disease | #9 |
| relapse relapse prevention | #9 |
| vitality subscale | #9 |
| medications evidence | #9 |
| letrozole day | #9 |
| cipn patients | #9 |
| topical antimetabolites | #9 |
| radiationinduced esophagitis | #9 |
| 5 nausea | #9 |
| mometasone furoate placebo | #9 |
| oxaliplatin placebo | #9 |
| 43 trials | #9 |
| cutaneous aged anesthetics | #9 |
| lamotrigine pain | #9 |
| acid amines | #9 |
| disease recurrence recurrence | #9 |
| incidence colorectal adenomas | #9 |
| skindex16 scores | #9 |
| numbness fingers | #9 |
| genistein tumor growth | #9 |
| flash control | #9 |
| fosaprepitant | #9 |
| lymphedema prevention | #9 |
| patients provided | #9 |
| lymphedema hrqol | #9 |
| antiemetic properties | #9 |
| patients hot | #9 |
| aged pilot | #9 |
| flashes hot | #9 |
| lmwh injections | #9 |
| follow tests | #9 |
| cancerrelated fatigue fatigue | #10 |
| randomized placebo | #10 |
| oxaliplatin peripheral | #10 |
| asco guideline | #10 |
| 40 arm | #10 |
| nonhormonal therapies | #10 |
| antineoplastic agents humans | #10 |
| folfox 5fu | #10 |
| cancerassociated anemia | #10 |
| qol total | #10 |
| symptomatic malignant ascites | #10 |
| chemotherapy‐induced | #10 |
| aprepitant treatment | #10 |
| shark cartilage | #10 |
| adult cancers | #10 |
| patients neurotoxic chemotherapy | #10 |
| incidence stomatitis | #10 |
| doses citalopram | #10 |
| oxaliplatin trpa1 | #10 |
| nonhormonal treatment | #10 |
| ctcae grades | #10 |
| gabapentin | #10 |
| controlled randomized | #10 |
| life topic reproducibility | #10 |
| differences 5 years | #10 |
| δ − | #10 |
| humans megestrol | #10 |
| neoplasms neuralgia | #10 |
| recommendations general population | #10 |
| qol anemia | #10 |
| data relatedness | #10 |
| pain medications patients | #10 |
| trials demonstrated | #10 |
| factes | #10 |
| phase iii | #10 |
| venlafaxine arm | #10 |
| patients treatment period | #10 |
| advanced cancer life | #10 |
| megestrol acetate quality | #10 |
| sensitivity cancer | #10 |
| life dietary supplements | #10 |
| flash data | #10 |
| anorexia cachexia | #10 |
| cognitive chemotherapy | #10 |
| combination therapy relapse | #10 |
| frequency hot flashes | #10 |
| ecog kps | #10 |
| physical consequences | #10 |
| vaginal dryness | #10 |
| scrambler therapy patients | #10 |
| inhibit cyp2d6 | #10 |
| minocycline reduction | #10 |
| olanzapine chemotherapy | #11 |
| anastrozole 10 | #11 |
| cancer undergoing | #11 |
| difficulty patients | #11 |
| nicotine patch therapy | #11 |
| promising data | #11 |
| qol uniscale | #11 |
| diphenhydramine lidocaine | #11 |
| differences study arms | #11 |
| flashes | #11 |
| melt curve | #11 |
| ginseng placebo | #11 |
| erythropoietic response | #11 |
| antiemetic guidelines | #11 |
| physicians increased risk | #11 |
| gbu | #11 |
| ativan | #11 |
| institutional guideline | #11 |
| fsfi female | #11 |
| dalteparin major bleeding | #11 |
| combination treated | #11 |
| reported incidences | #11 |
| hydrazine sulfate | #11 |
| electroanalgesia | #11 |
| efficacy black cohosh | #11 |
| curve assay | #11 |
| translational component | #11 |
| vomiting cancer patients | #11 |
| prevalence neuropathic pain | #11 |
| sensory neurotoxicity | #11 |
| −307 | #12 |
| valerian placebo | #12 |
| venlafaxine hydrochloride | #12 |
| leptin cck8 | #12 |
| pluronic lecithin organogel | #12 |
| completed daily | #12 |
| recurrence comparisons | #12 |
| rash quality | #12 |
| reported peripheral | #12 |
| patients cipn symptoms | #12 |
| breast cancer letrozole | #12 |
| adjuvant communication decision | #12 |
| toxicity 4 weeks | #12 |
| oxaliplatin induced | #12 |
| gait testing | #12 |
| decreased libido | #12 |
| neurotoxic chemotherapy | #12 |
| probability prospective studies | #12 |
| cycles drugs | #12 |
| capsaicin cream | #12 |
| apixaban dalteparin | #12 |
| irox folfox | #12 |
| cipn development | #12 |
| venlafaxine women | #12 |
| individuals advanced adenomas | #12 |
| cachexia clinical trials | #12 |
| pilot trial levetiracetam | #12 |
| ctpm | #12 |
| hot flashes 95 | #12 |
| toxicities groups | #12 |
| hb response | #12 |
| oral anesthetics | #13 |
| 40 points 95 | #13 |
| rs3213619 | #13 |
| life neoplasm recurrence | #13 |
| flashes day | #13 |
| paroxetine hot flashes | #13 |
| patients diphenhydramine | #13 |
| anemia life | #13 |
| autonomic scale | #13 |
| patients advancedstage cancer | #13 |
| months smoking | #13 |
| newer antidepressants placebo | #13 |
| life investigation | #13 |
| neuropathy outcome | #13 |
| trial support | #13 |
| initial 3 months | #13 |
| neuropathic pain surgery | #13 |
| patients breakthrough cinv | #13 |
| education clinical practice | #13 |
| estimates prognosis | #13 |
| treatment advanced cancer | #13 |
| andropause | #13 |
| 2000 update | #13 |
| ais women | #13 |
| adjuvant colon cancer | #13 |
| therapy benefits | #13 |
| venlafaxine life | #13 |
| incident exposure | #13 |
| severity hot flashes | #13 |
| acute treatment vte | #13 |
| troubling | #13 |
| ncctg | #13 |
| hot flashes baseline | #13 |
| valerian sleep | #13 |
| weight cachexia | #13 |
| adenomas aspirin | #13 |
| megestrol acetate therapy | #13 |
| median hb | #13 |
| bmd 1 year | #13 |
| troublesome symptoms | #13 |
| adjuvant benefit | #13 |
| major bleeding doac | #13 |
| venlafaxine paroxetine | #13 |
| 10 range | #13 |
| nausea patients | #13 |
| common toxicity | #13 |
| improve cancer | #13 |
| abh gel | #13 |
| marked toxicity | #14 |
| smokers placebo | #14 |
| palliate | #14 |
| oxaliplatin vivo | #14 |
| based topical | #14 |
| genital symptoms | #14 |
| provided data | #14 |
| 5fu surgery | #14 |
| patients pain scores | #14 |
| benefit toxicity | #14 |
| life anemia | #14 |
| oral iron | #14 |
| diagnosis localized disease | #14 |
| fluoxymesterone | #14 |
| prophylactic agent | #14 |
| flash activity | #14 |
| recurrences patients | #14 |
| phase 3 months | #14 |
| stool dna | #14 |
| biomarkers bone formation | #14 |
| evidence treatment options | #15 |
| 16–28 | #15 |
| adjuvant aromatase | #15 |
| therapy nicotine | #15 |
| vaginal dryness dyspareunia | #15 |
| persistent incisional pain | #15 |
| treatment weeks patients | #15 |
| advanced malignant disease | #15 |
| bfq | #15 |
| mastectomy irradiation | #15 |
| life life survivors | #15 |
| monoclonal carcinoma antibodies | #15 |
| aes treatment | #15 |
| suggestion guideline | #15 |
| highly emetogenic | #15 |
| week baseline | #15 |
| grade age | #15 |
| acceptability device | #15 |
| advanced cancer methods | #15 |
| androgen ablation therapy | #15 |
| clinician perception | #15 |
| triazoles zoledronic | #15 |
| sternal skin conductance | #15 |
| trials gabapentin | #15 |
| agents life | #15 |
| lidocaine patch | #15 |
| folfox irox | #15 |
| acute diarrhea patients | #15 |
| week darbepoetin | #15 |
| oxaliplatininduced neurotoxicity | #15 |
| syndromes peripheral | #15 |
| duloxetine cipn | #15 |
| prognosis quality life | #15 |
| academic oncologists | #15 |
| taste alterations | #15 |
| endpoints baseline | #16 |
| rash pruritus | #16 |
| venlafaxine patients | #16 |
| female cancer survivors | #16 |
| patch therapy | #16 |
| treatment cancer vte | #16 |
| product time | #16 |
| premenopausal women chemotherapy | #16 |
| breast gynecologic cancer | #16 |
| antiemetic agent | #16 |
| advancedstage cancer patients | #16 |
| vte apixaban | #16 |
| symptoms numbness | #16 |
| measurable evaluable disease | #16 |
| induced hot | #16 |
| stool dna test | #16 |
| dalteparin 95 | #16 |
| diarrhoea time | #16 |
| tingling pain | #16 |
| paclitaxel oxaliplatin | #16 |
| randomized trial aspirin | #16 |
| findings education | #16 |
| patients venlafaxine | #16 |
| loss appetite | #16 |
| mfsi | #16 |
| flashes tamoxifen | #17 |
| inadequate control | #17 |
| oxaliplatin treated | #17 |
| crc patients patients | #17 |
| institute common | #17 |
| arhgef10 | #17 |
| leptin concentrations groups | #17 |
| vaginal symptoms | #17 |
| dfs folfox | #17 |
| women metastatic | #17 |
| adenomas 1 | #17 |
| recommendation suggestion | #17 |
| breast cancer oestrogen | #17 |
| 786 patients | #17 |
| screen detection | #17 |
| reduction fatigue | #17 |
| device women | #17 |
| leap study | #17 |
| oxaliplatin doses | #17 |
| 18 months women | #17 |
| venlafaxine | #17 |
| fractional co2 | #17 |
| arthralgias | #17 |
| rs11849538 | #17 |
| study tetracycline | #17 |
| cancer menopause | #17 |
| patients irox | #18 |
| subsets age | #18 |
| symptoms hormone | #18 |
| oral dronabinol | #18 |
| oncology providers patients | #18 |
| receiving head | #18 |
| patients overview | #18 |
| patients informed decisions | #18 |
| sternal skin | #18 |
| sigmoidoscopy tomography | #18 |
| randomized trials women | #18 |
| severity cipn | #18 |
| severity hot | #18 |
| postmenopausal women letrozole | #18 |
| baseline 4 | #18 |
| menopausal problems | #18 |
| mri mastectomy | #18 |
| flash frequencies | #18 |
| intervention guidelines | #18 |
| placebo 04 | #18 |
| prophylactic antiemetic therapy | #18 |
| 5 adjuvant | #18 |
| 120000 | #18 |
| secondary endpoint analysis | #18 |
| data followup | #18 |
| treatment osteopenia | #18 |
| patients hb | #18 |
| standard prognostic | #18 |
| 95 46 | #19 |
| mastectomy methotrexate | #19 |
| acute cancer | #19 |
| minimal adverse effects | #19 |
| double blinded | #19 |
| oxaliplatin carboplatin | #19 |
| panax quinquefolius | #19 |
| previous colorectal | #19 |
| induced mucositis | #19 |
| flash reduction | #19 |
| treatment mastectomy | #19 |
| folfox fluorouracil | #19 |
| patients based chemotherapy | #19 |
| evidence status | #19 |
| rs7349683 | #19 |
| groups infliximab | #19 |
| neoplasms peripheral | #19 |
| physician reported | #19 |
| oxaliplatin neurotoxicity | #19 |
| ncdf | #19 |
| unpleasant taste | #19 |
| life gabapentin | #19 |
| bmd neoplasms chemotherapy | #19 |
| 7 outcomes | #19 |
| n6 n5 | #19 |
| pilot trials | #20 |
| numbness | #20 |
| cancer cancer therapy | #20 |
| major bleeding treatment | #20 |
| appetite nutritional status | #20 |
| revisitation | #20 |
| life skindex16 | #20 |
| placebo cream | #20 |
| palliating | #20 |
| surveillance protocol | #20 |
| placebo smokers | #20 |
| reducing pain | #20 |
| therapeutic options treatment | #20 |
| receiving pelvic | #20 |
| diseases randomized | #20 |
| fecal occult | #20 |
| baseline week | #20 |
| advanced cancer study | #20 |
| progestational agents | #20 |
| moderate pain patients | #20 |
| fatigue 4 | #20 |
| emetogenic chemotherapy | #20 |
| study ginseng | #20 |
| trial 12 months | #21 |
| receptorpositive breast cancer | #21 |
| substantial problem | #21 |
| radiationinduced dermatitis | #21 |
| refractory cachexia | #21 |
| studies methylphenidate | #21 |
| oral mucositis pain | #21 |
| crossover analysis | #21 |
| treatment options women | #21 |
| female menopause | #21 |
| cancer starting | #21 |
| acetate patients | #21 |
| therapy adverse effects | #21 |
| chemotherapy agents | #21 |
| cipn symptoms | #21 |
| routine test | #21 |
| management cachexia | #21 |
| metastatic breast carcinoma | #21 |
| pharmacokinetics infliximab | #22 |
| emetogenic | #22 |
| location stage | #22 |
| projects quality | #22 |
| median time initiation | #22 |
| 150 groups | #22 |
| npy leptin | #22 |
| crossover phase | #22 |
| patients 5 weeks | #22 |
| severity adverse events | #22 |
| n9741 | #22 |
| candidate single | #22 |
| guideline intervention | #22 |
| subcutaneous testosterone | #22 |
| optumlabs | #22 |
| scores ≤ | #22 |
| gain patients | #22 |
| patients testosterone | #22 |
| doc time | #22 |
| asco panel | #22 |
| stool dna testing | #23 |
| acupuncture hot | #23 |
| aes qol | #23 |
| detecting recurrence | #23 |
| mascc isoo | #23 |
| life ascites | #23 |
| fsdsr | #23 |
| versus delayed | #23 |
| acetate middle | #23 |
| 5 pounds | #23 |
| sucralfate patients | #23 |
| decision adjuvant | #23 |
| followup tests | #23 |
| potential toxicities | #23 |
| mcf7 cells genistein | #23 |
| replacement testosterone | #24 |
| weeks primary | #24 |
| aged anorexia | #24 |
| adjuvant decision making | #24 |
| aged amines | #24 |
| mirtazapine patients | #24 |
| apixaban treatment | #24 |
| n56 | #24 |
| ortho biotech | #24 |
| topic design severity | #24 |
| randomized 1 | #24 |
| abstract5fluorouracil | #24 |
| pilot clinical | #24 |
| every3 | #24 |
| hrt survival | #24 |
| design rcts | #24 |
| female hot | #24 |
| prevention chemotherapy | #24 |
| tamoxifen octreotide | #24 |
| day chemotherapy | #24 |
| doses schedules | #25 |
| vte trial | #25 |
| trial pilot | #25 |
| criteria adverse | #25 |
| cco guideline | #25 |
| prevention nausea | #25 |
| severe nausea vomiting | #25 |
| antiepileptic agent | #25 |
| placebo arm treatment | #25 |
| nausea olanzapine | #25 |
| bpisf | #25 |
| mmf placebo | #25 |
| qol tools | #25 |
| neoplasia screening | #25 |
| recommendations basis | #25 |
| lymphedema incidence | #25 |
| women adjuvant tamoxifen | #25 |
| cancerassociated weight loss | #25 |
| institutional guidelines | #25 |
| 2005 update | #26 |
| colorectal adenomas patients | #26 |
| treatment arms | #26 |
| neoplasms estrogens | #26 |
| receiving oxaliplatin | #26 |
| prior week | #26 |
| mfsisf | #26 |
| induced musculoskeletal | #26 |
| undergoing adjuvant | #26 |
| joints muscles | #26 |
| aiinduced | #26 |
| agents prevention | #26 |
| nci ctc | #26 |
| regional breast | #26 |
| combination weight loss | #26 |
| oncology journals | #26 |
| clinical trials chemotherapy | #26 |
| syndrome menopause | #26 |
| trial evaluate | #26 |
| irradiation mastectomy | #26 |
| dose gabapentin | #26 |
| cachexia carcinoma | #26 |
| fubased | #27 |
| adjuvant 5fu | #27 |
| events ctcae | #27 |
| smoking bupropion | #27 |
| series trials | #27 |
| antiemetic | #27 |
| valerian | #27 |
| hot flashes hf | #27 |
| recommendations trials | #27 |
| patients short term | #27 |
| lmwh survival | #27 |
| neuropathy symptoms | #27 |
| lymphedema arm | #27 |
| prophylactic antiemetic | #27 |
| nurse survey | #27 |
| gynecologic cancer survivors | #28 |
| newer | #28 |
| standard prognostic factors | #28 |
| fluoxetine citalopram | #28 |
| intractable palliative | #28 |
| primary endpoint proportion | #28 |
| treatment hot flushes | #28 |
| chest rays | #28 |
| prevent colorectal adenomas | #28 |
| muscles joints | #28 |
| describers | #28 |
| mastectomy rate | #28 |
| matched general population | #28 |
| lidocaine patches | #28 |
| alliance | #28 |
| definitively | #28 |
| efficacy venlafaxine | #29 |
| pain cancer survivors | #29 |
| blood screening | #29 |
| placebo arm | #29 |
| paclitaxel cipn | #29 |
| difluoromethylornithine dfmo | #29 |
| biological predictors | #29 |
| points study | #29 |
| smokers bupropion | #29 |
| feet hands | #29 |
| statistical controversies | #29 |
| vitamin incidence | #29 |
| citalopram placebo | #29 |
| asco guideline update | #29 |
| survival arms | #29 |
| chemotherapy cipn | #29 |
| patients paclitaxel | #29 |
| mucositis study | #29 |
| taxanebased chemotherapy | #29 |
| phase iii comparison | #30 |
| management oral mucositis | #30 |
| contralateral axillary | #30 |
| twoyear followup | #30 |
| usual oncology | #30 |
| middle aged postmenopause | #30 |
| benadryl | #30 |
| development cipn | #30 |
| postmenopause predictive | #30 |
| cipn pain | #30 |
| pain oral | #30 |
| mild nausea | #30 |
| diseases peripheral | #30 |
| small pilot | #30 |
| anthrapyrazoles | #30 |
| month duration | #30 |
| loss postmenopausal | #30 |
| alfa darbepoetin | #30 |
| calcium magnesium | #31 |
| treatment paclitaxel | #31 |
| symptomatic ascites | #31 |
| middle aged perimenopause | #31 |
| term rectal | #31 |
| prevention oral mucositis | #31 |
| arms placebo | #31 |
| patients races | #31 |
| treatment acute vte | #31 |
| efficacy methylphenidate | #31 |
| mastectomy mri | #31 |
| patients secondary analysis | #31 |
| pain quality life | #31 |
| ixabepilone patients | #31 |
| benefit dfs | #31 |
| management menopausal symptoms | #31 |
| sixtysix patients | #31 |
| female services | #32 |
| breast cancer symptoms | #32 |
| camg | #32 |
| rash severity | #32 |
| women lymphedema | #32 |
| receiving highly | #32 |
| oncologist patients | #32 |
| delayed chemotherapy | #32 |
| doubleblind trial | #32 |
| evidencebased guidance | #32 |
| guideline endorsement | #32 |
| vera gel | #32 |
| fingers hands | #33 |
| aloe vera gel | #33 |
| painful cipn | #33 |
| questionnaires total | #33 |
| neoplasms carboplatin | #33 |
| acupuncture hot flashes | #33 |
| isoo | #33 |
| hands feet | #33 |
| 4week followup | #33 |
| chemotherapeutic regimens | #33 |
| blind manner | #33 |
| patients cinv | #33 |
| increased difficulty | #33 |
| smokers randomized | #33 |
| therapy bupropion | #33 |
| dose megestrol | #33 |
| survival advanced cancer | #33 |
| week treatment | #33 |
| sensitivity polyps | #33 |
| breast neoplasms life | #33 |
| patients taxol | #33 |
| toxicity breast | #33 |
| pursuant | #33 |
| instruments life | #33 |
| neuropathy patients | #33 |
| continuation study | #34 |
| patients nausea | #34 |
| patients acitretin | #34 |
| chemotherapy hec | #34 |
| toxicity fluorouracil | #34 |
| united states hrqol | #35 |
| formal consensus process | #35 |
| 4 week | #35 |
| prevention chemotherapyinduced nausea | #35 |
| carcinoembryonic antigen levels | #35 |
| inhibitors venlafaxine | #35 |
| treating cancer | #35 |
| moderatetosevere patients | #35 |
| major bleeding lmwh | #35 |
| cipn severity | #35 |
| patients tools | #35 |
| levels week | #35 |
| cancer international society | #35 |
| trial designed | #35 |
| dawley statistics | #35 |
| stomatitis | #35 |
| primary outcomes trials | #35 |
| pyrexia patients | #36 |
| lymphedema treatment | #36 |
| mometasone placebo | #36 |
| head neck radiotherapy | #36 |
| doxepin | #36 |
| stages colorectal cancer | #36 |
| myalgias | #36 |
| pain pilot | #36 |
| secondary prevention measures | #36 |
| tnfα study | #36 |
| cohosh | #36 |
| nk1ras | #36 |
| cancerrelated fatigue | #37 |
| symptoms cancer | #37 |
| planned sample size | #37 |
| topic humans life | #37 |
| p00052 | #37 |
| mc5 | #37 |
| alleviation | #37 |
| nausea neoplasms | #37 |
| ctcae | #37 |
| global impression | #37 |
| study intravenous | #37 |
| early integrated | #37 |
| topic stomatitis | #37 |
| chronic nausea | #37 |
| survival supportive | #37 |
| tests controlled trials | #38 |
| women metastatic disease | #38 |
| sensitization nociceptors | #38 |
| 5ht3ras | #38 |
| patients taxanes | #38 |
| oncology providers | #38 |
| trial conducted | #38 |
| illness purpose | #38 |
| relationships populations | #38 |
| patients highdose melphalan | #38 |
| fluorouracil based | #38 |
| individual item | #38 |
| arm difference | #39 |
| acids drug | #39 |
| chi2 tests | #39 |
| menopause gsm | #39 |
| 3 agents | #39 |
| european organisation cancer | #39 |
| crushed ice | #39 |
| cohort type | #39 |
| study double | #39 |
| arm placebo | #39 |
| treatment breakthrough | #39 |
| qol clinical trials | #39 |
| blind crossover | #39 |
| trials oncology | #39 |
| grade 2 toxicity | #39 |
| arthralgia breast | #40 |
| treatment analyses | #40 |
| initial mastectomy | #40 |
| cachexia clinical | #40 |
| difluoromethylornithine | #40 |
| method fatigue | #40 |
| patients lamotrigine | #40 |
| prevent colorectal | #40 |
| topic reproducibility surveys | #40 |
| single dose placebo | #40 |
| mastectomy chemotherapy | #40 |
| terminology criteria | #40 |
| appetite patients | #40 |
| bupropion smokers | #41 |
| drug evaluation studies | #41 |
| undergoing androgen | #41 |
| united states guidelines | #41 |
| treatment period | #41 |
| trial performed | #41 |
| symptoms 12 months | #41 |
| zoledronic acid bmd | #41 |
| smokers weight | #41 |
| cure recurrence | #41 |
| relapse 3 months | #41 |
| gabapentin placebo | #41 |
| patients completed | #42 |
| patients incurable | #42 |
| randomized doubleblind trial | #42 |
| placebo venlafaxine | #42 |
| chemotherapy day | #42 |
| nortriptyline placebo | #42 |
| neuronal protection | #42 |
| appetite body | #42 |
| transdermal gel | #42 |
| oral gabapentin | #42 |
| treating institution | #42 |
| location age | #42 |
| preliminary insights | #43 |
| median weight | #43 |
| desipramine patients | #43 |
| postsurgical | #43 |
| baseline fatigue | #43 |
| sex location | #43 |
| highdose interferon | #43 |
| dietary supplements life | #43 |
| 5 induced | #43 |
| trial benefit | #44 |
| bupropion placebo | #44 |
| vaginal moisturizer | #44 |
| nonpain | #44 |
| chemotherapyinduced nausea vomiting | #44 |
| sensory symptoms | #44 |
| surveillance united states | #44 |
| weeks efficacy | #44 |
| risk cipn | #44 |
| disagreement | #44 |
| pain reduction patients | #44 |
| outcome gamma | #44 |
| collaborative effort | #44 |
| historic controls | #45 |
| 5 years incidence | #45 |
| menogaril | #45 |
| piroxantrone | #45 |
| humans peripheral | #45 |
| genitourinary syndrome menopause | #45 |
| acute pain patients | #45 |
| rash grade | #45 |
| fisher tests | #45 |
| survivors colorectal cancer | #45 |
| conclusion trial | #45 |
| objective tumor regression | #45 |
| ginseng panax quinquefolius | #45 |
| current manuscript | #46 |
| study gaba | #46 |
| nonpharmacological therapy | #46 |
| item measures | #46 |
| factor prognostic | #46 |
| acute skin toxicity | #46 |
| radiationinduced oral mucositis | #46 |
| epoetin alfa placebo | #46 |
| middle aged patient | #46 |
| cisplatin neuropathy | #46 |
| randomized comparison | #46 |
| clinical problem | #46 |
| megestrol acetate treatment | #46 |
| longitudinal methods | #46 |
| vaccines melanoma | #46 |
| adverse symptoms | #46 |
| putative mechanism | #46 |
| chemotherapy antineoplastic | #46 |
| patients advanced adenomas | #46 |
| iii colon cancer | #46 |
| phase iii life | #46 |
| radiotherapy randomized | #46 |
| neoplasms parenteral nutrition | #47 |
| dose paclitaxel | #47 |
| darbepoetin alfa patients | #47 |
| average pain | #47 |
| aged mometasone | #47 |
| genetic predictors | #47 |
| differences pros | #47 |
| bipn | #47 |
| cachexia female | #47 |
| mascc | #47 |
| twopart | #47 |
| screening setting | #47 |
| stratification factor | #48 |
| nausea day | #48 |
| qol female humans | #48 |
| placebo gabapentin | #48 |
| physical examinations | #48 |
| neck radiotherapy | #48 |
| oxybutynin | #48 |
| menopause life | #48 |
| genitourinary symptoms | #48 |
| female cancer | #49 |
| chemotherapy nausea | #49 |
| sham arm | #49 |
| flie | #49 |
| patientclinician communication | #49 |
| time conclusions | #50 |
| cancer survivors fatigue | #50 |
| replens | #50 |
| models stage | #50 |
| placebos randomized | #50 |
| receiving androgen | #50 |
| mastectomy pain | #50 |
| pain numbness | #50 |
| cachexia | #50 |
| antiserotonergic | #50 |
| hot flashes hfs | #50 |
| vomiting chemotherapy | #51 |
| effective treating | #51 |
| patients cancer pain | #51 |
| transdermal testosterone | #51 |
| genitourinary syndrome | #51 |
| cisplatin humans | #51 |
| patients 8 weeks | #51 |
| regional hypothermia | #51 |
| blinded placebo | #51 |
| differences treatment arms | #52 |
| 80k | #52 |
| treatment adt | #52 |
| trastuzumab orr | #52 |
| risk bone loss | #52 |
| management chemotherapy | #52 |
| metaanalysis incidence | #52 |
| aged orchiectomy | #52 |
| black cohosh | #52 |
| toxicity time | #53 |
| tamoxifen antineoplastic agents | #53 |
| cancer venous | #53 |
| purposepatients | #53 |
| receiving radiotherapy | #53 |
| control nausea | #53 |
| nervous peripheral | #53 |
| potential adjuvant | #53 |
| standard placebo | #54 |
| pilot trial | #54 |
| antiemetics antineoplastic | #54 |
| severe hot | #54 |
| treatment months | #54 |
| 20 data | #54 |
| levetiracetam treatment | #54 |
| life topic humans | #54 |
| blood testing | #54 |
| recurrent disease | #54 |
| double‐blind trial | #54 |
| scalp cooling | #55 |
| fatigue inventory | #55 |
| acupuncture cancer | #55 |
| treatment tobacco dependence | #55 |
| cachexia therapy | #55 |
| symptoms therapy | #55 |
| bupropion treatment | #55 |
| cancerdirected therapy | #55 |
| serial levels | #55 |
| time placebo | #56 |
| adjuvant endocrine treatment | #56 |
| carboplatin female humans | #56 |
| symptoms hot | #56 |
| xaliproden | #56 |
| diseases antineoplastic | #56 |
| undergoing chemotherapy | #56 |
| recurrence symptoms | #57 |
| benefit scale | #57 |
| adjuvant colon | #57 |
| placebo solution | #57 |
| common terminology | #57 |
| 12 courses | #57 |
| completion adjuvant chemotherapy | #58 |
| ferric gluconate | #58 |
| limited degree | #58 |
| quality life questionnaire | #58 |
| cachexia weight loss | #58 |
| major bleeding enoxaparin | #58 |
| compared oral | #58 |
| points placebo | #58 |
| undergoing treatment | #58 |
| pain peripheral | #58 |
| topical gel | #58 |
| skin dermatitis | #58 |
| chemotherapy cognitive | #59 |
| safety rivaroxaban | #59 |
| patients hec | #59 |
| ocular irritation | #59 |
| data understanding | #59 |
| coprescription | #59 |
| placebo citalopram | #59 |
| weight appetite | #59 |
| chemotherapyinduced nausea | #59 |
| osteopaenia | #59 |
| hb baseline | #60 |
| study medication | #60 |
| colonoscopically | #60 |
| anticonvulsants antidepressive | #60 |
| patients mirtazapine | #60 |
| serotonergic effects | #60 |
| lymphedema women | #61 |
| topic surveys life | #61 |
| standard dosing | #61 |
| emla cream | #61 |
| doubleblind | #61 |
| bleomycin patients | #61 |
| pipn | #61 |
| caregivers pain | #61 |
| paroxetine fluoxetine | #61 |
| tamoxifen metabolism | #61 |
| 1 week treatment | #61 |
| cancer patients study | #61 |
| sensitivity individuals | #61 |
| 3 randomized | #61 |
| induced taste | #62 |
| recurrent disease patients | #62 |
| efficacy fluoxetine | #62 |
| venlafaxine placebo | #62 |
| fluorouracil induced | #62 |
| chemotherapy dose | #62 |
| alpha weight | #62 |
| ocular toxicity | #62 |
| pain bleeding | #62 |
| dermatological toxicities | #62 |
| ncictc | #63 |
| 105 months | #63 |
| patients disease recurrence | #63 |
| prior chemotherapy regimen | #63 |
| integrative oncology | #63 |
| anorexia patients | #63 |
| aged placebos | #63 |
| lessen | #63 |
| antibodies monoclonal carcinoma | #63 |
| carboplatin oxaliplatin | #64 |
| treatment chemotherapy | #64 |
| cyproheptadine | #64 |
| alleviate | #64 |
| cyclohexanols | #64 |
| patients cancer types | #64 |
| rivaroxaban enoxaparin | #64 |
| allelic variability | #64 |
| aged nausea | #64 |
| improvement sexual function | #64 |
| painful peripheral neuropathy | #64 |
| versus placebo | #64 |
| incidence rash | #64 |
| bupropion nicotine | #64 |
| appetite weight loss | #65 |
| patients comparisons | #65 |
| dalteparin treatment | #65 |
| agents double | #65 |
| 75 daily | #65 |
| administration paclitaxel | #65 |
| efficacy toxicity | #65 |
| 4 weeks week | #65 |
| patients minocycline | #65 |
| validated patient | #65 |
| survivorship issues | #65 |
| acetate therapy | #66 |
| study gabapentin | #66 |
| nicotine nasal | #66 |
| oncology clinical | #66 |
| food intake patients | #66 |
| placebo months | #66 |
| diseases neoplasms | #66 |
| clinician training | #67 |
| estrogen suppression | #67 |
| life topic | #67 |
| target doses | #67 |
| qol fatigue | #67 |
| hec | #68 |
| cachexia weight | #68 |
| pilocarpine treatment | #68 |
| baseline study | #68 |
| induced dermatitis | #68 |
| subcutaneous dalteparin | #68 |
| prevention smoking | #68 |
| 46 95 | #68 |
| patients randomized | #68 |
| hormonal therapies | #68 |
| fsfi score | #69 |
| gained weight | #69 |
| skin surveys | #69 |
| debilitating | #69 |
| ongoing loss | #69 |
| vasomotor symptoms women | #69 |
| surgery cancer | #70 |
| induced ovarian | #70 |
| multifactorial syndrome | #70 |
| chemotherapy anemia | #70 |
| nonsignificant trends | #70 |
| women ais | #70 |
| item score | #70 |
| development severity | #70 |
| major bleeding apixaban | #71 |
| weight compared | #71 |
| incidence severity | #71 |
| anthrapyrazole | #71 |
| infliximab combination | #71 |
| week percentage | #71 |
| life referral | #71 |
| oral drug administration | #72 |
| placebo patches | #72 |
| patients pilot | #72 |
| effects ginseng | #72 |
| systemic retinoids | #72 |
| cisplatin treated | #72 |
| trials planning | #72 |
| humans lignans | #72 |
| ergotamines | #73 |
| placebo | #73 |
| weeks placebo | #73 |
| chemoprevention trial | #73 |
| prospective pilot trial | #73 |
| ginseng treatment | #73 |
| chemotherapy supportive | #73 |
| stage primary | #73 |
| dronabinol | #74 |
| women estrogen therapy | #74 |
| fractional co2 laser | #74 |
| receiving chemotherapy | #74 |
| rcts systematic reviews | #74 |
| qli | #74 |
| rash | #74 |
| trial evaluating | #74 |
| anemia antineoplastic | #74 |
| 353 patients | #75 |
| nervous diseases | #75 |
| cancerrelated fatigue crf | #75 |
| prevention | #75 |
| acid supplement | #75 |
| acute skin | #76 |
| cycles cycle | #76 |
| blind clinical | #76 |
| weekly arm | #76 |
| inhibitors tamoxifen | #76 |
| alliance patients | #77 |
| week p005 | #77 |
| cancer randomized | #77 |
| tamoxifen postmenopausal | #77 |
| hospice staff | #77 |
| breast cancer paclitaxel | #77 |
| anemia darbepoetin | #77 |
| 95 01 | #77 |
| anorexia weight loss | #77 |
| dose 90 | #77 |
| female humans insurance | #78 |
| 3 arm | #78 |
| values data | #78 |
| tamoxifen postmenopausal women | #78 |
| patients zoledronic acid | #78 |
| efficacy lamotrigine | #79 |
| surgery year | #79 |
| week schedule | #79 |
| therapy antineoplastic | #79 |
| patients darbepoetin alfa | #79 |
| vte recurrence | #79 |
| symptoms sensitivity | #79 |
| pain syndrome | #79 |
| serum concentrations infliximab | #79 |
| zoledronic acid treatment | #80 |
| isoflavone supplements | #80 |
| foot syndrome | #80 |
| time mastectomy | #80 |
| vomiting antiemetics | #80 |
| week 4 | #80 |
| life phase iii | #80 |
| patients treatment arms | #81 |
| study march | #81 |
| guideline recommendation | #81 |
| patient qol | #81 |
| period crossover | #81 |
| lowmolecular weight heparin | #81 |
| oral oncology | #81 |
| bupropion smoking | #82 |
| suggestion | #82 |
| greater weight gain | #82 |
| backgroundchemotherapy | #82 |
| paroxetine patients | #82 |
| standard clinical | #82 |
| trpv1 trpa1 | #83 |
| patients participating | #83 |
| recommendations article | #83 |
| day weeks | #83 |
| orbital stability | #83 |
| zinc sulfate | #84 |
| cinv patients | #84 |
| method female | #84 |
| trpm8 trpa1 | #84 |
| cancer weight | #85 |
| systematic reviews rcts | #85 |
| neoplasm metastasis neoplasms | #85 |
| ice pack | #85 |
| cryotherapy patients | #86 |
| treatment nicotine dependence | #86 |
| mayo clinic | #86 |
| ttf survival | #86 |
| receiving placebo | #86 |
| week 5 | #87 |
| methodspatients | #87 |
| therapyinduced | #87 |
| serum hepcidin levels | #87 |
| baseline arms | #87 |
| incidence osteoporosis | #87 |
| frequency severity | #87 |
| life cachexia | #87 |
| pilot study safety | #87 |
| nicotine nasal spray | #87 |
| primary symptom | #87 |
| acp documentation | #88 |
| integrative therapies | #88 |
| anecdotal reports | #88 |
| treatment fatigue | #89 |
| cancer vte | #89 |
| iu daily | #89 |
| putative mediator | #89 |
| clinical oncology asco | #90 |
| morphine pharmacokinetics | #90 |
| outcome venlafaxine | #90 |
| male chemotherapy | #90 |
| arm treatment | #91 |
| scores placebo | #91 |
| ncorp | #91 |
| symptoms including | #91 |
| tolerated patients | #91 |
| iii efficacy | #91 |
| delayed cinv | #91 |
| endoxifen concentrations | #91 |
| nerve pain | #92 |
| trials treatment | #92 |
| patients paroxetine | #92 |
| cisplatin oxaliplatin | #92 |
| patients upfront | #92 |
| completion chemotherapy | #92 |
| ameliorating | #93 |
| quiet stance | #94 |
| breast cancer survivors | #94 |
| 1 primary | #94 |
| questionnaires survival | #94 |
| anemic patients | #94 |
| arm 3 | #94 |
| apixaban dose | #94 |
| neoplasms quality life | #94 |
| mometasone | #94 |
| duloxetine hydrochloride | #94 |
| cancerrelated pain | #95 |
| alfa patients | #95 |
| patients appetite | #95 |
| common symptoms | #95 |
| 0 10 | #96 |
| udi | #96 |
| failure chemotherapy | #96 |
| patients completion | #96 |
| prevention management | #96 |
| ccop | #96 |
| mayo clinic rochester | #96 |
| hlaa2 patients | #96 |
| oral mucositis patients | #97 |
| adjuvant therapy survival | #97 |
| pyrexia | #97 |
| acute vte | #97 |
| paclitaxel patient | #97 |
| completed study | #98 |
| painful area | #98 |
| preliminary data | #98 |
| crnmb | #98 |
| 15 points | #98 |
| treatment tolerability | #98 |
| identical placebo | #98 |
| alleviating | #98 |
| text review | #98 |
| agents paclitaxel | #98 |
| patient medical | #99 |
| 4 weeks baseline | #99 |
| topic cyclophosphamide | #99 |
| difference incidence | #99 |
| bcca | #99 |
| fatigue insomnia | #99 |
| 5fu leucovorin | #99 |
| patient questionnaires | #99 |
| 5fluorouracil oxaliplatin | #99 |
| induced esophagitis | #99 |
| pregnadienediols | #99 |
| male sex factors | #100 |
| oncology outpatients | #100 |
| 10 doses | #100 |
| qlq | #100 |
| survival nsclc | #100 |
| clinician communication | #100 |
| 5 based | #101 |
| humans life | #101 |
| 275 patients | #101 |
| oncology asco | #101 |
| nortriptyline | #101 |
| antineoplastic agents life | #101 |
| lung cancer chemoprevention | #101 |
| oncology clinicians | #101 |
| postresection | #101 |
| lidocaine lidocaine | #101 |
| methods trial | #102 |
| placebo 1 year | #102 |
| variance clinical trials | #103 |
| reported effects | #103 |
| 3106 | #104 |
| quality life data | #104 |
| purposeprevious | #104 |
| patients anorexia | #104 |
| races ethnicities | #104 |
| diseases treatment | #105 |
| patients 150 | #105 |
| 12 24 months | #105 |
| leap | #105 |
| chemotherapy cycle | #105 |
| phytogenic clinical trials | #105 |
| dalteparin patients | #106 |
| trial studies | #106 |
| stool samples patients | #106 |
| nutritional determinants | #106 |
| compounds oxaliplatin | #106 |
| dfmo | #106 |
| infusion site | #106 |
| months relapse | #106 |
| neuropathy | #106 |
| cycle cycles | #107 |
| epoetin alfa patients | #107 |
| pain intensity ratings | #107 |
| valeriana officinalis | #107 |
| versus dexamethasone | #107 |
| anastrozole letrozole | #107 |
| urogenital diseases | #107 |
| humans menopause | #107 |
| life topic severity | #108 |
| relapse prevention | #108 |
| breast cancer tamoxifen | #108 |
| time toxicity | #108 |
| women experience | #108 |
| week study | #108 |
| women vasomotor symptoms | #109 |
| mouthwash | #109 |
| patients guideline | #109 |
| female urogenital | #109 |
| treatment cancer pain | #109 |
| strong prognostic factor | #109 |
| levocarnitine | #109 |
| patients cancer treatment | #110 |
| clinic rochester | #110 |
| combined paclitaxel | #110 |
| life adverse events | #110 |
| oxaliplatin therapy | #110 |
| vomiting adult | #111 |
| prevention bone loss | #111 |
| egfr inhibitor | #111 |
| cmf chemotherapy | #111 |
| function suppression | #112 |
| dosing schedules | #112 |
| insomnia pain | #112 |
| vestibulitis | #113 |
| functional iron deficiency | #113 |
| visits patient | #113 |
| vaginal diseases | #113 |
| treatment arms patients | #113 |
| adverse events ctcae | #113 |
| reassess | #113 |
| agents hormonal | #113 |
| colorectal neoplasia | #113 |
| –iii | #113 |
| patients arms | #113 |
| single nucleotide variants | #114 |
| hfsd | #114 |
| cachexia humans | #114 |
| diseases breast | #114 |
| alopecia patients | #114 |
| therapy induced | #114 |
| patients olanzapine | #114 |
| months 3 | #114 |
| qol patient | #114 |
| dietary lignans | #114 |
| acitretin | #114 |
| letrozole tamoxifen | #115 |
| patients anthracycline | #115 |
| laser therapy lasers | #115 |
| rivaroxaban venous | #115 |
| crci | #115 |
| studies randomized | #115 |
| combination nicotine | #115 |
| placebo postmenopausal women | #116 |
| treatment arm | #116 |
| symptoms chemotherapy | #117 |
| nk1 receptor antagonist | #117 |
| 2007 guidelines | #117 |
| patients peripheral neuropathy | #117 |
| induction ornithine decarboxylase | #117 |
| oral factor | #117 |
| recurrence diagnosis | #118 |
| oral antineoplastic agents | #118 |
| appetite stimulant | #118 |
| preventive therapies | #119 |
| 3915 | #119 |
| patients weekly paclitaxel | #119 |
| trials conducted | #119 |
| trpa1 trpv1 | #119 |
| noradrenaline reuptake | #119 |
| diseases pain | #119 |
| clinical histories | #120 |
| definition classification | #120 |
| participants arms | #120 |
| treatment weeks | #120 |
| olanzapine placebo | #120 |
| resultswhile | #120 |
| 750 day | #120 |
| original report | #120 |
| hormonal agents | #121 |
| patients cancers | #121 |
| untoward | #121 |
| placebo double | #121 |
| induced ocular | #121 |
| fullerton | #121 |
| postmenopausal postmenopause | #121 |
| nervous agents | #122 |
| cancer multiple | #122 |
| oxaliplatin folfox | #122 |
| rolapitant | #123 |
| stable dose | #123 |
| cancer quality | #123 |
| acute oral | #123 |
| weeks 4 | #123 |
| objective review | #123 |
| skin pain | #123 |
| netupitant | #123 |
| surgery analysis | #123 |
| pros baseline | #124 |
| survivors breast cancer | #124 |
| patients diploid tumors | #124 |
| isoflavones genistein | #124 |
| rivaroxaban compared | #124 |
| treatment letrozole | #124 |
| neuropathic pain patients | #124 |
| 1 month patients | #125 |
| 90 dose | #125 |
| week dose | #125 |
| resultsfour | #126 |
| neurotoxic agents | #126 |
| factors odds | #126 |
| genetic quality | #127 |
| promising agents | #127 |
| diagnosis metastatic disease | #127 |
| hormonal breast | #127 |
| fsfi | #127 |
| recurrent adenomas | #127 |
| patients physicians | #127 |
| anorexia | #127 |
| cancerassociated vte | #128 |
| belladonna | #128 |
| arms patients | #128 |
| alfa erythropoietin | #128 |
| weight concerns | #128 |
| uncommon variants | #128 |
| resultsforty | #129 |
| vomiting cinv | #129 |
| agents neoplasms | #129 |
| 5 leucovorin | #129 |
| neoplasms quality | #129 |
| clinical trial patients | #129 |
| postural instability | #129 |
| serum baseline | #130 |
| problem patients | #130 |
| patientreported outcome | #130 |
| control arms | #130 |
| cancer fatigue | #131 |
| 150 iu | #131 |
| treatment toxicities | #131 |
| function fsfi | #131 |
| prognostic variables | #131 |
| bmd tscore | #131 |
| relapse smoking | #132 |
| cancerrelated symptoms | #132 |
| efficacy vitamin | #132 |
| neurotoxicity syndromes | #132 |
| onycholysis | #132 |
| pilot data | #132 |
| progress report | #133 |
| cachexia patients | #133 |
| topical treatment | #133 |
| assessable | #133 |
| 5 placebo | #134 |
| ganglion block | #134 |
| ginseng panax | #134 |
| endodermal sinus tumor | #134 |
| symptom control | #134 |
| toxt | #135 |
| 150 women | #135 |
| chemotherapy 5 | #135 |
| bmd postmenopausal women | #135 |
| common adverse effects | #135 |
| cancers patients | #135 |
| agents generation | #135 |
| cold hyperalgesia | #135 |
| bothersome | #136 |
| patientlevel pooled analysis | #136 |
| npy levels | #136 |
| symptomatic benefit | #136 |
| painful neuropathy | #136 |
| weekly therapy | #136 |
| life physical function | #137 |
| severe fatigue | #137 |
| study trials | #137 |
| agents bortezomib | #137 |
| poor qol | #137 |
| stage cancer | #137 |
| substantial benefit | #137 |
| percentage reduction | #137 |
| intrapatient | #137 |
| zoledronic | #138 |
| hfs patients | #138 |
| grade stage | #138 |
| accrued | #138 |
| advanced lung | #139 |
| therapy breast | #139 |
| incurable cancer | #139 |
| factbr | #139 |
| chemoprevention studies | #139 |
| underwent mastectomy | #139 |
| patients advanced cancer | #140 |
| breast chest wall | #140 |
| liquid suspension | #140 |
| oxaliplatin chemotherapy | #141 |
| patients placebo | #141 |
| paclitaxel weekly | #141 |
| financial concerns | #142 |
| disclose | #142 |
| tamoxifen placebo | #142 |
| patients levetiracetam | #142 |
| fluorouracil 5 | #143 |
| protocols breast | #143 |
| medicine clinical | #143 |
| preoperative magnetic | #144 |
| european organisation | #144 |
| allopurinol placebo | #144 |
| snv | #144 |
| evidence loe | #145 |
| eortc qlq | #145 |
| debilitating condition | #145 |
| agents bone | #145 |
| fluorouracil humans | #145 |
| vaginal cytology | #145 |
| surgery type | #146 |
| eligible women | #146 |
| volatile plants | #148 |
| oral olanzapine | #148 |
| dietary counselling | #148 |
| backgroundwomen | #148 |
| numeracy | #149 |
| desipramine treatment | #149 |
| venlafaxine treatment | #150 |
| n201 | #150 |
| adjuvant systemic | #150 |
| predict recurrence | #150 |
| multinational association | #151 |
| prior chemotherapy regimens | #151 |
| methodologic | #151 |
| daily diaries | #151 |
| women estrogen | #151 |
| response rate survival | #151 |
| patients receive | #151 |
| intravenous access | #151 |
| balance impairments | #152 |
| tumor recurrence patients | #152 |
| ovarian function suppression | #152 |
| 14 week | #152 |
| caa patients | #152 |
| oral mucositis | #152 |
| groups symptoms | #152 |
| cramping | #153 |
| 80 dose | #154 |
| carboplatin trastuzumab | #154 |
| adjuvant systemic therapy | #155 |
| cindices | #155 |
| dermatomes | #155 |
| hyperalimentation | #156 |
| combination chemotherapy cisplatin | #156 |
| fsds | #156 |
| mangafodipir | #156 |
| infliximab 5 | #156 |
| integrated palliative | #156 |
| life randomized | #156 |
| vinblastine bleomycin | #156 |
| methods randomized | #156 |
| women breast carcinoma | #157 |
| racially diverse | #157 |
| common terminology criteria | #157 |
| breast cancer trastuzumab | #157 |
| gait stability | #157 |
| vomiting nausea | #158 |
| study initiation | #158 |
| oncology study | #158 |
| arm versus | #158 |
| physicians patients | #159 |
| iii clinical | #159 |
| induced nausea | #159 |
| weekly doses | #159 |
| survivors colorectal | #159 |
| chemotherapy breast cancer | #159 |
| major problem | #160 |
| chemotherapy quality | #160 |
| cancer pain patients | #160 |
| treatment postmenopausal women | #160 |
| paclitaxel taxol | #160 |
| european organisation treatment | #160 |
| stellate ganglion | #160 |
| women hormone therapy | #161 |
| validity life | #161 |
| estrogen depletion | #161 |
| risk infertility | #161 |
| data efficacy | #163 |
| neoplasms pain | #164 |
| efficacy women | #164 |
| mometasone furoate | #165 |
| current project | #165 |
| cisplatin vinblastine | #165 |
| patients 1 month | #166 |
| pharmacokinetic analyses | #166 |
| skeletal events | #166 |
| osteoporosis prevention | #167 |
| life topic surveys | #167 |
| illness surveys questionnaires | #167 |
| chemotherapy groups | #168 |
| chemotherapy‐induced nausea | #168 |
| anthracycline | #168 |
| direct inhibitors | #168 |
| 432 patients | #169 |
| patients adenomas | #169 |
| dosing patients | #169 |
| patients data | #169 |
| menopause symptoms | #169 |
| ixabepilone | #170 |
| management chronic pain | #170 |
| rochester | #171 |
| daily placebo | #171 |
| global quality | #171 |
| disease cmt | #171 |
| prospective clinical trials | #171 |
| chemotherapy completion | #172 |
| prestudy | #172 |
| impaired balance | #173 |
| judicious | #173 |
| lamotrigine placebo | #173 |
| placebos | #173 |
| label pilot | #173 |
| 1 year therapy | #173 |
| hot flushes | #173 |
| methylphenidate placebo | #174 |
| pilot feasibility study | #174 |
| phase iii trial | #174 |
| prospective evaluation | #174 |
| diarrhoea patients | #174 |
| arthralgia | #175 |
| physician order | #175 |
| decreased quality | #175 |
| male breast cancer | #175 |
| cancer cancer treatment | #175 |
| baseline weight | #176 |
| weeks women | #177 |
| treatment 14 | #177 |
| life assessments | #177 |
| bodyweights | #178 |
| thirty percent | #178 |
| bolus fluorouracil | #179 |
| life baseline | #179 |
| bothered | #179 |
| expected benefits | #179 |
| treatmentrelated toxicity | #179 |
| sufferer | #180 |
| phase evaluation | #181 |
| oxaliplatin 5fluorouracil | #182 |
| gain weight | #182 |
| escalations | #182 |
| darbepoetin | #182 |
| ginseng | #182 |
| toxicity criteria | #183 |
| organisation treatment | #183 |
| peri postmenopausal women | #183 |
| prognostic criteria | #184 |
| acetyll | #184 |
| white smokers | #184 |
| effects chemotherapy | #184 |
| biostatisticians | #184 |
| received oral | #184 |
| acute pain | #184 |
| infliximab antibodies | #184 |
| tube primary | #184 |
| reported sexual | #185 |
| outcome measures life | #185 |
| additional chemotherapy | #185 |
| arm volume | #186 |
| cinv | #187 |
| treating | #187 |
| treatment 4 weeks | #187 |
| patients drug | #187 |
| delayed nausea | #187 |
| troublesome | #188 |
| week follow | #188 |
| management breast cancer | #188 |
| reduction therapy | #188 |
| strong prognostic | #188 |
| lessened | #188 |
| tamoxifen letrozole | #188 |
| adjuvant decision | #188 |
| aching | #189 |
| oxaliplatin dose | #189 |
| neoplasia female humans | #189 |
| antiemetic regimens | #190 |
| protocol therapy | #190 |
| week 1 | #190 |
| survivors breast | #190 |
| aged nitriles | #190 |
| placebo study | #190 |
| twentyfive patients | #191 |
| cancer cancer survivors | #191 |
| completed baseline | #191 |
| treatment cancer patients | #192 |
| manuscript | #192 |
| aches | #192 |
| chronic lymphedema | #192 |
| aspirin incidence | #192 |
| fortysix patients | #192 |
| patients increases | #192 |
| toxicity patients | #192 |
| cimicifuga racemosa | #193 |
| humans isoflavones | #193 |
| assigned receive | #193 |
| 25 women | #194 |
| effective agents | #194 |
| weekly trastuzumab | #194 |
| pain breast | #195 |
| 3 fatty | #195 |
| weight loss patients | #195 |
| ornithine decarboxylase activity | #195 |
| acids double | #196 |
| resultsdata | #196 |
| pituitaryadrenal axis | #197 |
| palonosetron dexamethasone | #197 |
| trial designs | #197 |
| surveillance strategy | #198 |
| resultstwo | #198 |
| postmenopausal patients | #198 |
| toxicity profiles | #198 |
| delayed emesis | #199 |
| women menopause | #199 |
| culminates | #199 |
| nicotine patch | #199 |
| organization treatment | #199 |
| patients letrozole | #199 |
| accent | #199 |
| adjuvant interferon | #200 |
| percent reduction | #200 |
| menopause premature | #201 |
| oral glutamine | #201 |
| item responses | #202 |
| imiquimod | #202 |
| primary goal | #202 |
| treatment bmd | #202 |
| greater 5 | #202 |
| treatment week | #202 |
| bmd postmenopausal | #203 |
| cancer anemia | #203 |
| hormonal treatments | #203 |
| plo | #204 |
| pelvic radiation therapy | #204 |
| composition cachexia | #204 |
| treated placebo | #204 |
| induced oral | #205 |
| unwilling | #206 |
| placebo 8 | #206 |
| chemotherapy drugs | #206 |
| udi6 | #206 |
| leucovorin patients | #206 |
| dalteparin | #206 |
| mice cisplatin | #207 |
| heat hyperalgesia | #207 |
| pharmacologic interventions | #207 |
| 4 8 weeks | #208 |
| humans leucovorin | #208 |
| reduced food intake | #208 |
| incurable | #208 |
| chemotherapy | #209 |
| hands patients | #209 |
| 5 daily | #209 |
| lamotrigine | #210 |
| estrogen receptor modulators | #210 |
| methotrexate 5 | #210 |
| controlled evaluation | #210 |
| gel application | #211 |
| regionally advanced | #212 |
| initials | #212 |
| diagnosis recurrence | #212 |
| vomiting patients | #212 |
| methodsthis | #212 |
| docetaxel cyclophosphamide | #213 |
| trial vitamin | #213 |
| charcotmarietooth disease | #213 |
| placebo 6 weeks | #214 |
| dexamethasone control | #214 |
| patient weight | #214 |
| oncology practices | #214 |
| oxaliplatin | #215 |
| olanzapine 5 | #215 |
| antiemetic therapy | #215 |
| december patients | #215 |
| 15 minutes | #215 |
| prostate cancer survivors | #216 |
| neoplasms cross | #216 |
| tamoxifen users | #217 |
| gabapentin humans | #217 |
| patients duloxetine | #217 |
| women tamoxifen | #217 |
| women breast cancer | #217 |
| current management | #218 |
| 10 daily | #218 |
| purposethe purpose | #218 |
| aprepitant | #218 |
| —reply | #218 |
| hot | #218 |
| nonmajor | #218 |
| placebo weeks | #218 |
| transdermal fentanyl | #219 |
| life humans | #219 |
| palliative oncology | #219 |
| nmscs | #219 |
| sublingual administration | #220 |
| sexual symptoms | #220 |
| nonabsorbable | #220 |
| pregabalin patients | #221 |
| ornithine decarboxylase odc | #221 |
| moderate pain | #221 |
| painful peripheral | #221 |
| society clinical oncology | #221 |
| relieving | #222 |
| prospective study women | #222 |
| ginkgo biloba egb | #222 |
| lymphedema patients | #222 |
| methylphenidate modafinil | #222 |
| treatment postmenopausal | #222 |
| primary breast cancer | #222 |
| neoplasms palliative | #222 |
| randomized doubleblind study | #223 |
| furoate | #223 |
| prevention patients | #224 |
| quinquefolius | #225 |
| computerized physician | #225 |
| 99 months | #225 |
| vaginal estrogen | #226 |
| agent patients | #226 |
| partial mastectomy | #226 |
| turmoil | #227 |
| pain presence | #227 |
| bupropion | #227 |
| trial | #228 |
| clinical situation | #228 |
| nondiploid | #229 |
| 200 iu | #229 |
| secondary endpoint | #229 |
| eating disorders humans | #230 |
| hospice patients | #230 |
| placebo 10 | #230 |
| anthracycline cardiotoxicity | #230 |
| editorials | #230 |
| antidepressive | #230 |
| physicians quality | #230 |
| cancer recommendations | #230 |
| akt inhibitor | #230 |
| vitamin effects | #231 |
| rashes | #231 |
| based adjuvant | #231 |
| lightheadedness | #232 |
| conclusionsthe | #232 |
| time study | #232 |
| cachexia cytokines | #232 |
| handfoot syndrome | #232 |
| nonpharmacologic | #233 |
| fluoxetine paroxetine | #233 |
| acute symptoms | #234 |
| treatment vte | #234 |
| 4 doses | #234 |
| thirty women | #234 |
| women hot | #234 |
| 375 day | #235 |
| sucralfate | #235 |
| day response | #235 |
| arm 95 | #235 |
| relieve | #235 |
| tamoxifen neoplasms chemotherapy | #235 |
| effective treatments | #236 |
| premenopausal patients | #237 |
| placebo gel | #237 |
| survivors treatment | #238 |
| postoperative monitoring | #238 |
| antiemetics | #238 |
| letrozole patients | #238 |
| incidence grade | #238 |
| flash | #238 |
| menopause middle | #239 |
| chemotherapy placebo | #239 |
| overexpressing metastatic | #239 |
| improved bioavailability | #239 |
| methodswomen | #239 |
| nonpharmacologic interventions | #239 |
| adjuvant 5 | #239 |
| oncology clinic | #239 |
| neoadjuvant therapy surgery | #240 |
| oral complications | #240 |
| cachexia syndrome | #240 |
| treatment breast cancer | #240 |
| independent tests | #241 |
| stinging | #242 |
| participants randomized | #242 |
| aged paclitaxel | #243 |
| small doses | #243 |
| tetracycline | #244 |
| 3 arms | #245 |
| epoetin alfa | #245 |
| appetite stimulants | #246 |
| common practice | #246 |
| adjuvant oxaliplatin | #246 |
| efficacy placebo | #247 |
| cachexia cancer | #248 |
| mouthwashes | #248 |
| 800 iu | #249 |
| dysgeusia | #249 |
| survivors adult | #250 |
| item scores | #250 |
| randomized sham | #250 |
| loss bmd | #250 |
| major problems | #251 |
| 689 | #251 |
| patients physical | #251 |
| menopause women | #252 |
| topic vitamin | #252 |
| coasting | #252 |
| randomised studies | #253 |
| armodafinil | #253 |
| primary point | #253 |
| average intensity | #254 |
| moderate degree | #254 |
| nasal spray | #254 |
| chemotherapy breast | #255 |
| recurrence registries | #255 |
| longitudinal followup | #256 |
| prospective clinical | #256 |
| antidepressant | #257 |
| neoplasms randomized | #257 |
| cancer treatment | #257 |
| therapy women | #257 |
| dyspareunia | #258 |
| women treated | #258 |
| pretreatment levels | #258 |
| new therapeutic approaches | #258 |
| rigors | #259 |
| hydrochloride | #259 |
| tube cancer | #260 |
| opioid doseresponse relationship | #260 |
| inhibitors treatment | #260 |
| patients cancer | #261 |
| common problem | #261 |
| repeated measures | #261 |
| 1 baseline | #261 |
| chronic post | #262 |
| patients ovarian cancer | #262 |
| citalopram treatment | #262 |
| management options | #263 |
| months treatment | #263 |
| dosage levels | #263 |
| decision framework | #263 |
| duloxetine placebo | #264 |
| hematinics | #264 |
| phytogenic | #264 |
| treatment oxaliplatin | #264 |
| recommendations quality | #265 |
| outcome administration | #265 |
| treatmentrelated deaths | #266 |
| preoperative mri | #266 |
| individual items | #267 |
| substantiation | #267 |
| paresthesia | #267 |
| treatment cancer | #267 |
| surgery adjuvant | #267 |
| placebo 8 weeks | #267 |
| impact quality | #268 |
| adult cancer survivors | #268 |
| 208 patients | #269 |
| signaled | #270 |
| ginkgo biloba | #270 |
| patients rash | #270 |
| nausea | #270 |
| patients octreotide | #271 |
| 80 90 | #271 |
| estrogen antagonists | #271 |
| moderate correlations | #271 |
| score baseline | #272 |
| control trials | #272 |
| treatment 95 | #272 |
| bridged ring | #272 |
| weekly | #272 |
| distressing | #272 |
| dna test | #272 |
| performance status patients | #272 |
| placebo‐controlled trial | #273 |
| abstinence rates | #273 |
| oncology clinical trials | #274 |
| dryness | #274 |
| sham treatment | #274 |
| induced cisplatin | #275 |
| valeriana | #275 |
| gross disease | #275 |
| patients caa | #276 |
| chemoprevention trials | #277 |
| treatment breast | #278 |
| perspiration | #278 |
| biomarkers disease humans | #279 |
| prominent | #279 |
| patients symptoms | #279 |
| therapeutic options | #279 |
| cimicifuga | #279 |
| patients hospice | #279 |
| individual patient | #280 |
| breast cancer outcomes | #280 |
| cartilage patients | #280 |
| patients frequency | #280 |
| cholinergic antagonists | #280 |
| zoledronic acid patients | #281 |
| psychometric testing | #281 |
| doxorubicin cyclophosphamide | #281 |
| stage colon | #282 |
| chamomile | #282 |
| antidepressive agents | #282 |
| completed questionnaires | #284 |
| women effects | #284 |
| greater severity | #284 |
| gabapentin treatment | #285 |
| smoking abstinence | #285 |
| early discontinuation | #286 |
| fatigue crf | #286 |
| acid adult | #287 |
| colorectal lung | #287 |
| paps | #287 |
| weeks patients | #287 |
| female hormone | #287 |
| function quality | #287 |
| symptoms function | #287 |
| aromatase inhibitor therapy | #288 |
| hot flush | #288 |
| life survival | #290 |
| eligible patients | #291 |
| treatment target | #292 |
| clinical trial participation | #292 |
| common symptom | #292 |
| qualitative approach | #292 |
| discouraged | #292 |
| mucositis oral | #293 |
| pain symptoms | #294 |
| 1636 | #294 |
| cbdca | #294 |
| weight gain patients | #294 |
| citalopram | #295 |
| testosterone supplementation | #295 |
| vinca alkaloids | #295 |
| monographs | #295 |
| bone loss patients | #295 |
| toxicity evaluation | #296 |
| primary peritoneal cancer | #297 |
| patients entered | #298 |
| aspirin placebo | #298 |
| questionnaires treatment | #298 |
| peripheral nervous | #299 |
| neoplasms cyclophosphamide | #299 |
| feet | #299 |
| hypothetical scenarios | #300 |
| inhibitors ais | #300 |
| radiation dermatitis | #300 |
| treated combination | #301 |
| shooting | #301 |
| survival trials | #302 |
| nogalamycin | #302 |
| octreotide | #302 |
| acute neurotoxicity | #303 |
| treatment serum | #303 |
| stage grade | #303 |
| subscale scores | #304 |
| symptoms pain | #304 |
| nausea vomiting | #304 |
| complementary therapies | #305 |
| placebo groups | #305 |
| prime time | #305 |
| prospective clinical trial | #305 |
| schedule female | #305 |
| global quality life | #306 |
| factg | #306 |
| shortread | #307 |
| aromatase inhibitor | #307 |
| placebo treatment | #307 |
| prochlorperazine | #307 |
| inflammatory breast cancer | #307 |
| drug embryo | #308 |
| neoplasms chemotherapy | #308 |
| apixaban | #308 |
| aged cancer | #308 |
| darbepoetin alfa | #309 |
| zoledronic acid | #310 |
| studies double | #310 |
| individual subject | #311 |
| cancer receiving | #311 |
| lung docetaxel | #311 |
| riskstratification | #311 |
| advanced cancer | #311 |
| testosterone placebo | #312 |
| epoetin | #312 |
| placebo‐controlled | #312 |
| patients cycle | #313 |
| musculoskeletal symptoms | #313 |
| cancer adjuvant | #314 |
| or10 | #314 |
| syndrome aps | #314 |
| new primary | #315 |
| operative chemotherapy | #315 |
| article evidence | #316 |
| organoplatinum | #316 |
| blinded | #317 |
| double‐blind | #317 |
| bfi | #317 |
| symptoms breast | #317 |
| ambulatory patients | #317 |
| sesame oil | #317 |
| rivaroxaban patients | #318 |
| efficacy treatment | #319 |
| irox | #319 |
| informed decisions | #321 |
| dietary counseling | #322 |
| life differences | #322 |
| thromboembolism anticoagulants | #323 |
| smokers nicotine | #324 |
| glutamine humans | #324 |
| monthly intervals | #324 |
| preventing | #325 |
| nsclc chemotherapy | #326 |
| breast radiotherapy | #326 |
| patients ductal carcinoma | #327 |
| titrate | #327 |
| compared baseline | #327 |
| continuation phase | #328 |
| treatment 1 year | #329 |
| oral nutritional supplements | #329 |
| patients resected | #329 |
| vte cancer patients | #329 |
| lymphedema | #329 |
| conducted evaluate | #329 |
| antagonists female | #329 |
| future clinical trials | #330 |
| controlled clinical | #330 |
| arms | #330 |
| potential efficacy | #330 |
| patients nasal | #330 |
| polymerase inhibitor | #331 |
| diagnosed primary | #332 |
| cancer ontario | #332 |
| lozenge | #332 |
| 80 anemia | #334 |
| placebo patients | #334 |
| patients daily | #334 |
| time disease | #335 |
| 128 patients | #336 |
| pain scale | #336 |
| relative benefits | #336 |
| paclitaxel therapy | #336 |
| ongoing clinical | #336 |
| 5 fluorouracil | #337 |
| adjuvant letrozole | #337 |
| sublingual | #337 |
| surveillance guidelines | #338 |
| survival 5 years | #338 |
| discernible | #339 |
| flutamide | #340 |
| order entry | #340 |
| patients 4 weeks | #341 |
| eligible participants | #341 |
| mastectomy radiotherapy | #341 |
| treatment proportion | #341 |
| fallopian tube cancer | #342 |
| cancer cachexia | #342 |
| osteopenia osteoporosis | #342 |
| society clinical | #343 |
| tooth disease | #343 |
| diseases quality | #343 |
| pilot randomized | #344 |
| epha5 | #345 |
| skeletal neoplasms | #345 |
| clinicians patients | #345 |
| mk2206 | #346 |
| clinical problems | #346 |
| accruing | #346 |
| adverse events groups | #347 |
| coumarin | #347 |
| therapy pain | #347 |
| mucositis patients | #348 |
| sham acupuncture | #349 |
| antineoplastic therapy | #349 |
| vast majority | #350 |
| induced acute | #350 |
| adjuvant folfox | #350 |
| baseline quality | #350 |
| dehydroepiandrosterone dhea | #351 |
| treatment citalopram | #351 |
| dose schedule | #351 |
| study therapy | #352 |
| patientreported outcomes | #353 |
| endodermal sinus | #353 |
| paclitaxel | #353 |
| response letter | #353 |
| risedronate | #355 |
| cancer life | #355 |
| letrozole | #355 |
| pain baseline | #356 |
| vomiting | #359 |
| skin toxicities | #359 |
| adjuvant colonic | #359 |
| potential benefit | #360 |
| wellknown | #360 |
| cryotherapy | #360 |
| clin oncol | #360 |
| ductal situ carcinoma | #360 |
| diaries | #361 |
| began | #361 |
| direct oral | #362 |
| pelvic radiation | #362 |
| ovarian suppression | #363 |
| flaxseed | #363 |
| nonpharmacological | #363 |
| cancer surveillance | #363 |
| pain measures | #363 |
| calculators | #363 |
| ovarian fallopian | #365 |
| local prognosis receptor | #365 |
| completing | #365 |
| cddp | #365 |
| docetaxel paclitaxel | #365 |
| patients delayed | #366 |
| bioavailable testosterone | #366 |
| management cancer | #366 |
| optimal frequency | #366 |
| pain cancer | #366 |
| scalp | #367 |
| 5‐year | #368 |
| weeks study | #368 |
| scale 0 | #368 |
| scheduled | #369 |
| aged neoplasms | #369 |
| hrt risk | #370 |
| skeletalrelated events | #371 |
| cancer received | #371 |
| gamma aminobutyric acid | #372 |
| orally daily | #372 |
| skin toxicity | #373 |
| 5fluorouracil 5fu | #373 |
| symptoms patients | #373 |
| resected stage | #374 |
| ecogps | #374 |
| irreversible damage | #374 |
| clinical oncology | #374 |
| paclitaxel dose | #374 |
| ovarian failure | #374 |
| −005 | #375 |
| decreasing | #376 |
| women breast | #376 |
| therapy based | #376 |
| blood test | #377 |
| medroxyprogesterone acetate | #377 |
| assessable patients | #378 |
| polyneuropathy | #378 |
| drowsiness | #378 |
| week patients | #378 |
| humans specificity | #378 |
| nociceptors | #379 |
| national cancer institute | #380 |
| telerehabilitation | #381 |
| loss skeletal | #381 |
| fura | #381 |
| 4 treatment | #382 |
| organoplatinum compounds | #383 |
| unacceptable toxicity | #383 |
| leucovorin | #383 |
| trials involving | #384 |
| adverse event | #384 |
| disputes | #384 |
| patients capecitabine | #384 |
| 402 | #384 |
| target dose | #384 |
| function pain | #384 |
| conservation agents | #385 |
| leptin patients | #385 |
| 5fluorouracil leucovorin | #385 |
| density conservation | #386 |
| fourths | #386 |
| 2 treatment | #388 |
| androgendeprivation therapy | #389 |
| treatment women | #390 |
| glutathione gsh | #390 |
| advanced adenomas | #391 |
| aromatase inhibitors ais | #392 |
| sexual desire | #392 |
| 4 weeks | #394 |
| dying patients | #394 |
| adjuvant trials | #394 |
| early palliative | #395 |
| discontinuation rates | #396 |
| life breast | #396 |
| performance score | #397 |
| cytotoxics | #397 |
| ring compounds | #397 |
| olanzapine | #397 |
| humans mastectomy | #397 |
| patients randomly | #398 |
| 1280 | #398 |
| paired tests | #398 |
| life data | #399 |
| withdrew | #400 |
| peripheral neurotoxicity | #400 |
| intramuscular | #400 |
| chemotherapy colorectal | #400 |
| questionnaires treatment outcome | #400 |
| fatty acid supplementation | #400 |
| 3 cohorts | #401 |
| estrogen receptors biomarkers | #401 |
| assigned | #401 |
| 8090 | #401 |
| evidencebased | #402 |
| entered | #402 |
| loe | #402 |
| female humans life | #403 |
| sadenosyllmethionine | #403 |
| acid female | #403 |
| 5 weeks | #405 |
| female fluorouracil | #406 |
| baseline demographics | #406 |
| responding patients | #408 |
| cisplatin induced | #409 |
| keratolytic | #410 |
| life aged | #411 |
| patients 5fu | #411 |
| female hemorrhage humans | #412 |
| topic neoplasms | #412 |
| ornithine decarboxylase | #414 |
| regimens patients | #414 |
| oxaliplatin based | #415 |
| acetate | #415 |
| pain qol | #415 |
| based chemotherapy | #415 |
| placebo 2 | #415 |
| patient factors | #416 |
| carboplatin patients | #416 |
| oncology neoplasms | #416 |
| platinum agents | #417 |
| prospective pilot | #417 |
| gabapentinoids | #417 |
| delayed | #417 |
| receiving | #418 |
| adjuvant hormonal therapy | #419 |
| nighttime sleep | #419 |
| metastatic breast cancer | #419 |
| case series patients | #419 |
| 0 4 | #419 |
| antiemetic prophylaxis | #420 |
| cancer purpose | #421 |
| controlled pilot | #421 |
| study entry | #421 |
| tcl1a | #421 |
| tamoxifen women | #421 |
| selfreported symptoms | #422 |
| directed therapy | #422 |
| severities | #422 |
| fourth week | #422 |
| pyridones | #423 |
| arm 2 | #423 |
| adequately | #423 |
| 5 trials | #423 |
| neurophysiologic | #424 |
| tamoxifen | #425 |
| androgen ablation | #425 |
| anastrozole | #425 |
| complementary alternative | #426 |
| ongoing clinical trials | #426 |
| prevention vte | #427 |
| baseline 6 weeks | #427 |
| primary peritoneal | #428 |
| treating patients | #428 |
| gain adult | #428 |
| greater percentage | #429 |
| creatine | #429 |
| desipramine | #430 |
| adjectives | #430 |
| detection colorectal | #431 |
| hgb | #431 |
| methodsa | #431 |
| contraindicated | #431 |
| laser therapy | #431 |
| fatigue humans | #431 |
| glycitein | #431 |
| symptom management | #432 |
| diploid tumors | #432 |
| sunscreen | #433 |
| joint symptoms | #433 |
| antiseizure | #433 |
| purpose objectives | #434 |
| resultsone | #434 |
| cancer tamoxifen | #434 |
| 115 patients | #434 |
| oral calcium | #435 |
| 1157 | #436 |
| topic treatment | #436 |
| pains | #436 |
| nutrition cancer | #436 |
| olanzapine treatment | #436 |
| anthracyclinebased chemotherapy | #438 |
| absolute terms | #438 |
| clinical cancer | #438 |
| nodenegative breast cancer | #439 |
| postoperative follow | #440 |
| administration cutaneous | #440 |
| expected survival | #441 |
| diminish | #441 |
| neoplasms cancer | #441 |
| vasomotor | #442 |
| yoga | #442 |
| baseline 1 month | #444 |
| hgpin | #444 |
| receive | #445 |
| screening colorectal | #445 |
| doxorubicin drug administration | #445 |
| life efficacy | #445 |
| loss aged | #445 |
| preoperative breast | #445 |
| agents antineoplastic | #446 |
| marie | #446 |
| day dexamethasone | #447 |
| acid aged | #447 |
| treatment regimen | #447 |
| 2 months | #448 |
| european organization | #448 |
| patients qol | #448 |
| patients weight | #448 |
| climacteric | #449 |
| estrogen therapy | #449 |
| baseline patient | #450 |
| premature discontinuation | #451 |
| baseline 4 weeks | #452 |
| cancer symptoms | #452 |
| study feasibility | #453 |
| outline | #453 |
| arms arm | #454 |
| nodepositive breast cancer | #454 |
| dhea | #455 |
| postmenopause | #455 |
| 5fu patients | #456 |
| geranium | #456 |
| axillary metastases | #457 |
| diphenhydramine | #458 |
| evaluate efficacy | #459 |
| mucositis | #460 |
| patients venous thromboembolism | #461 |
| questionnaires terminology | #461 |
| enforced | #461 |
| helpful | #462 |
| 6 weeks | #462 |
| cytokines patients | #462 |
| patients baseline | #462 |
| increased weight | #463 |
| potential interventions | #463 |
| therapy stage | #464 |
| cancer institute | #468 |
| asco | #468 |
| clin | #468 |
| lung humans | #469 |
| referral centers | #469 |
| radiation enteritis | #469 |
| consensus guideline | #470 |
| sexual distress | #470 |
| purposethis | #471 |
| treatment options patients | #471 |
| esophagitis patients | #471 |
| chemotherapy regimens | #472 |
| new treatment | #473 |
| subscale | #474 |
| 432 | #474 |
| pilocarpine | #474 |
| hormonal replacement therapy | #475 |
| groups 6 months | #475 |
| symptoms menopause | #475 |
| uncertain | #476 |
| appears | #477 |
| single item | #477 |
| preliminary studies | #477 |
| clinical decision making | #478 |
| placebo 24 weeks | #478 |
| iii colon | #479 |
| onco | #479 |
| doubleblind study | #479 |
| 95 placebo | #479 |
| variables age | #479 |
| alopecia | #480 |
| vitamin placebo | #480 |
| enrollment patients | #480 |
| osteoporosis osteopenia | #481 |
| crc 95 | #482 |
| moderatetosevere | #482 |
| higher dose | #483 |
| reluctance | #484 |
| adjuvant therapy | #484 |
| endpoints included | #485 |
| neurotoxicity patients | #485 |
| locoregional disease | #485 |
| tpn | #485 |
| 655 | #486 |
| cure | #486 |
| blind | #488 |
| taqman pcr | #488 |
| induced neuropathic | #489 |
| estrogen deprivation | #491 |
| doselimiting toxicity | #491 |
| pain scores | #491 |
| cancer cardiovascular disease | #492 |
| plant preparations | #493 |
| primary breast | #493 |
| combined modality treatment | #493 |
| narcotics | #494 |
| patients stage disease | #495 |
| decarboxylase activity | #498 |
| dropout rates | #499 |
| fentanyl humans | #500 |
| patients breast cancer | #500 |
| “ ” | #501 |
| received placebo | #501 |
| life questionnaires survivors | #502 |
| kps | #502 |
| placebo‐controlled study | #502 |
| pilot studies | #502 |
| metastatic cancer | #503 |
| loss patients | #504 |
| mesonephroma | #504 |
| chest ray | #505 |
| awaited | #506 |
| survival chemotherapy | #509 |
| pain inventory | #510 |
| smoking nicotine | #511 |
| placebo trial | #511 |
| preventative | #512 |
| breast diseases | #513 |
| therapy aged | #513 |
| trials data | #513 |
| flic | #514 |
| nonmetastatic breast cancer | #514 |
| advance planning acp | #514 |
| evidencebased interventions | #515 |
| letrozole treatment | #516 |
| premature menopause | #516 |
| women receiving | #516 |
| serum albumin levels | #517 |
| outcome antineoplastic | #517 |
| acute diarrhea | #519 |
| achievements | #520 |
| pain medications | #520 |
| eflornithine | #521 |
| cbcs | #521 |
| pharmaceutic | #522 |
| gamma aminobutyric | #522 |
| poorer quality life | #523 |
| mastectomy middle | #525 |
| chills | #525 |
| symptoms fatigue | #525 |
| resultsto | #527 |
| controlled crossover | #528 |
| adverse events placebo | #528 |
| prophylactic therapy | #528 |
| patients clinical trial | #529 |
| abt888 | #529 |
| cmf | #529 |
| phytogenic area | #529 |
| therapy prostate | #530 |
| oncologists | #531 |
| radiodermatitis | #531 |
| pregabalin | #531 |
| centrally | #531 |
| patients vitamin | #532 |
| iii trial | #533 |
| 30 minutes | #534 |
| genitourinary | #535 |
| patients evaluated | #536 |
| medications treatment | #536 |
| antineoplastic agents | #537 |
| superficial bladder | #538 |
| weeks therapy | #538 |
| agents chemotherapy | #538 |
| study week | #538 |
| patients clinical trials | #539 |
| terminally | #540 |
| patients assigned | #541 |
| pharmacologic | #542 |
| pain patients | #543 |
| topic severity | #543 |
| dehydroepiandrosterone | #543 |
| week 6 | #544 |
| risedronic | #544 |
| pain score | #544 |
| 329 | #545 |
| 592 | #546 |
| peripheral | #548 |
| patients scheduled | #548 |
| unable | #549 |
| bmd baseline | #550 |
| receiving adjuvant | #550 |
| differences study | #551 |
| 3 95 | #552 |
| dabrafenib trametinib | #552 |
| axonal transport | #553 |
| hypesthesia | #553 |
| adenomas patients | #554 |
| leucovorin oxaliplatin | #555 |
| neoplasms drug | #556 |
| regular aspirin | #556 |
| co2 laser | #556 |
| dysplastic lesions | #556 |
| evaluable | #556 |
| 300 day | #557 |
| abh | #557 |
| vasomotor symptoms | #559 |
| 80000 | #560 |
| reported outcomes | #560 |
| emesis | #560 |
| rbc transfusions | #560 |
| day treatment | #561 |
| methylphenidate | #561 |
| moisturizer | #561 |
| mesna | #562 |
| lmwh patients | #564 |
| hands | #564 |
| method drug | #565 |
| time detection | #565 |
| induced cold | #565 |
| trial data | #566 |
| treatment periods | #566 |
| survival stage | #567 |
| 4 8 | #567 |
| supportive cancer | #567 |
| 11 months | #568 |
| scientifically | #569 |
| calgb | #569 |
| therapy primary | #569 |
| adjuvant clinical trials | #569 |
| decarboxylase odc | #571 |
| topic treatment outcome | #571 |
| lower dose | #571 |
| bibliometric analysis | #572 |
| paclitaxel patients | #573 |
| fluorouracil oxaliplatin | #578 |
| topical capsaicin | #578 |
| methods systematic review | #580 |
| patients candidates | #580 |
| refute | #580 |
| hwe | #581 |
| treatment phase | #581 |
| paced | #583 |
| breakthrough pain | #583 |
| life questionnaire | #584 |
| paracentesis | #584 |
| desvenlafaxine | #585 |
| moderate correlation | #585 |
| drug toxicity | #587 |
| neoplasms nutritional | #587 |
| paclitaxel carboplatin | #588 |
| limited efficacy | #589 |
| multiple cancers | #589 |
| oxaliplatin patients | #589 |
| aged occult | #589 |
| muscle cramps | #589 |
| emotional functioning | #589 |
| osteopenia | #590 |
| taxane chemotherapy | #590 |
| aminobutyric | #590 |
| acrin | #591 |
| crossover trial | #592 |
| ablation therapy | #592 |
| median time progression | #592 |
| platinum drugs | #593 |
| chemotherapy benefit | #595 |
| compounded | #596 |
| pentoxifylline | #596 |
| exanthema | #597 |
| fatigue female | #597 |
| radiotherapy breast | #597 |
| sst2 | #597 |
| topic depressive disorder | #598 |
| multisite | #598 |
| publication administration | #599 |
| patients mastectomy | #599 |
| initial surgery | #599 |
| thromboembolism vte | #600 |
| effects breast | #600 |
| patients etanercept | #600 |
| discretion | #601 |
| 1093 | #601 |
| health providers | #601 |
| oral solution | #601 |
| statistically differences | #601 |
| patient decision | #601 |
| vte cancer | #602 |
| prevention measures | #602 |
| cfibers | #603 |
| exposed patients | #604 |
| anthracycline based | #604 |
| cancer survivors | #604 |
| toxicity profile | #605 |
| endoxifen | #607 |
| toes | #608 |
| chemotherapy administration | #608 |
| 16 women | #608 |
| agents antidepressive | #609 |
| iron supplementation | #609 |
| management symptoms | #609 |
| agents tricyclic | #611 |
| topic reproducibility | #612 |
| 2 95 | #613 |
| pilot | #613 |
| updated analysis | #614 |
| montanide | #615 |
| animal data | #616 |
| qol baseline | #616 |
| humans quality | #617 |
| 118 patients | #617 |
| commonly | #618 |
| appetite | #620 |
| antacid | #620 |
| aic | #621 |
| persistent symptoms | #621 |
| urinary frequency | #621 |
| follow median | #622 |
| itching | #625 |
| gangliosides humans | #626 |
| analyzable | #626 |
| cisplatin etoposide | #627 |
| life quality | #630 |
| 1 month | #631 |
| iii patients | #632 |
| authors knowledge | #633 |
| biological targets | #634 |
| mistletoe | #634 |
| month patients | #637 |
| female sexual function | #638 |
| assessment cancer | #640 |
| serum hepcidin | #640 |
| dose placebo | #640 |
| eligible | #641 |
| poorer quality | #642 |
| hormonal aromatase | #643 |
| inhibitors breast | #643 |
| prostatic intraepithelial | #644 |
| placebo time | #645 |
| multiple studies | #646 |
| palliative quality | #647 |
| nasal symptoms | #647 |
| 300 patients | #648 |
| malignant melanomas | #648 |
| syndrome acute | #649 |
| symptoms | #649 |
| doses patients | #651 |
| flushes | #651 |
| sores | #651 |
| method humans | #651 |
| appeared | #652 |
| dose limiting | #653 |
| opioid analgesic | #653 |
| limiting toxicity | #653 |
| patients 16 | #655 |
| poms | #657 |
| prior chemotherapy | #658 |
| complete response patients | #659 |
| grade glioma | #660 |
| twentysix patients | #661 |
| patients chemotherapy | #662 |
| colorectal adenocarcinoma | #662 |
| 62 months | #663 |
| 95 − | #665 |
| neoplasms patient | #666 |
| alternative treatments | #666 |
| cancer prospective | #666 |
| active agent | #666 |
| nonparametric surveys | #667 |
| life radiotherapy | #667 |
| levetiracetam | #668 |
| cancer treatments | #668 |
| treatment trials | #669 |
| women chemotherapy | #670 |
| paclitaxel docetaxel | #671 |
| marie tooth | #671 |
| axonopathy | #674 |
| pain adult | #674 |
| p00004 | #674 |
| 1822 | #674 |
| pharmacologic management | #675 |
| maintenance disorders | #675 |
| induced cognitive | #676 |
| racially | #676 |
| patients standard | #678 |
| 5 consecutive | #678 |
| controlled study | #679 |
| routine follow | #680 |
| diethylstilbestrol | #681 |
| reported outcome | #681 |
| purpose report | #682 |
| study samples | #684 |
| highdose melphalan | #685 |
| popularly | #685 |
| oncology practice | #685 |
| deprivation therapy | #686 |
| fluorouracil leucovorin | #687 |
| therapy cancer | #687 |
| neurologic injury | #688 |
| charcot marie | #688 |
| practice settings | #688 |
| sulindac | #688 |
| life survivors | #692 |
| pharmacological targeting | #692 |
| guideline update | #693 |
| rescue medication | #693 |
| phlebitis | #694 |
| administration schedule | #694 |
| randomized treatment | #695 |
| based testing | #698 |
| desmethyl | #699 |
| potential benefits | #699 |
| descriptive statistics | #700 |
| versa | #701 |
| appearing | #702 |
| chemopreventive agent | #704 |
| postmenopausal | #704 |
| v30 | #705 |
| medical oncologists | #706 |
| effective interventions | #707 |
| tens | #709 |
| locoregionally advanced | #710 |
| capecitabine patients | #711 |
| randomized studies | #712 |
| 160 | #712 |
| erythropoiesis stimulating | #712 |
| tube neoplasms | #714 |
| newer agents | #714 |
| prevention cancer | #715 |
| breast magnetic | #716 |
| inflammatory breast | #717 |
| lowmolecularweight heparin | #717 |
| convened | #719 |
| endorsement | #719 |
| ameliorate | #720 |
| data baseline | #722 |
| erythropoietin female | #722 |
| palliative medicine | #725 |
| cyclophosphamide methotrexate | #725 |
| humans neoplasms | #725 |
| 6 months 95 | #725 |
| therapeutic equivalency | #727 |
| physicians predictive | #728 |
| 4 hours | #728 |
| joint pain | #729 |
| patients radiation therapy | #730 |
| odc activity | #731 |
| induced human | #731 |
| study treatment | #731 |
| charcotmarietooth | #732 |
| women undergoing | #733 |
| nucleotide variants | #734 |
| medroxyprogesterone | #735 |
| vinca | #735 |
| adjuvant clinical | #736 |
| secondary prevention | #737 |
| induced neurotoxicity | #738 |
| chemotherapy women | #738 |
| opd | #739 |
| mirtazapine | #741 |
| 4 weeks patients | #742 |
| locoregional therapy | #742 |
| prescribing practices | #742 |
| fist | #744 |
| baseline 1 year | #745 |
| armamentarium | #745 |
| women placebo | #745 |
| patients breast | #747 |
| bone loss | #748 |
| ecog | #748 |
| chemotherapy initiation | #749 |
| trials patients | #749 |
| superficial bladder cancer | #750 |
| 271 | #750 |
| alfa | #750 |
| psychostimulant | #750 |
| cervical dysplasia | #752 |
| rand | #752 |
| compared placebo | #753 |
| complementary medicine | #753 |
| oct2 | #754 |
| radiation skin | #754 |
| 4·2 | #754 |
| antigen levels | #754 |
| 46 | #755 |
| trouble | #755 |
| paclitaxel chemotherapy | #755 |
| secondary points | #755 |
| patients insomnia | #756 |
| metastatic breast | #757 |
| hepcidin levels | #758 |
| reduction pain | #759 |
| local anesthetics | #759 |
| rifngamma | #759 |
| prostate adenocarcinoma | #760 |
| sulfasalazine | #760 |
| additional data | #762 |
| pain quality | #763 |
| ambulatory setting | #765 |
| occult blood | #766 |
| 81 patients | #766 |
| seventy patients | #766 |
| acid 4 | #768 |
| medroxyprogesterone acetate mpa | #768 |
| neoplasms prospective | #768 |
| baseline pain | #769 |
| humans imidazoles | #769 |
| actual | #770 |
| activity breast | #770 |
| sensory neuropathy | #771 |
| breast carcinoma ductal | #772 |
| modified radical mastectomy | #772 |
| sweating | #772 |
| relatedness | #772 |
| premenopausal women | #773 |
| keratinocyte growth factor | #773 |
| women enrolled | #773 |
| primary endpoint | #773 |
| 10 day | #774 |
| emla | #774 |
| fifty patients | #774 |
| patients colon | #774 |
| neoplasms breast | #774 |
| aged peripheral | #775 |
| octreotide treatment | #776 |
| acupuncture therapy | #776 |
| oral administration | #777 |
| 257 | #777 |
| gsm | #778 |
| p00002 | #778 |
| charcot | #778 |
| 137 patients | #781 |
| severity patients | #782 |
| menopausal symptoms | #783 |
| agents phytogenic | #784 |
| cutaneous administration | #785 |
| benefits patients | #785 |
| skin conductance | #785 |
| prognostic survival | #787 |
| enoxaparin | #788 |
| management | #788 |
| symptom experience | #791 |
| anesthetics local | #792 |
| women reported | #793 |
| subsequent cycles | #793 |
| colon rectal cancer | #796 |
| baseline period | #797 |
| estrogen levels | #798 |
| potential treatments | #798 |
| neuralgia pain | #801 |
| clinical questions | #801 |
| life outcomes | #801 |
| osteoporosis women | #802 |
| erythropoiesisstimulating agents | #802 |
| day 3 | #804 |
| lack efficacy | #804 |
| randomized phase trial | #804 |
| glutathione | #805 |
| primary points | #805 |
| double | #806 |
| effects patients | #806 |
| 894 | #807 |
| opioid analgesia | #807 |
| 80 antineoplastic | #808 |
| continue | #808 |
| placebotreated patients | #808 |
| etoposide cisplatin | #808 |
| 3 day | #808 |
| 0025 | #809 |
| complete response | #811 |
| abrogate | #812 |
| odc | #812 |
| previous reports | #816 |
| mild symptoms | #817 |
| disease genes | #818 |
| lorazepam | #819 |
| agents clinical | #820 |
| eastern cooperative | #820 |
| etoposide patients | #823 |
| randomly | #824 |
| tolerated | #826 |
| statisticians | #826 |
| 148 patients | #827 |
| cancer control | #828 |
| rasch model | #828 |
| suggestive | #830 |
| administration oral | #830 |
| placebo 6 months | #830 |
| cancer phase | #830 |
| dabrafenib | #832 |
| neoplasms bone | #832 |
| subset analysis | #833 |
| humans medical | #833 |
| similarities differences | #835 |
| 366 | #836 |
| advanced malignancies | #836 |
| mandelic | #837 |
| prognosis quality | #837 |
| numeric | #838 |
| eventual | #844 |
| breast neoplasms | #845 |
| herbal products | #846 |
| adverse events aes | #846 |
| p006 | #847 |
| 142 patients | #848 |
| global qol | #848 |
| detection rates | #849 |
| eortc | #850 |
| toxicities | #850 |
| taxol | #851 |
| prostate cancer patients | #852 |
| oncotype | #853 |
| n55 | #853 |
| stage ovarian | #853 |
| palliative services | #855 |
| daily dosing | #858 |
| taxoids | #859 |
| vaginal bleeding | #859 |
| assessment management | #859 |
| published data | #860 |
| stratification patients | #860 |
| strongest | #864 |
| etidronic | #866 |
| placebo baseline | #868 |
| unacceptable | #868 |
| patients trial | #868 |
| efficacious | #873 |
| jellies | #873 |
| peritoneal cancer | #874 |
| treatment completion | #875 |
| timepoints | #878 |
| 5ht3 | #879 |
| nonpharmacological interventions | #880 |
| symptomatic women | #880 |
| phytogenic carcinoma | #880 |
| midlife women | #881 |
| 450 | #883 |
| study placebo | #883 |
| antineoplastic | #883 |
| monoclonal antineoplastic agents | #885 |
| neurotoxic | #889 |
| mitigates | #889 |
| topic female | #890 |
| monoclonal female humans | #891 |
| data article | #892 |
| concomitant chemotherapy | #893 |
| cancer guidelines | #894 |
| caa | #894 |
| control arm | #896 |
| completed | #900 |
| oxy | #901 |
| neoplasms hormone | #901 |
| women hormone | #902 |
| nodal status | #903 |
| percent | #903 |
| inconvenience | #903 |
| nmsc | #904 |
| provided | #905 |
| survival surgery | #905 |
| chemotherapy response | #905 |
| 00006 | #905 |
| hospices | #909 |
| chemotherapeutic | #910 |
| increased risk death | #910 |
| cancer studies | #913 |
| national cancer | #914 |
| weight maintenance | #914 |
| norepinephrine reuptake | #915 |
| paroxetine | #916 |
| life cancer patients | #916 |
| gynecomastia | #918 |
| prospective pilot study | #919 |
| cycle chemotherapy | #920 |
| advanced cancer patients | #921 |
| mouth mucosa | #921 |
| evidence practice | #923 |
| population cohort | #924 |
| manuscripts | #924 |
| illness female humans | #925 |
| primary objectives | #926 |
| chemotherapy study | #927 |
| upper extremities | #929 |
| oral dosing | #929 |
| lasa | #930 |
| oncol | #931 |
| starting | #932 |
| fluoxetine | #933 |
| minocycline | #935 |
| cytotoxic therapy | #937 |
| day placebo | #938 |
| electronic health record | #939 |
| serotonin uptake | #939 |
| treatment symptoms | #940 |
| visual analogue | #940 |
| 138 patients | #942 |
| uptake inhibitors | #943 |
| high‐risk | #943 |
| advanced adenoma | #943 |
| letter editor | #944 |
| colorectal adenomas | #944 |
| patient population | #944 |
| gp100 | #945 |
| iii topic | #945 |
| beckman | #945 |
| 1year survival | #946 |
| fluorouracil | #948 |
| arm patients | #949 |
| natural menopause | #951 |
| recurrence score | #952 |
| compare | #953 |
| jci | #954 |
| orally | #954 |
| evaluating | #955 |
| participating centers | #955 |
| cooperative oncology | #957 |
| adjuvant therapies | #958 |
| hfs | #958 |
| rheumatologic | #958 |
| aloe vera | #958 |
| leukopenia | #959 |
| erythropoietic | #959 |
| moderately | #961 |
| monoclonal carcinoma | #962 |
| trpm8 | #963 |
| pjnk | #963 |
| received adjuvant | #964 |
| serum cytokine | #966 |
| menopause | #968 |
| 1160 | #969 |
| mart1 | #970 |
| earlystage disease | #972 |
| table | #972 |
| randomized pilot | #973 |
| gluconate | #976 |
| olmsted county | #977 |
| restarted | #977 |
| 1 10 | #978 |
| hypercalcemia | #978 |
| mechanical allodynia | #980 |
| 1month | #980 |
| 2700 | #982 |
| 150 | #984 |
| 1 week | #984 |
| antidotes | #984 |
| threequarters | #989 |
| patients venous | #989 |
| adjuvant | #992 |
| pain reduction | #993 |
| multiple logistic regression | #997 |
| analyses data | #998 |
| mayo | #1003 |
| bother | #1003 |
| cancer chemoprevention | #1005 |
| publication analgesics | #1007 |
| 71 | #1010 |
| continued | #1014 |
| patients metastatic disease | #1015 |
| organ systems | #1016 |
| neurocutaneous | #1018 |
| anthraquinones | #1019 |
| patients mri | #1020 |
| reported pain | #1021 |
| life symptoms | #1023 |
| trial participation | #1026 |
| 145 patients | #1027 |
| fatigue patients | #1028 |
| enteritis | #1028 |
| urogenital | #1030 |
| alternative treatment | #1031 |
| delayed treatment | #1031 |
| pill | #1037 |
| evidence treatment | #1037 |
| ” “ | #1038 |
| androgen deprivation therapy | #1042 |
| validity responsiveness | #1043 |
| prx | #1044 |
| postural control | #1044 |
| randomized trial patients | #1046 |
| colorectal tumor | #1047 |
| prevention intervention | #1047 |
| patients safety | #1047 |
| substantial | #1050 |
| frey | #1051 |
| nutritional supplementation | #1051 |
| 30 40 | #1053 |
| life | #1053 |
| doxorubicin female humans | #1056 |
| postchemotherapy | #1056 |
| minority | #1057 |
| feeding eating | #1059 |
| primary analysis | #1059 |
| osteoporosis treatment | #1059 |
| 10 weeks | #1060 |
| day study | #1061 |
| tricyclic | #1061 |
| prospective validation | #1063 |
| oncologist | #1063 |
| fruitful | #1063 |
| endocrine resistance | #1064 |
| 347 | #1064 |
| loss weight | #1066 |
| ongoing studies | #1066 |
| therapy | #1069 |
| disappointing | #1069 |
| suggested | #1069 |
| practical guidance | #1070 |
| metastatic lung | #1070 |
| descriptive | #1073 |
| tobacco dependence | #1075 |
| nccn | #1078 |
| monoclonal humans | #1078 |
| concurrent chemotherapy | #1078 |
| women treatment | #1079 |
| placebo day | #1080 |
| patients bone metastases | #1081 |
| women received | #1083 |
| advance planning | #1084 |
| placebo participants | #1085 |
| prompted | #1089 |
| breast cancer recurrence | #1089 |
| duloxetine | #1089 |
| patients adjuvant therapy | #1090 |
| low intermediate | #1091 |
| prospective multicenter study | #1092 |
| progestogens | #1094 |
| palonosetron | #1095 |
| postoperative surveillance | #1095 |
| adult breast | #1097 |
| 25 day | #1098 |
| intravenous iron | #1099 |
| favor | #1099 |
| previous chemotherapy | #1100 |
| agents treatment | #1100 |
| functional ability | #1100 |
| 54 | #1103 |
| phytoestrogens | #1103 |
| prospective trial | #1106 |
| peripheral neuropathies | #1108 |
| acknowledged | #1110 |
| 3 6 months | #1112 |
| transdermal | #1114 |
| randomized | #1115 |
| 1 year treatment | #1116 |
| prevention trials | #1119 |
| treatment life | #1121 |
| life death | #1122 |
| inhaler | #1124 |
| interprofessional relations | #1126 |
| cancer trials | #1126 |
| dmc | #1127 |
| unpleasant | #1127 |
| prilocaine | #1127 |
| based evidence | #1128 |
| mexiletine | #1129 |
| participants received | #1131 |
| patients versus | #1133 |
| clinician | #1133 |
| sunscreening | #1136 |
| lecithins | #1137 |
| opioid therapy | #1139 |
| 25 micrograms | #1139 |
| hormonal therapy | #1140 |
| practice guideline | #1140 |
| cancer | #1141 |
| purposeto | #1144 |
| inhibit | #1144 |
| randomized crossover | #1146 |
| egb | #1146 |
| cancer pain | #1146 |
| locoregionally | #1147 |
| illness surveys | #1148 |
| taste disorders | #1149 |
| premature ovarian failure | #1150 |
| shark | #1150 |
| purpose determine | #1150 |
| 730 | #1153 |
| nervousness | #1153 |
| smoking prevention | #1154 |
| hormonal | #1154 |
| detrimental | #1154 |
| flecainide | #1157 |
| 325 | #1159 |
| 481 | #1161 |
| 22 | #1162 |
| rinse | #1162 |
| doac | #1163 |
| educate | #1164 |
| toxicity assessment | #1167 |
| purposethis study | #1167 |
| comparative efficacy | #1172 |
| ceramides | #1173 |
| painful | #1174 |
| therapy estrogens | #1174 |
| intervention trials | #1175 |
| receptor modulators | #1176 |
| patients syndrome | #1177 |
| clinical trial | #1178 |
| inadequately | #1179 |
| projects | #1180 |
| lowest risk | #1181 |
| chemotherapy regimen | #1182 |
| chose | #1184 |
| aged prostatic | #1185 |
| growing population | #1186 |
| physician patient | #1187 |
| electrostimulation | #1188 |
| prior treatment | #1189 |
| international consensus | #1189 |
| mastectomy breast | #1190 |
| acetate treatment | #1190 |
| usage | #1193 |
| gained | #1196 |
| olmsted | #1197 |
| diary | #1197 |
| estrogen replacement therapy | #1197 |
| experiencing | #1198 |
| alternative therapies | #1200 |
| caregivers patients | #1202 |
| male smokers | #1204 |
| 552 | #1204 |
| partial responses | #1204 |
| panax | #1205 |
| clinical trials patients | #1207 |
| magnesium | #1208 |
| breast cancer | #1212 |
| satisfied | #1212 |
| induced skin | #1213 |
| 611 | #1215 |
| patients pts | #1215 |
| communication skills | #1215 |
| likert | #1217 |
| adjuvant endocrine | #1218 |
| precludes | #1219 |
| sexuality | #1219 |
| secondary endpoints | #1219 |
| 8 week | #1221 |
| phase clinical trial | #1223 |
| higher numbers | #1223 |
| limiting | #1224 |
| editor | #1227 |
| thighs | #1227 |
| participants reported | #1229 |
| organogel | #1230 |
| 8 weeks | #1232 |
| primary melanomas | #1232 |
| 52 | #1233 |
| n54 | #1234 |
| discontinue | #1235 |
| randomized phase | #1235 |
| clinical syndrome | #1241 |
| tricyclic antidepressants | #1241 |
| baseline values | #1245 |
| symptoms diagnosis | #1248 |
| review data | #1248 |
| day 2 | #1248 |
| decided | #1249 |
| female sexual | #1250 |
| etiologies | #1250 |
| postmenopausal women | #1252 |
| bedtime | #1252 |
| il1β tnfα | #1253 |
| estrogens female | #1255 |
| diarrhea patients | #1257 |
| diphosphonates | #1258 |
| combination docetaxel | #1258 |
| thromboembolism patients | #1258 |
| hypochromic | #1259 |
| trametinib | #1259 |
| patients 4 | #1259 |
| rasch | #1260 |
| kidney dysfunction | #1260 |
| pain medication | #1261 |
| neurologic humans | #1263 |
| doubts | #1263 |
| tumor promotion | #1265 |
| dna ploidy | #1265 |
| esophagitis | #1266 |
| sae | #1266 |
| protocols chemotherapy | #1268 |
| magnesium oxide | #1270 |
| phytotherapy | #1271 |
| qol scores | #1272 |
| drug double | #1272 |
| situ carcinoma ductal | #1273 |
| short form36 | #1273 |
| patients families | #1274 |
| preoperative chemotherapy | #1274 |
| preclude | #1276 |
| cutaneous melanomas | #1278 |
| taxanes | #1279 |
| tamoxifen patients | #1279 |
| median ttp | #1280 |
| dosing interval | #1281 |
| heparin lmwh | #1282 |
| label trial | #1284 |
| male medication adherence | #1285 |
| medical oncology | #1286 |
| adjuvant tamoxifen | #1287 |
| opposed | #1289 |
| adjuvant therapy patients | #1289 |
| cyclophosphamide doxorubicin | #1289 |
| folfox | #1291 |
| 109 patients | #1292 |
| acupuncture treatment | #1294 |
| cochran | #1294 |
| data clinical | #1296 |
| prevalence severity | #1296 |
| antimetabolites antineoplastic | #1297 |
| neurosensory | #1298 |
| neoplasms disease | #1300 |
| emetic | #1301 |
| women cancer | #1303 |
| abstinent | #1307 |
| 8 cycles | #1307 |
| stimulating agents | #1309 |
| survival 5 | #1310 |
| motion rom | #1310 |
| critical review | #1312 |
| sportdiscus | #1313 |
| gynecologic cancers | #1314 |
| melanoma antigen | #1315 |
| gsh | #1315 |
| biotech | #1315 |
| breast biopsy | #1317 |
| durations | #1318 |
| contacted | #1318 |
| etanercept | #1320 |
| health‐related quality | #1320 |
| investigative | #1321 |
| chemotherapeutic agents | #1321 |
| oncology patients | #1321 |
| controlled | #1321 |
| primary outcome measure | #1322 |
| patients quality | #1322 |
| pain interference | #1322 |
| ointments | #1323 |
| nerve damage | #1326 |
| appetite loss | #1327 |
| patient physician | #1328 |
| life scores | #1328 |
| cardiac toxicity | #1329 |
| agents colorectal | #1329 |
| life surveys | #1337 |
| adjuvant breast | #1339 |
| 375 | #1340 |
| published reports | #1341 |
| evenly | #1342 |
| 2 week | #1345 |
| ambulatory monitoring | #1346 |
| platinum compounds | #1347 |
| breast cancer women | #1347 |
| colonoscopic | #1350 |
| experienced | #1350 |
| tibolone | #1351 |
| karnofsky | #1352 |
| benefit patients | #1353 |
| cancer experience | #1353 |
| malignant ascites | #1354 |
| carcinoembryonic | #1356 |
| period patients | #1358 |
| eligibility criteria | #1359 |
| wks | #1360 |
| agents cancer | #1367 |
| effects treatment | #1368 |
| attribution | #1369 |
| postural balance | #1372 |
| continues | #1376 |
| combination female humans | #1377 |
| hopes | #1379 |
| titrated | #1381 |
| n29 | #1382 |
| patients colon cancer | #1382 |
| n32 | #1382 |
| duplicates | #1386 |
| mastectomy | #1387 |
| hydrazines | #1387 |
| snvs | #1388 |
| patients 40 | #1391 |
| femoral neck bmd | #1396 |
| medical literature | #1397 |
| ajcc | #1399 |
| cancer adult | #1400 |
| cancer therapies | #1403 |
| pain neuropathic | #1404 |
| somnolence | #1406 |
| polyneuropathies | #1407 |
| rifn | #1407 |
| replete | #1408 |
| physical activity level | #1410 |
| treats | #1411 |
| integrative medicine | #1412 |
| fisher test | #1415 |
| viscum | #1416 |
| wilcoxon | #1416 |
| combination chemotherapy | #1417 |
| cessation treatment | #1418 |
| quality life | #1420 |
| treatment recommendations | #1423 |
| subjective symptoms | #1424 |
| noncompliance | #1424 |
| sleep initiation | #1424 |
| biloba | #1425 |
| methodsdata | #1426 |
| therapy initiation | #1426 |
| cancer quality life | #1427 |
| prevent | #1427 |
| cytotoxic chemotherapy | #1428 |
| aromatase | #1431 |
| hormonal treatment | #1431 |
| and or | #1432 |
| 5fu | #1433 |
| weight heparin | #1433 |
| radiation injuries | #1434 |
| statistically difference | #1434 |
| daily intake | #1435 |
| primary objective | #1437 |
| caloric intake | #1439 |
| adults cancer | #1440 |
| female humans illness | #1442 |
| goserelin | #1445 |
| proctitis | #1445 |
| aminobutyric acid | #1446 |
| postacute | #1447 |
| ehrs | #1447 |
| cancer clinical trials | #1449 |
| incidences | #1449 |
| assigning | #1450 |
| coulter | #1453 |
| treatment pain | #1454 |
| patients ovarian | #1454 |
| nccn guidelines | #1454 |
| infliximab | #1455 |
| cognitive testing | #1456 |
| bruising | #1457 |
| hrqol | #1458 |
| 63 | #1459 |
| individual patients | #1461 |
| dna testing | #1461 |
| effective management | #1461 |
| adjuvant treatment | #1463 |
| life cancer | #1466 |
| aged quality | #1466 |
| haloperidol humans | #1467 |
| network meta | #1467 |
| discrepancies | #1467 |
| crossover | #1468 |
| nutritional support | #1469 |
| locally advanced head | #1469 |
| physical activity patients | #1470 |
| recurrent vte | #1475 |
| hormone dependent | #1477 |
| life treatment | #1477 |
| resultsa | #1479 |
| substantial proportion | #1479 |
| lower extremities | #1483 |
| oral aged | #1484 |
| tumor promoter | #1484 |
| pik3ca mutation | #1485 |
| aromatase inhibitors | #1492 |
| nrs | #1493 |
| cancer society | #1494 |
| ongoing | #1495 |
| systemic chemotherapy | #1498 |
| mood states | #1499 |
| planned | #1500 |
| paclitaxel cisplatin | #1501 |
| resultsafter | #1501 |
| mpa | #1509 |
| anti anxiety | #1510 |
| colon cancer patients | #1510 |
| perimenopause | #1513 |
| gynecologic cancer | #1513 |
| premalignant | #1514 |
| neuropeptide npy | #1518 |
| bowel function | #1520 |
| efficacy | #1523 |
| hair loss | #1523 |
| biweekly | #1523 |
| p0024 | #1525 |
| diagnosed cancer | #1525 |
| root ganglion | #1526 |
| oncology | #1526 |
| 3 weeks | #1528 |
| interfered | #1530 |
| balanced | #1532 |
| gastrointestinal toxicity | #1533 |
| cck8 | #1537 |
| cytotoxic agents | #1537 |
| survivors | #1538 |
| physical examination | #1542 |
| cycle patients | #1546 |
| warranted | #1548 |
| guideline recommendations | #1549 |
| tamoxifen treatment | #1550 |
| treatment induced | #1556 |
| adult cancer | #1560 |
| male breast | #1562 |
| blind randomized | #1562 |
| pounds | #1567 |
| transfusion requirements | #1568 |
| design considerations | #1569 |
| response rates | #1572 |
| or1 | #1574 |
| pharmacologic treatment | #1576 |
| iii disease | #1576 |
| 5 day | #1579 |
| bibliographies | #1580 |
| rivaroxaban | #1583 |
| crushed | #1583 |
| patients small | #1583 |
| rate survival | #1584 |
| vaginal | #1587 |
| prospective trials | #1588 |
| postmenopausal breast | #1589 |
| updates | #1590 |
| image body | #1593 |
| dissent | #1593 |
| phase iii study | #1595 |
| localized disease | #1599 |
| trpa1 | #1600 |
| stratification | #1600 |
| therapy cyclophosphamide | #1602 |
| completion | #1603 |
| aged cross | #1603 |
| advanced colorectal cancer | #1604 |
| disagreements | #1605 |
| modafinil | #1606 |
| allopurinol | #1608 |
| ≥70 | #1611 |
| bid | #1612 |
| dosing | #1619 |
| aged antineoplastic | #1620 |
| accrual | #1623 |
| oncology nursing | #1624 |
| 970 | #1624 |
| dna markers | #1626 |
| cream | #1627 |
| 176 | #1628 |
| prophylactic treatment | #1629 |
| tumor type | #1633 |
| 227 | #1634 |
| vte | #1636 |
| upfront | #1637 |
| potential channels | #1642 |
| respiratory depression | #1643 |
| combined modality therapy | #1649 |
| cardiovascular toxicity | #1650 |
| 49 | #1651 |
| controlled phase | #1652 |
| 2003 | #1652 |
| monthly | #1656 |
| cancer stage | #1660 |
| current treatment | #1661 |
| limited data | #1663 |
| pelvic radiotherapy | #1664 |
| referencing | #1666 |
| breast cancer patients | #1667 |
| populationbased cohort | #1667 |
| evaluation female | #1670 |
| treated breast | #1676 |
| patient preference | #1679 |
| therapy hrt | #1680 |
| ovid medline | #1682 |
| hb | #1683 |
| agents carcinoma | #1687 |
| blood tests | #1689 |
| publication attitude | #1691 |
| neoplasms practice | #1693 |
| anticancer therapy | #1693 |
| weight patients | #1694 |
| percent patients | #1695 |
| stopping | #1695 |
| ≤2 | #1696 |
| methyldopa | #1696 |
| patients bone | #1698 |
| nootropic | #1698 |
| randomization | #1698 |
| morpholines | #1700 |
| patients control | #1701 |
| symptom distress | #1701 |
| endpoint | #1703 |
| enrolled patients | #1705 |
| glutamine | #1705 |
| reported symptoms | #1706 |
| study groups | #1707 |
| chisquare | #1708 |
| chemotherapy patients | #1709 |
| 595 | #1709 |
| endocrine treatment | #1711 |
| incorrectly | #1714 |
| inhibitor therapy | #1715 |
| crossover study | #1716 |
| hyperalgesia male | #1717 |
| antineoplastic agents carcinoma | #1719 |
| interventions patients | #1720 |
| human epidermal | #1726 |
| effects cancer | #1726 |
| referral consultation | #1728 |
| selective estrogen | #1728 |
| 652 | #1729 |
| testosterone treatment | #1729 |
| nineteen | #1730 |
| orchiectomy | #1731 |
| neuropathic pain | #1731 |
| lmwh | #1738 |
| paucity | #1740 |
| life questionnaires | #1741 |
| p450 cyp2d6 | #1746 |
| topical | #1746 |
| oxcarbazepine | #1749 |
| ≥10 | #1749 |
| scores patients | #1751 |
| fifty | #1752 |
| recommendations patients | #1753 |
| unique challenges | #1754 |
| neoplasms early | #1754 |
| insufficient evidence | #1762 |
| greater reduction | #1762 |
| treatment data | #1762 |
| cramps | #1764 |
| fall risk | #1765 |
| grade 2 | #1766 |
| massage | #1766 |
| progression survival | #1770 |
| anticoagulants doacs | #1772 |
| urinary symptoms | #1775 |
| performance status | #1779 |
| clinical endpoints | #1781 |
| 95 0 | #1781 |
| objective responses | #1784 |
| fingers | #1784 |
| behavioral interventions | #1785 |
| lignans | #1785 |
| pros | #1787 |
| dizziness | #1789 |
| facts | #1790 |
| survival outcomes patients | #1791 |
| anorectic | #1791 |
| life assessment | #1791 |
| drug therapy | #1792 |
| rbc transfusion | #1794 |
| transient receptor | #1795 |
| primary therapy | #1796 |
| alternative medicine | #1796 |
| descriptive analysis | #1798 |
| decision aids | #1800 |
| investigator | #1802 |
| treatment cycles | #1803 |
| acetylcarnitine | #1803 |
| median survival time | #1804 |
| severe toxicity | #1804 |
| supporting | #1805 |
| premenopause | #1807 |
| adjunct | #1808 |
| analgesic efficacy | #1811 |
| topic | #1812 |
| 16 patients | #1813 |
| agents female | #1813 |
| breast surgery | #1816 |
| trpm | #1818 |
| evidencebased recommendations | #1818 |
| ql | #1821 |
| receptor potential | #1822 |
| cancer women | #1823 |
| 327 | #1823 |
| effective therapy | #1825 |
| evaluable patients | #1825 |
| anxiety agents | #1827 |
| humans neoplasm | #1831 |
| ganglion neurons | #1831 |
| neoplasms prognosis | #1835 |
| longterm survival patients | #1835 |
| suffering | #1836 |
| menopausal transition | #1837 |
| administration topical | #1849 |
| active cancer | #1850 |
| months 12 | #1851 |
| comprehensive cancer | #1851 |
| 23 months | #1853 |
| patients prognosis | #1853 |
| neuropathic | #1853 |
| dermatological | #1853 |
| providers patients | #1857 |
| aged postmenopause | #1858 |
| cancer types | #1858 |
| initial dose | #1858 |
| rationale design | #1863 |
| antimitotic | #1864 |
| univariate analyses | #1867 |
| antimetabolites | #1871 |
| europe female humans | #1873 |
| humans pain | #1873 |
| secondary objective | #1876 |
| continuing | #1877 |
| vice | #1878 |
| induced pain | #1879 |
| resultsa total | #1879 |
| antigen colorectal | #1881 |
| analysis adult | #1881 |
| musculoskeletal pain | #1881 |
| leucovorin male | #1886 |
| galvanic | #1887 |
| weeks | #1888 |
| 15 weeks | #1890 |
| questionnaires time | #1891 |
| keratinocyte | #1891 |
| schedules | #1891 |
| mainstay | #1892 |
| sexual functioning | #1893 |
| hospice | #1896 |
| triazoles | #1897 |
| sensory motor | #1898 |
| problematic | #1899 |
| stellate | #1899 |
| psqi | #1903 |
| topic surveys | #1910 |
| treatment modality | #1911 |
| neuropeptide | #1913 |
| evidence recommendations | #1918 |
| serum cortisol | #1922 |
| creams | #1924 |
| unwanted | #1928 |
| symptoms women | #1933 |
| pain | #1940 |
| prematurely | #1946 |
| health personnel attitude | #1946 |
| patients prostate cancer | #1949 |
| 5year followup | #1950 |
| treatment trial | #1951 |
| peritoneal neoplasms | #1952 |
| imidazoles | #1953 |
| cancer survivorship | #1955 |
| diagnosed breast | #1956 |
| cannabidiol | #1964 |
| signed | #1966 |
| nipple | #1969 |
| iii breast | #1971 |
| primary aim | #1971 |
| warrant | #1972 |
| articles | #1974 |
| surveillance colonoscopy | #1974 |
| initiating | #1975 |
| clinical patients | #1978 |
| estrogen replacement | #1978 |
| hand foot | #1979 |
| intravaginal | #1982 |
| collaborative | #1982 |
| dose melphalan | #1983 |
| controlled trial | #1985 |
| wasting syndrome | #1989 |
| androgen antagonists | #1994 |
| cancer patient | #1994 |
| current treatments | #2002 |
| stool samples | #2004 |
| patients dose | #2005 |
| effective therapies | #2011 |
| dose reductions | #2012 |
| gastrointestinal neoplasms | #2017 |
| phytotherapy plant | #2018 |
| form36 | #2018 |
| fallopian tube | #2019 |
| topic clinical trials | #2022 |
| steroidal aspirin | #2023 |
| critics | #2025 |
| perimenopausal | #2025 |
| neuromuscular diseases | #2026 |
| cardiotoxicity | #2029 |
| testing patients | #2031 |
| patients arm | #2032 |
| outpatient visits | #2034 |
| doses | #2036 |
| eortc qlqc30 | #2038 |
| transcutaneous | #2041 |
| exercise interventions | #2042 |
| recurrence survival | #2044 |
| dnr | #2045 |
| functional impairment | #2046 |
| breast cancer treatment | #2047 |
| evidence base | #2056 |
| status patients | #2056 |
| concentration time | #2058 |
| doxorubicin female | #2059 |
| 35 patients | #2063 |
| antibodies monoclonal antibodies | #2064 |
| head neck cancers | #2065 |
| chest | #2066 |
| cancer population | #2069 |
| relaxation therapy | #2069 |
| 120 patients | #2070 |
| contention | #2073 |
| inhibitor treatment | #2074 |
| daily | #2075 |
| safety pharmacokinetics | #2075 |
| hb level | #2075 |
| vinblastine | #2076 |
| 50 reduction | #2076 |
| nk1 | #2077 |
| benefit | #2080 |
| methysergide | #2081 |
| 20 day | #2082 |
| iii | #2087 |
| younger women | #2087 |
| patients caregivers | #2088 |
| advanced cancers | #2090 |
| nursing practice | #2090 |
| antidote | #2090 |
| major bleeding | #2094 |
| cco | #2094 |
| 66 years | #2097 |
| weekly paclitaxel | #2097 |
| anticonvulsants | #2102 |
| density bone | #2103 |
| mcg | #2104 |
| mitomycins | #2107 |
| therapy chemotherapy | #2109 |
| eicosapentaenoic acid | #2110 |
| tmt | #2111 |
| orally administered | #2111 |
| menopausal status | #2113 |
| day 1 | #2114 |
| 65 | #2115 |
| ≥2 | #2121 |
| bmd lumbar spine | #2121 |
| 5fluorouracil | #2122 |
| 96 patients | #2124 |
| treatment study | #2124 |
| journals | #2125 |
| hb levels | #2126 |
| mildly | #2126 |
| ttr | #2127 |
| bpi | #2128 |
| hormone concentrations | #2129 |
| hepcidins | #2130 |
| neoplasms clinical | #2133 |
| osteolytic | #2135 |
| secondary objectives | #2136 |
| egfr inhibitors | #2136 |
| 525 | #2136 |
| concerned | #2136 |
| aggressive disease | #2140 |
| qol | #2142 |
| levamisole | #2150 |
| tolerable | #2153 |
| carcinoembryonic antigen | #2154 |
| regimens | #2157 |
| item | #2158 |
| prt | #2160 |
| preventive strategies | #2161 |
| baseline | #2166 |
| evidence efficacy | #2166 |
| anemic | #2169 |
| treatment acute | #2169 |
| aloe | #2175 |
| women | #2177 |
| pain syndromes | #2179 |
| album | #2179 |
| worst | #2179 |
| tosyl | #2181 |
| physician | #2182 |
| detailed description | #2185 |
| fatigue pain | #2188 |
| 44 patients | #2195 |
| nervous | #2197 |
| severe symptoms | #2204 |
| questionnaires survivors | #2207 |
| 455 | #2208 |
| dose intensity | #2208 |
| female head | #2210 |
| prescription drugs | #2210 |
| age race | #2210 |
| 1 7 | #2212 |
| ensuing | #2213 |
| hypnosis | #2213 |
| weight loss | #2214 |
| recurrences | #2220 |
| 1–4 | #2220 |
| cmt | #2224 |
| adenosyl | #2225 |
| premenopausal | #2226 |
| myalgia | #2233 |
| osteonecrosis jaw | #2235 |
| 9 weeks | #2235 |
| 138 | #2242 |
| 60 minutes | #2243 |
| adrenal axis | #2247 |
| failed | #2247 |
| patient populations | #2251 |
| dermatologic | #2256 |
| life severity | #2257 |
| preliminary evidence | #2262 |
| summarized | #2265 |
| exercise female humans | #2266 |
| clinically meaningful | #2270 |
| patients metastatic melanoma | #2271 |
| 566 | #2272 |
| differences patients | #2273 |
| irritation | #2277 |
| bioelectrical impedance | #2284 |
| 1 year patients | #2285 |
| oophorectomy | #2285 |
| occult | #2288 |
| metastatic melanoma | #2290 |
| osteoporosis postmenopausal | #2291 |
| sloan | #2292 |
| gastrointestinal cancer | #2293 |
| likewise | #2298 |
| 800 | #2299 |
| therapy adt | #2301 |
| life illness | #2301 |
| regular | #2302 |
| dysfunction physiological | #2303 |
| incisional | #2308 |
| future trials | #2309 |
| polymerase inhibitors | #2310 |
| conclusionthe | #2310 |
| patch | #2311 |
| recommendation | #2311 |
| cramp | #2312 |
| genetic variations | #2314 |
| therapeutic strategies | #2320 |
| topic risk | #2326 |
| baclofen | #2327 |
| 74 | #2327 |
| weight breast | #2328 |
| worse | #2329 |
| burning | #2333 |
| 36 | #2333 |
| mastectomy segmental | #2333 |
| toxicity | #2334 |
| modest | #2334 |
| subcutaneously | #2335 |
| receptor positive | #2337 |
| exclusion criteria | #2338 |
| week | #2342 |
| opioid analgesics | #2347 |
| society | #2347 |
| improve quality | #2349 |
| androgen deprivation | #2349 |
| curve analysis | #2352 |
| 46 patients | #2352 |
| endorsed | #2357 |
| adult antineoplastic | #2359 |
| density bmd | #2365 |
| cyp2d6 | #2365 |
| increased risks | #2367 |
| baseline treatment | #2367 |
| nonrandomized | #2371 |
| 669 | #2373 |
| agent | #2374 |
| bibliometric | #2375 |
| rom | #2378 |
| health practice guidelines | #2379 |
| taste | #2389 |
| cancer clinical | #2390 |
| ornithine | #2391 |
| treatment duration | #2393 |
| difference 95 | #2396 |
| justification | #2397 |
| neoplasms survival | #2399 |
| neurological complications | #2400 |
| counteract | #2405 |
| 266 | #2405 |
| titles | #2406 |
| inadequate | #2407 |
| treatment baseline | #2407 |
| remaining patients | #2412 |
| postural | #2418 |
| rectal cancer patients | #2419 |
| poor performance | #2419 |
| ovid | #2420 |
| documenting | #2421 |
| advanced prostate cancer | #2425 |
| 5 patients | #2425 |
| symptom scores | #2426 |
| limited evidence | #2426 |
| debate | #2433 |
| 761 | #2436 |
| practiced | #2437 |
| 71 patients | #2437 |
| estrogen deficiency | #2439 |
| patients crc | #2439 |
| response evaluation | #2442 |
| acupuncture | #2442 |
| outpatient treatment | #2443 |
| phase trials | #2449 |
| 56 years | #2452 |
| chemotherapy adjuvant | #2453 |
| receptor antagonist | #2460 |
| common cancers | #2462 |
| iiic | #2463 |
| common adverse | #2464 |
| factor inhibitors | #2469 |
| assessment scale | #2469 |
| 207 | #2474 |
| fallopian | #2474 |
| patients quality life | #2477 |
| weight gain | #2478 |
| bleomycin | #2480 |
| guidelines patients | #2481 |
| practical approach | #2485 |
| network metaanalysis | #2491 |
| crossed | #2493 |
| approached | #2494 |
| melanomas | #2495 |
| raloxifene | #2496 |
| discontinuing | #2497 |
| 6 patients | #2502 |
| sexual function | #2507 |
| ginkgo | #2510 |
| 61 | #2510 |
| locoregional | #2510 |
| patients colorectal cancer | #2519 |
| children cancer | #2524 |
| topic clinical | #2526 |
| venous thromboembolism | #2527 |
| regimen | #2531 |
| cooperative | #2537 |
| asked | #2542 |
| amitriptyline | #2542 |
| radiation induced | #2544 |
| rescue | #2545 |
| 12 24 | #2556 |
| treatment methods | #2556 |
| carryover | #2557 |
| symptom | #2558 |
| galectin3 | #2562 |
| mandated | #2564 |
| randomised clinical trial | #2567 |
| telopeptide | #2567 |
| nitriles | #2568 |
| treatment selection | #2570 |
| reuptake | #2570 |
| stage small | #2573 |
| earlystage breast cancer | #2573 |
| conjunctivitis | #2574 |
| secondary analyses | #2592 |
| trials | #2592 |
| ideally | #2595 |
| carboplatin | #2597 |
| effects drugs | #2598 |
| 2 cycles | #2602 |
| erbb2 receptors | #2608 |
| parenteral | #2610 |
| arm | #2612 |
| pruritus | #2614 |
| patient education | #2617 |
| antineoplastic combined | #2624 |
| outcome united | #2624 |
| consented | #2626 |
| apr | #2626 |
| suspicious | #2627 |
| symptoms quality | #2629 |
| dorsal root | #2629 |
| life hrqol | #2631 |
| increased likelihood | #2639 |
| managing | #2642 |
| prefer | #2644 |
| remedy | #2648 |
| 55 | #2649 |
| races | #2657 |
| thromboembolism | #2657 |
| 0001 patients | #2657 |
| attenuate | #2662 |
| scores | #2663 |
| total parenteral nutrition | #2663 |
| lasted | #2667 |
| basal cell | #2670 |
| testosterone | #2672 |
| cancer outcomes | #2673 |
| imprecise | #2675 |
| comparable | #2676 |
| poorer survival | #2677 |
| symptoms treatment | #2685 |
| 817 | #2686 |
| prescribed | #2687 |
| prevention interventions | #2692 |
| statistically | #2696 |
| randomized controlled | #2699 |
| direct oral anticoagulants | #2701 |
| prevalence smoking | #2705 |
| impotence | #2707 |
| advanced colorectal | #2711 |
| data synthesis | #2713 |
| primary lung | #2717 |
| myelosuppression | #2724 |
| 1000 | #2735 |
| 01 | #2741 |
| modestly | #2745 |
| chemotherapy protocols | #2745 |
| thermal hyperalgesia | #2748 |
| multiple factors | #2749 |
| acp | #2749 |
| patients pain | #2750 |
| topic drug | #2752 |
| efficacies | #2753 |
| taxane | #2758 |
| advanced breast | #2760 |
| male medical | #2761 |
| ttf | #2762 |
| 250 | #2764 |
| neurotoxicity | #2769 |
| pyrazoles | #2774 |
| 1 4 | #2775 |
| male neoplasms | #2775 |
| 237 | #2776 |
| breast carcinoma | #2777 |
| convenience sample | #2780 |
| selfreport | #2781 |
| syndrome aged | #2788 |
| cryosurgery | #2789 |
| pooled data | #2790 |
| paraneoplastic syndromes | #2790 |
| neoplasia | #2791 |
| undergone | #2792 |
| adverse | #2793 |
| ascites | #2794 |
| isoflavones | #2794 |
| agents | #2797 |
| complete data | #2799 |
| nv | #2801 |
| thrice | #2801 |
| doacs | #2802 |
| acid epa | #2806 |
| cox model | #2812 |
| additional studies | #2813 |
| shortness | #2814 |
| continuous infusion | #2815 |
| preferred | #2817 |
| neurofeedback | #2823 |
| 750 | #2827 |
| breast | #2834 |
| sexual health | #2837 |
| muscle weakness | #2840 |
| 1 3 | #2842 |
| meeting | #2844 |
| opioids | #2844 |
| primary outcomes | #2845 |
| 38 | #2845 |
| cancer aged | #2854 |
| cohen | #2857 |
| n31 | #2857 |
| linseed | #2859 |
| breakthrough | #2859 |
| pharmacogenomic | #2860 |
| neoplasms | #2860 |
| sham | #2861 |
| statistical methods | #2866 |
| breaths | #2867 |
| activity level | #2867 |
| anticipate | #2869 |
| purposethe | #2869 |
| covariate | #2870 |
| fertility preservation | #2875 |
| surveillance patients | #2876 |
| 5 years patients | #2886 |
| task force | #2886 |
| ellipse | #2893 |
| survival dose | #2895 |
| p04 | #2895 |
| decarboxylase | #2912 |
| functional assessment | #2915 |
| endodermal | #2917 |
| packyears | #2918 |
| screening tests | #2920 |
| measurable | #2922 |
| p0002 | #2927 |
| placebo response | #2930 |
| condylomata | #2931 |
| prior | #2931 |
| phase clinical | #2933 |
| p008 | #2941 |
| topic design | #2945 |
| review articles | #2949 |
| identifier | #2949 |
| dosing regimens | #2949 |
| colonoscopy colorectal | #2951 |
| auc | #2954 |
| laser treatment | #2955 |
| utility | #2956 |
| week 12 | #2961 |
| 2 groups | #2962 |
| humans infusions | #2963 |
| hirsutism | #2966 |
| combined chemotherapy | #2969 |
| search terms | #2971 |
| curable | #2974 |
| chest wall | #2975 |
| intraepithelial neoplasia | #2977 |
| prophylactic | #2982 |
| placebo difference | #2983 |
| questionnaires | #2985 |
| eicosapentaenoic | #2986 |
| calculator | #2988 |
| testimony | #2989 |
| stopped | #2990 |
| started | #2991 |
| calories | #2991 |
| severity symptoms | #2995 |
| positive breast | #2998 |
| fatigue | #3000 |
| resected | #3004 |
| long acting | #3010 |
| objective response | #3012 |
| n5 | #3012 |
| topically | #3013 |
| time progression | #3014 |
| discomfort | #3014 |
| pathologic complete response | #3019 |
| patients 5 | #3022 |
| mianserin | #3026 |
| bone fractures | #3029 |
| ifosfamide | #3033 |
| nci | #3034 |
| skeletal muscle mass | #3038 |
| reuptake inhibitors | #3041 |
| her2 status | #3041 |
| dermatoses | #3042 |
| placebo week | #3052 |
| sided | #3053 |
| risk colorectal | #3058 |
| relief | #3058 |
| dukes | #3058 |
| tumor activity | #3066 |
| outcome measure | #3067 |
| curve auc | #3067 |
| 264 | #3068 |
| clonidine | #3069 |
| malignancy | #3071 |
| hyperhidrosis | #3072 |
| ctx | #3074 |
| sternal | #3076 |
| histograms | #3092 |
| sexual dysfunction | #3097 |
| nicotine dependence | #3098 |
| loss adult | #3099 |
| intergroup | #3103 |
| patients day | #3107 |
| tumor grade | #3108 |
| bmd | #3111 |
| cancer female humans | #3111 |
| vera | #3111 |
| 66 | #3116 |
| neurokinin1 | #3121 |
| 26 | #3121 |
| reversing | #3135 |
| cognitive dysfunction | #3139 |
| schedule | #3143 |
| 12 weeks | #3144 |
| treatment oral | #3146 |
| life measures | #3147 |
| clinical stage | #3150 |
| trpv1 | #3154 |
| infusions intravenous | #3155 |
| randomized controlled study | #3161 |
| χ2 | #3165 |
| subsequent development | #3166 |
| strongest association | #3168 |
| lifestyle factors | #3178 |
| phase 3 | #3180 |
| reasonable | #3181 |
| systematic literature search | #3183 |
| current approaches | #3185 |
| supportive | #3185 |
| leuprolide | #3186 |
| relevant articles | #3188 |
| 617 | #3189 |
| intravenous | #3190 |
| wore | #3192 |
| cannabinoids | #3193 |
| 64 | #3196 |
| podophyllotoxin | #3197 |
| abstracted | #3201 |
| menopausal | #3208 |
| case reports | #3210 |
| constellation | #3218 |
| 42 | #3222 |
| joint committee | #3225 |
| intervention trial | #3225 |
| nonsmallcell lung cancer | #3226 |
| 39 | #3226 |
| cochrane central register | #3231 |
| pain perception | #3235 |
| enrolled | #3238 |
| breathing | #3239 |
| medical record | #3240 |
| paraneoplastic | #3245 |
| itch | #3260 |
| therapy combination | #3260 |
| intervention patients | #3263 |
| oral mucosa | #3264 |
| designed | #3264 |
| 236 | #3266 |
| prior studies | #3269 |
| disagree | #3269 |
| treatment efficacy | #3270 |
| n30 | #3271 |
| 5 10 | #3272 |
| skin biopsies | #3278 |
| supplementary | #3279 |
| finished | #3282 |
| expert panel | #3284 |
| 2030 | #3287 |
| root ganglia | #3287 |
| 80 antibodies | #3288 |
| 695 | #3290 |
| 885 | #3290 |
| lymphoma patients | #3290 |
| previous analyses | #3291 |
| 576 | #3294 |
| understudied | #3296 |
| 0026 | #3303 |
| neuralgia | #3313 |
| suffer | #3314 |
| undertook | #3316 |
| resection colorectal | #3319 |
| impression | #3320 |
| treatment placebo | #3320 |
| electronic health | #3321 |
| chlorhexidine | #3322 |
| prostate cancer risk | #3328 |
| acuminata | #3334 |
| 171 | #3334 |
| risk vte | #3339 |
| systemically | #3350 |
| platinum based | #3352 |
| terminology | #3356 |
| erythema | #3358 |
| historic | #3360 |
| female breast | #3365 |
| breast prostate | #3368 |
| bone metastases | #3370 |
| doubt | #3370 |
| thirty | #3374 |
| preclinical studies | #3375 |
| relapse free | #3380 |
| chemoprevention | #3386 |
| acute chronic | #3392 |
| equivalency | #3395 |
| advanced prostate | #3396 |
| iii trials | #3399 |
| answers | #3400 |
| preceding | #3406 |
| oral | #3408 |
| lymph node excision | #3411 |
| prostatic neoplasms | #3415 |
| delaying | #3417 |
| anilides | #3418 |
| severity | #3422 |
| delineated | #3425 |
| axillary lymph | #3426 |
| administering | #3437 |
| npy | #3438 |
| higher scores | #3444 |
| 012 | #3446 |
| screening methods | #3446 |
| subsequent | #3452 |
| aminoquinolines | #3460 |
| utilizing | #3463 |
| 64 patients | #3463 |
| sprays | #3464 |
| survival benefits | #3468 |
| listed | #3468 |
| pts | #3468 |
| chemotherapy radiation | #3471 |
| anthracyclines | #3471 |
| multicenter randomized | #3473 |
| lidocaine | #3475 |
| lower rate | #3477 |
| mailed | #3479 |
| cross validation | #3480 |
| cessation smoking | #3481 |
| 3 6 | #3484 |
| attempt | #3489 |
| antidepressants | #3490 |
| intent | #3495 |
| reviewing | #3499 |
| ctc | #3500 |
| malignant disease | #3501 |
| — | #3505 |
| chemotherapeutic agent | #3512 |
| recommend | #3524 |
| allodynia | #3529 |
| carries | #3539 |
| metastatic disease | #3544 |
| points | #3545 |
| opiates | #3559 |
| stage breast | #3561 |
| 148 | #3565 |
| faced | #3566 |
| patients metastatic | #3574 |
| phase topic | #3583 |
| survival women | #3583 |
| correlational | #3583 |
| 135 | #3586 |
| carboplatin paclitaxel | #3586 |
| oestrogen | #3587 |
| chemotherapy cycles | #3588 |
| patients experiences | #3588 |
| treatment decisions | #3595 |
| 211 | #3596 |
| gold standard | #3607 |
| objective measures | #3608 |
| life qol | #3608 |
| periodically | #3610 |
| thiotepa | #3615 |
| stage iiia | #3618 |
| oral adult | #3619 |
| ≥30 | #3620 |
| benefits risks | #3620 |
| survival cancer | #3620 |
| therapeutic benefit | #3623 |
| improvement quality | #3629 |
| antacids | #3630 |
| 29 patients | #3631 |
| survivals | #3634 |
| racial differences | #3639 |
| complete responses | #3648 |
| ordinal | #3650 |
| colon cancer | #3650 |
| patients adjuvant chemotherapy | #3650 |
| adjuvant chemotherapy patients | #3652 |
| ≥18 years | #3655 |
| parp inhibitor | #3660 |
| bodymass | #3661 |
| 34 patients | #3666 |
| acid antagonists | #3674 |
| sigmoidoscopy | #3682 |
| 673 | #3682 |
| preceded | #3685 |
| proportion | #3686 |
| 580 | #3686 |
| aps | #3688 |
| thirty patients | #3689 |
| cardio | #3690 |
| chemotherapies | #3695 |
| redness | #3700 |
| moxibustion | #3702 |
| options | #3705 |
| electron rats | #3706 |
| relapsefree survival | #3707 |
| study evidence | #3708 |
| cancer chemotherapy | #3712 |
| annually | #3714 |
| instructed | #3716 |
| adjuvant chemotherapy | #3718 |
| 5000 | #3719 |
| exception | #3721 |
| 911 | #3725 |
| breast tissue | #3731 |
| impressive | #3738 |
| combination female | #3741 |
| foams | #3742 |
| randomized clinical trial | #3742 |
| practicing | #3743 |
| anabolic | #3746 |
| late effects | #3752 |
| lymphatic vessels | #3754 |
| weight status | #3758 |
| longterm survival | #3768 |
| menopausal women | #3774 |
| symptom severity | #3782 |
| vertigo | #3788 |
| adversely | #3789 |
| cancer drugs | #3795 |
| compassionate | #3800 |
| 567 | #3801 |
| hormone replacement therapy | #3804 |
| external beam | #3805 |
| sixth | #3806 |
| 600 | #3807 |
| terminal | #3811 |
| anesthetics | #3811 |
| hormone replacement | #3811 |
| colchicine | #3815 |
| phase trial | #3816 |
| centric | #3817 |
| etoposide | #3822 |
| pain control | #3825 |
| cancer prostate | #3830 |
| ploidies | #3831 |
| intramuscularly | #3834 |
| patients experienced | #3834 |
| 136 | #3839 |
| 16 weeks | #3839 |
| patients moderate | #3843 |
| cutaneous | #3846 |
| trpv | #3847 |
| contraindications | #3847 |
| seventy | #3854 |
| blinding | #3854 |
| sharks | #3855 |
| patients grade | #3855 |
| internally | #3858 |
| treatment metastatic | #3861 |
| 23 | #3861 |
| 04 | #3866 |
| futility | #3867 |
| 786 | #3875 |
| individually | #3880 |
| queried | #3882 |
| flushing | #3886 |
| midwestern | #3888 |
| adenomas | #3895 |
| compelling | #3897 |
| dfs survival | #3905 |
| modulators | #3906 |
| received chemotherapy | #3909 |
| sponsored | #3917 |
| bone turnover | #3919 |
| 24 weeks | #3921 |
| hyperactivation | #3922 |
| keywords | #3927 |
| vte patients | #3928 |
| therapies | #3933 |
| publication clinical trials | #3940 |
| myoclonus | #3940 |
| discontinued | #3942 |
| grade 1 | #3945 |
| 61 patients | #3947 |
| bf | #3950 |
| food drug administration | #3951 |
| difficulty | #3953 |
| colorectal | #3955 |
| inhibitors female | #3956 |
| prostate carcinoma | #3961 |
| capsaicin | #3969 |
| manifested | #3970 |
| study drug | #3973 |
| 25 | #3975 |
| accidental | #3976 |
| pain severity | #3977 |
| adenosine triphosphate | #3980 |
| pluronic | #3983 |
| 20 | #3988 |
| 30 years | #3991 |
| toxic effects | #3993 |
| 449 | #3994 |
| lasting | #4002 |
| weight | #4002 |
| 370 | #4004 |
| gait | #4005 |
| sideeffects | #4006 |
| 692 | #4008 |
| kras mutations | #4014 |
| surgery radiation | #4018 |
| estrogenic | #4023 |
| audio | #4034 |
| patients intervention | #4034 |
| year patients | #4039 |
| lumbar spine | #4044 |
| thirteen patients | #4047 |
| tid | #4052 |
| prostatic | #4062 |
| erythropoietin | #4062 |
| nonusers | #4066 |
| flax | #4068 |
| cancer therapy | #4069 |
| conjunction | #4069 |
| 516 | #4075 |
| intravenously | #4077 |
| extremities | #4084 |
| strong evidence | #4087 |
| meaningful | #4099 |
| revisions | #4102 |
| rose | #4108 |
| 2–4 | #4116 |
| iii study | #4120 |
| bone neoplasms | #4124 |
| dermatitis | #4125 |
| noninfiltrating | #4126 |
| favoring | #4126 |
| sphase | #4131 |
| documentation | #4132 |
| 7 months | #4134 |
| tablets | #4138 |
| topic practice patterns | #4138 |
| definitions | #4138 |
| malignant melanoma | #4139 |
| femoral neck | #4139 |
| 269 | #4143 |
| combination therapy | #4144 |
| mbc | #4157 |
| interleukin6 il6 | #4159 |
| 4 months | #4164 |
| 326 | #4175 |
| effective | #4194 |
| noxious | #4196 |
| 10 months | #4199 |
| calcium vitamin | #4201 |
| depressants | #4210 |
| cancer bone | #4210 |
| undertaken | #4211 |
| 2006 | #4220 |
| treatment option | #4223 |
| twothirds | #4232 |
| 18 months | #4236 |
| platinumbased chemotherapy | #4238 |
| drug response | #4250 |
| quinazolines | #4254 |
| anemia patients | #4256 |
| contraindication | #4258 |
| neoplasms colorectal | #4258 |
| serially | #4268 |
| treatment discontinuation | #4268 |
| cation channels | #4271 |
| 58 patients | #4278 |
| 2 4 | #4283 |
| survival quality | #4284 |
| bone density | #4284 |
| day | #4285 |
| utilized | #4289 |
| inconsistencies | #4289 |
| colorectal neoplasms | #4297 |
| rheumatism | #4301 |
| node negative | #4307 |
| aged breast | #4313 |
| bioavailable | #4314 |
| chemotherapy treatment | #4323 |
| prednisolone | #4326 |
| reductions | #4326 |
| vast | #4327 |
| bone diseases | #4330 |
| healthy women | #4331 |
| primary endpoints | #4331 |
| reply | #4340 |
| firstline chemotherapy | #4343 |
| treatment studies | #4355 |
| equally | #4357 |
| neoplasms combined | #4359 |
| institute | #4359 |
| participated | #4360 |
| detrimental effects | #4367 |
| outcome data | #4368 |
| 3 months | #4373 |
| sleeping | #4376 |
| discontinuation | #4381 |
| preliminary | #4385 |
| carcinoma ductal | #4389 |
| time surgery | #4393 |
| therapies patients | #4394 |
| judgment | #4395 |
| 12 week | #4396 |
| drug combinations | #4402 |
| repeatedly | #4402 |
| hyperalgesia | #4411 |
| grouping | #4414 |
| minnesota | #4415 |
| purpose | #4417 |
| “ | #4424 |
| evaluate | #4425 |
| 1015 | #4427 |
| 14 months | #4429 |
| balance | #4430 |
| studies colorectal | #4431 |
| 80 breast | #4431 |
| low doses | #4436 |
| drg neurons | #4437 |
| pain relief | #4438 |
| documented | #4440 |
| relevant studies | #4445 |
| day patients | #4446 |
| improve patient | #4446 |
| summarize | #4450 |
| clinical predictors | #4455 |
| clinical parameters | #4460 |
| humanized antineoplastic | #4464 |
| pain measurement | #4465 |
| 80 | #4465 |
| fecal | #4466 |
| clinical practice guidelines | #4490 |
| 05 | #4494 |
| risk breast cancer | #4499 |
| humans lymph | #4501 |
| received | #4504 |
| drug administration | #4505 |
| stimulants | #4510 |
| axillary | #4521 |
| 5 | #4523 |
| daily activities | #4523 |
| sedation | #4529 |
| gynecologic | #4530 |
| ganglion | #4530 |
| ductal breast | #4530 |
| disease recurrence | #4531 |
| cancer methods | #4534 |
| hematology | #4535 |
| disabling | #4536 |
| stimulant | #4536 |
| sphingolipids | #4537 |
| natural | #4537 |
| diarrhea | #4540 |
| drug effects | #4540 |
| journal | #4544 |
| impairments | #4546 |
| 3 4 | #4550 |
| ganglia spinal | #4552 |
| continuation | #4558 |
| outcome measures | #4561 |
| financial | #4562 |
| clinical | #4564 |
| rescue therapy | #4564 |
| 376 | #4567 |
| rbc | #4569 |
| reliability validity | #4575 |
| 4 | #4575 |
| successes | #4577 |
| single blind | #4583 |
| tumor regression | #4587 |
| explore | #4588 |
| risk bleeding | #4591 |
| hydroxytryptamine | #4591 |
| mmf | #4592 |
| cumulative | #4604 |
| tenderness | #4606 |
| 115 | #4609 |
| longer duration | #4612 |
| chemopreventive | #4617 |
| emphasizes | #4620 |
| neoplasms dna | #4626 |
| throat | #4633 |
| caf | #4636 |
| patients increase | #4642 |
| neuropathies | #4647 |
| 6 12 | #4647 |
| daily dose | #4647 |
| tumor recurrence | #4653 |
| 1 study | #4661 |
| data studies | #4662 |
| 96 | #4664 |
| dose chemotherapy | #4665 |
| adpribose | #4665 |
| increased incidence | #4669 |
| treatments | #4674 |
| qol patients | #4679 |
| vitality | #4683 |
| peaked | #4684 |
| hazards | #4689 |
| deprivation | #4691 |
| 29 | #4693 |
| secondary analysis | #4699 |
| treatment survival | #4701 |
| dose | #4704 |
| low dose | #4708 |
| dose reduction | #4712 |
| reference lists | #4722 |
| preliminary study | #4733 |
| ” | #4734 |
| mediastinum | #4734 |
| assessment tool | #4740 |
| phase 2 trial | #4741 |
| vigor | #4751 |
| percentage patients | #4752 |
| cgy | #4762 |
| efficacy tolerability | #4773 |
| analysis neoplasm | #4783 |
| recommended | #4785 |
| adt | #4790 |
| invasive breast cancer | #4792 |
| 353 | #4795 |
| proven | #4798 |
| corticosteroid | #4806 |
| 009 | #4806 |
| 538 | #4810 |
| tears | #4810 |
| evaluations | #4813 |
| circulating concentrations | #4817 |
| cancer compared | #4818 |
| improved quality | #4818 |
| acetylcysteine | #4821 |
| capecitabine | #4829 |
| musculoskeletal | #4830 |
| multicenter | #4836 |
| symptom burden | #4836 |
| bridged | #4837 |
| carcinoma small | #4837 |
| seer program | #4841 |
| tubulin | #4841 |
| aes | #4846 |
| 60 | #4848 |
| 55 patients | #4854 |
| receipt | #4857 |
| 381 | #4861 |
| patients recurrence | #4868 |
| patients prostate | #4870 |
| individual patient data | #4876 |
| amines | #4886 |
| neck neoplasms humans | #4890 |
| 048 | #4901 |
| receptor egfr | #4904 |
| fisher | #4910 |
| crc patients | #4911 |
| lastly | #4917 |
| systemic therapy | #4921 |
| harms | #4922 |
| platinum | #4924 |
| stage iiib | #4925 |
| abstinence | #4926 |
| unfavorable | #4927 |
| existed | #4928 |
| basal cell carcinoma | #4933 |
| ≥1 | #4937 |
| 727 | #4942 |
| coadministration | #4946 |
| sensitization | #4956 |
| screening tool | #4956 |
| 9 months | #4960 |
| plethora | #4970 |
| subsequently | #4974 |
| eligibility | #4975 |
| equivocal | #4980 |
| cancer background | #4981 |
| optimal management | #4983 |
| depot | #4989 |
| deep vein thrombosis | #4992 |
| cumulative dose | #4996 |
| recurrence free | #4997 |
| exercise intervention | #5003 |
| lessons | #5005 |
| metastatic prostate | #5016 |
| situ carcinoma | #5017 |
| based cohort | #5018 |
| combined treatment | #5027 |
| routine clinical | #5028 |
| biphasic | #5029 |
| multicenter trial | #5039 |
| initiate | #5045 |
| sedative | #5055 |
| actively | #5058 |
| missing data | #5060 |
| favorably | #5071 |
| osteoporosis | #5073 |
| physical symptoms | #5075 |
| 3 trials | #5076 |
| methotrexate | #5077 |
| karnofsky performance | #5084 |
| genistein | #5084 |
| study incidence | #5086 |
| phenobarbital | #5091 |
| 100 patients | #5098 |
| 342 | #5099 |
| version | #5104 |
| pyrimidinones | #5104 |
| bortezomib | #5105 |
| cisplatin treatment | #5106 |
| published | #5116 |
| skin neoplasms | #5121 |
| ntprobnp | #5124 |
| conventional chemotherapy | #5126 |
| physical therapy | #5131 |
| reducing | #5131 |
| 120 | #5141 |
| topical application | #5142 |
| indomethacin | #5143 |
| medicine humans | #5149 |
| higher rate | #5154 |
| women early | #5155 |
| lower rates | #5157 |
| bisphosphonates | #5165 |
| resolve | #5169 |
| prognostic | #5176 |
| analysis randomized | #5177 |
| compiled | #5181 |
| cycle | #5186 |
| antiinflammatory agents | #5187 |
| supplement | #5201 |
| thalidomide | #5207 |
| 30 patients | #5214 |
| references | #5218 |
| cisplatin | #5225 |
| april | #5231 |
| medications | #5239 |
| identical | #5243 |
| dying | #5243 |
| randomised controlled trial | #5244 |
| humans lung | #5249 |
| article | #5249 |
| insomnia | #5255 |
| conventionally | #5257 |
| patients time | #5257 |
| mitoxantrone | #5265 |
| progestins | #5266 |
| resectable | #5269 |
| low molecular | #5270 |
| caring | #5270 |
| negative impact | #5277 |
| health disparities | #5278 |
| sed | #5291 |
| undergo | #5306 |
| gynecology | #5309 |
| parenteral nutrition | #5310 |
| vaporizers | #5317 |
| cancer prevention | #5319 |
| conflicting | #5325 |
| pelvic | #5326 |
| ineligible | #5327 |
| 404 | #5333 |
| anticipated | #5335 |
| alkaloids | #5335 |
| administered | #5339 |
| methods design | #5344 |
| patient data | #5349 |
| monophenol | #5351 |
| sensation | #5359 |
| perceived | #5359 |
| current practice | #5361 |
| colorectal cancers | #5362 |
| answered | #5376 |
| neurologists | #5377 |
| 346 | #5385 |
| adenosylmethionine | #5393 |
| isotretinoin | #5394 |
| declining | #5396 |
| judged | #5403 |
| responding | #5412 |
| study women | #5421 |
| officinalis | #5423 |
| stage iii | #5423 |
| 33 | #5425 |
| colonic polyps | #5444 |
| axilla | #5468 |
| 57 | #5470 |
| manner | #5473 |
| p0006 | #5481 |
| minutes | #5482 |
| baseline characteristics | #5486 |
| health records | #5490 |
| pufas | #5492 |
| based interventions | #5496 |
| 167 | #5504 |
| preclinical models | #5506 |
| methylases | #5508 |
| ovary | #5512 |
| thromboembolic events | #5518 |
| patient demographics | #5521 |
| neoplasms humans | #5525 |
| 410 | #5535 |
| pooled | #5548 |
| medical conditions | #5556 |
| 03 | #5571 |
| cancer center | #5573 |
| ready | #5580 |
| acne | #5582 |
| routine clinical practice | #5583 |
| stage patients | #5590 |
| dropped | #5593 |
| 002 | #5594 |
| current literature | #5598 |
| patient quality | #5604 |
| woman | #5605 |
| 41 | #5611 |
| polyps | #5620 |
| carnitine | #5623 |
| enteral | #5633 |
| sensory | #5638 |
| treatment approaches | #5638 |
| new therapies | #5642 |
| lung carcinoma | #5642 |
| 0007 | #5648 |
| concurrent | #5672 |
| treatment regimens | #5676 |
| guideline | #5679 |
| constipation | #5683 |
| sf36 | #5684 |
| n6 | #5687 |
| standard chemotherapy | #5688 |
| neuromodulation | #5689 |
| 50 | #5693 |
| dexamethasone | #5694 |
| renewed | #5694 |
| desire | #5695 |
| preserve | #5696 |
| online | #5699 |
| patients therapy | #5701 |
| nonsignificant | #5703 |
| multiplied | #5704 |
| raise | #5705 |
| cancer type | #5708 |
| androgen | #5716 |
| trials rcts | #5722 |
| complete | #5730 |
| specialist | #5730 |
| dna content | #5733 |
| serial | #5736 |
| provider | #5761 |
| interruption | #5762 |
| tumor breast | #5762 |
| tumor stage | #5762 |
| total score | #5766 |
| impair | #5770 |
| versus | #5773 |
| chance | #5779 |
| nicotine | #5783 |
| mucous | #5783 |
| carcinoma situ | #5783 |
| exploratory study | #5790 |
| node excision | #5795 |
| 345 | #5805 |
| higher doses | #5806 |
| 395 | #5814 |
| vitamin | #5817 |
| systemic effects | #5827 |
| patients aspirin | #5828 |
| patient experience | #5830 |
| 4 5 | #5837 |
| cancer breast | #5842 |
| leukocyte count | #5850 |
| intermediate risk | #5852 |
| selfreported | #5855 |
| patients survival | #5857 |
| stools | #5858 |
| subgroups patients | #5873 |
| 405 | #5877 |
| interfere | #5877 |
| excitatory amino | #5883 |
| enrollment | #5886 |
| neoplasm recurrence | #5887 |
| exercises | #5888 |
| totally | #5898 |
| response relationship | #5899 |
| potential mechanisms | #5909 |
| 3 | #5910 |
| 0 1 | #5917 |
| trastuzumab | #5925 |
| alternating | #5926 |
| gel | #5930 |
| acids omega3 | #5935 |
| humans injections | #5940 |
| pooled analysis | #5946 |
| dysplastic | #5947 |
| questionnaires adult | #5952 |
| treatment toxicity | #5954 |
| previous | #5955 |
| treatment failure | #5964 |
| symptoms depression | #5967 |
| returned | #5979 |
| confounding | #5990 |
| analogue | #5995 |
| devoted | #5996 |
| 239 | #5997 |
| evaluation studies | #5997 |
| icd9 | #6000 |
| sectional survey | #6002 |
| validated | #6007 |
| serum patients | #6010 |
| insulinlike growth factor | #6013 |
| 1977 | #6013 |
| prognostic indicator | #6018 |
| descriptions | #6019 |
| minute | #6019 |
| worsened | #6026 |
| sentinel node | #6028 |
| 0013 | #6041 |
| chemotherapy radiotherapy | #6041 |
| grade 3 | #6042 |
| 243 | #6045 |
| new evidence | #6049 |
| month | #6052 |
| institutional | #6061 |
| syndrome | #6065 |
| protective agents | #6066 |
| caution | #6067 |
| stool | #6070 |
| 480 | #6082 |
| subscales | #6083 |
| approved | #6097 |
| aspect | #6098 |
| 20 years | #6102 |
| 43 | #6104 |
| hormone therapy | #6108 |
| increment | #6109 |
| tests prognosis | #6116 |
| spitzer | #6118 |
| conducted | #6120 |
| randomized controlled trial | #6125 |
| routes | #6128 |
| surviving | #6156 |
| antiepileptic | #6164 |
| kilogram | #6167 |
| endpoints | #6173 |
| inception | #6184 |
| skin diseases | #6188 |
| 241 | #6189 |
| omega3 | #6193 |
| selective serotonin | #6195 |
| boronic | #6199 |
| intraepithelial | #6204 |
| 16 | #6215 |
| 900 | #6218 |
| female | #6221 |
| central venous | #6229 |
| combination treatment | #6232 |
| 62 | #6234 |
| epa | #6239 |
| randomized clinical trials | #6242 |
| invasive breast | #6249 |
| patients colorectal | #6253 |
| treated mice | #6255 |
| exploratory | #6257 |
| 58 | #6258 |
| asymptomatic patients | #6260 |
| metastasis neoplasm | #6261 |
| receptors progesterone | #6265 |
| historically | #6269 |
| palliative | #6270 |
| protocols | #6275 |
| psychotropic drugs | #6280 |
| disclosure | #6280 |
| ease | #6282 |
| 2000 | #6283 |
| xerostomia | #6284 |
| followup patients | #6293 |
| innovations | #6299 |
| scopus | #6300 |
| insignificant | #6302 |
| benzhydryl | #6302 |
| survival female | #6312 |
| 328 | #6314 |
| chi2 | #6320 |
| prospective | #6330 |
| lobular | #6343 |
| counseling | #6344 |
| 59 | #6346 |
| rigorous | #6347 |
| clinically | #6350 |
| endocrine therapy | #6365 |
| fentanyl | #6372 |
| aged | #6372 |
| 2007 | #6385 |
| venous thromboembolism vte | #6385 |
| infusions | #6393 |
| epidermal growth | #6393 |
| breadth | #6395 |
| physicians | #6402 |
| cronbach | #6404 |
| narcotic | #6407 |
| vitro model | #6413 |
| early intervention | #6424 |
| sexes | #6425 |
| initial treatment | #6426 |
| endocrinology | #6432 |
| 2 3 | #6433 |
| psychotropic | #6439 |
| pittsburgh | #6439 |
| entire | #6440 |
| multinational | #6440 |
| 361 | #6445 |
| counts | #6446 |
| soybeans | #6449 |
| sex hormones | #6452 |
| logs | #6453 |
| congeners | #6455 |
| quality | #6458 |
| termed | #6470 |
| intraluminal | #6471 |
| 75 | #6471 |
| life health | #6478 |
| n16 | #6481 |
| treatment guidelines | #6482 |
| patients 2 | #6485 |
| time diagnosis | #6486 |
| mcf7 cells | #6496 |
| records | #6498 |
| abcb1 | #6499 |
| ≥18 | #6501 |
| usual patients | #6512 |
| disease stage | #6515 |
| adenoma | #6520 |
| complementary | #6521 |
| consultation | #6524 |
| guidance | #6531 |
| iu | #6533 |
| ranked | #6536 |
| developments | #6540 |
| transfusions | #6551 |
| 004 | #6552 |
| tumor location | #6554 |
| 86 | #6567 |
| 0004 | #6575 |
| analog | #6576 |
| 53 | #6591 |
| abstracts | #6593 |
| baseline patients | #6598 |
| initiated | #6602 |
| acting | #6604 |
| colonic neoplasms | #6605 |
| pyrazines | #6608 |
| hemoglobins | #6612 |
| l3 | #6612 |
| 287 | #6614 |
| decisions | #6614 |
| fourth | #6615 |
| phase | #6617 |
| 02 | #6618 |
| surveys questionnaires | #6621 |
| hrt | #6622 |
| curative resection | #6623 |
| familiar | #6641 |
| guidelines | #6646 |
| pellet | #6646 |
| crf | #6648 |
| hormone receptor | #6651 |
| patients health | #6651 |
| courses | #6664 |
| randomized controlled trials | #6666 |
| emerging evidence | #6681 |
| osseous | #6682 |
| physical health | #6683 |
| tools | #6685 |
| figure | #6689 |
| dex | #6691 |
| caloric | #6694 |
| erectile dysfunction | #6694 |
| develops | #6696 |
| neoplasm metastasis | #6699 |
| radiotherapy chemotherapy | #6702 |
| hypothesized | #6702 |
| ketamine | #6710 |
| colorectal cancer patients | #6717 |
| consecutive | #6717 |
| interprofessional | #6728 |
| detailed | #6731 |
| testicular cancer | #6743 |
| score | #6745 |
| 295 | #6750 |
| replacement therapy | #6751 |
| quit | #6751 |
| difference | #6763 |
| grade | #6770 |
| lower incidence | #6773 |
| true | #6776 |
| ocular | #6783 |
| prevents | #6784 |
| titration | #6787 |
| pain management | #6793 |
| frequently | #6801 |
| longest | #6801 |
| search strategy | #6801 |
| chart review | #6802 |
| rounds | #6804 |
| 344 | #6806 |
| hepcidin | #6809 |
| controlled studies | #6810 |
| fulfilled | #6810 |
| participating | #6811 |
| mice treated | #6818 |
| detect | #6826 |
| ovarian function | #6841 |
| treatment advanced | #6842 |
| integrative | #6851 |
| early treatment | #6853 |
| exercise therapy | #6861 |
| classification | #6874 |
| inventory | #6877 |
| narrative | #6879 |
| drg | #6883 |
| routinely | #6887 |
| new drugs | #6889 |
| secondary | #6891 |
| concerns | #6896 |
| strength muscle | #6898 |
| differ | #6903 |
| 277 | #6904 |
| serum concentrations | #6912 |
| tumor formation | #6917 |
| 5 ht | #6918 |
| controversial | #6930 |
| summarizes | #6932 |
| mass loss | #6941 |
| cbd | #6942 |
| factors breast | #6942 |
| iiib | #6944 |
| laparotomy | #6953 |
| diarrhoea | #6955 |
| tartrate | #6960 |
| quarter | #6970 |
| regressions | #6981 |
| skin temperature | #6981 |
| ais | #6986 |
| wearing | #6990 |
| calorie | #6990 |
| quiet | #6990 |
| 35 | #6994 |
| definition | #6994 |
| seer | #7001 |
| promise | #7002 |
| patients developed | #7006 |
| 1 year | #7011 |
| initially | #7015 |
| women study | #7019 |
| hemorrhage humans | #7020 |
| breast cancers | #7030 |
| 051 | #7045 |
| metaanalyses | #7049 |
| animal doseresponse relationship | #7050 |
| neoplasms risk | #7063 |
| patients 1 | #7067 |
| interested | #7067 |
| 50 patients | #7068 |
| 31 | #7083 |
| screening middle | #7089 |
| total | #7097 |
| overview | #7098 |
| asian patients | #7111 |
| neu | #7113 |
| approval | #7114 |
| 97 | #7121 |
| neoplasms treatment | #7122 |
| polyadp | #7124 |
| prostate cancer | #7130 |
| neoplasms female | #7130 |
| 261 | #7131 |
| female gastrointestinal | #7143 |
| strengthened | #7144 |
| neuroprotection | #7147 |
| 833 | #7154 |
| therapy humans | #7165 |
| estrogens | #7171 |
| appropriateness | #7179 |
| breast cancer risk | #7187 |
| expect | #7188 |
| pik3ca | #7201 |
| confirm | #7211 |
| uncontrolled | #7220 |
| estrogen | #7228 |
| entity | #7234 |
| discusses | #7238 |
| agents steroidal | #7255 |
| 203 | #7262 |
| questionnaire | #7264 |
| ameliorates | #7264 |
| chosen | #7266 |
| popularity | #7283 |
| additionally | #7295 |
| neoplasms primary | #7296 |
| outpatients | #7296 |
| cinahl | #7333 |
| node biopsy | #7334 |
| increased survival | #7336 |
| 10 | #7340 |
| aged anti | #7343 |
| stages | #7347 |
| superficial | #7353 |
| evaluates | #7353 |
| radiotherapy adjuvant | #7358 |
| prognosis prospective | #7361 |
| firstline therapy | #7376 |
| epo | #7378 |
| eating | #7379 |
| short | #7384 |
| square distribution | #7390 |
| 47 | #7393 |
| noradrenergic | #7407 |
| curative | #7416 |
| rfs | #7416 |
| esr1 | #7417 |
| radiotherapy | #7433 |
| genital | #7435 |
| confirmatory | #7436 |
| emphasis | #7436 |
| receptor agonists | #7436 |
| naphthalenes | #7437 |
| cancer treated | #7438 |
| established | #7449 |
| 25 patients | #7456 |
| clinical evaluation | #7467 |
| 199 | #7478 |
| 1st | #7482 |
| 058 | #7484 |
| prognosis proportional | #7488 |
| wasting | #7488 |
| treatment strategy | #7489 |
| bolus | #7496 |
| genetic factors | #7499 |
| metastatic colorectal | #7501 |
| gonadotropin | #7504 |
| 259 | #7507 |
| november | #7509 |
| dysplasia | #7523 |
| transaminases | #7524 |
| objectively | #7526 |
| melanoma patients | #7528 |
| cancer vaccines | #7531 |
| infertility | #7534 |
| investigators | #7534 |
| october | #7539 |
| tumor colorectal | #7541 |
| local neoplasm | #7543 |
| 315 | #7558 |
| primary treatment | #7559 |
| adequacy | #7564 |
| concurrently | #7578 |
| kaplanmeier method | #7583 |
| intraductal | #7586 |
| 00001 | #7589 |
| patients head | #7594 |
| grades | #7605 |
| single dose | #7607 |
| tretinoin | #7608 |
| discussions | #7609 |
| chronic pain | #7615 |
| coumarins | #7616 |
| gain | #7620 |
| opinions | #7621 |
| interval | #7624 |
| ploidy | #7624 |
| receptor antagonists | #7632 |
| receptor erbb2 | #7633 |
| pharmacists | #7641 |
| local neoplasms | #7642 |
| sequelae | #7645 |
| metastatic colorectal cancer | #7656 |
| clinical benefit | #7666 |
| retinoids | #7678 |
| corticosteroids | #7684 |
| visits | #7691 |
| longterm effects | #7695 |
| evident | #7696 |
| monitored | #7699 |
| 1 day | #7699 |
| 026 | #7710 |
| publication biomarkers | #7713 |
| surveys | #7725 |
| 021 | #7725 |
| recurrence | #7726 |
| risk breast | #7728 |
| thrombophilia | #7734 |
| washout | #7744 |
| administration | #7744 |
| onethird | #7749 |
| nicotinic | #7751 |
| rank | #7758 |
| cancer recurrence | #7763 |
| independent predictors | #7776 |
| omega3 fatty | #7779 |
| treatment time | #7780 |
| serotonergic | #7785 |
| pathophysiology | #7796 |
| negative effects | #7805 |
| 14 | #7807 |
| ovarian neoplasms | #7811 |
| erectile | #7812 |
| clinicians | #7820 |
| gonadal | #7839 |
| 12 months | #7842 |
| swallowing | #7843 |
| subcutaneous | #7855 |
| pain intensity | #7856 |
| patient centered | #7866 |
| thiophenes | #7869 |
| 0 | #7876 |
| hemoglobins humans | #7892 |
| statistic | #7900 |
| physical function | #7917 |
| impacted | #7927 |
| ago | #7927 |
| 40 | #7933 |
| dysfunctions | #7950 |
| androgens | #7955 |
| comparing | #7956 |
| 5year survival | #7956 |
| advanced | #7957 |
| generally | #7963 |
| 305 | #7965 |
| ductal carcinoma | #7968 |
| ≤ | #7972 |
| actuarial | #7973 |
| 055 | #7975 |
| individualized | #7981 |
| collect | #7982 |
| situation | #7983 |
| female genital | #7985 |
| 062 | #8006 |
| 278 | #8020 |
| noninferiority | #8032 |
| powered | #8051 |
| preclinical | #8062 |
| intractable | #8063 |
| genders | #8063 |
| colorectal cancer crc | #8064 |
| 45 | #8065 |
| 208 | #8069 |
| 105 | #8086 |
| sixteen | #8088 |
| humans longitudinal | #8090 |
| relating | #8096 |
| expand | #8099 |
| resultant | #8100 |
| trial background | #8102 |
| occurred | #8107 |
| irrespective | #8127 |
| analgesics opioid | #8128 |
| 5 years | #8132 |
| reduce | #8141 |
| receptors estrogen | #8142 |
| methodswe | #8150 |
| entering | #8154 |
| translational | #8164 |
| facilitating | #8173 |
| dose escalation | #8185 |
| specific antigen | #8189 |
| edetic | #8191 |
| ondansetron | #8204 |
| withdrawal | #8206 |
| tnf alpha | #8213 |
| cancer detection | #8218 |
| popular | #8220 |
| b4 | #8224 |
| mild | #8234 |
| spearman | #8242 |
| regard | #8249 |
| patients adult | #8249 |
| committees | #8252 |
| stage | #8255 |
| parp | #8258 |
| dietary supplements | #8265 |
| treated | #8266 |
| modalities | #8269 |
| tobramycin | #8285 |
| antitumor activity | #8287 |
| neoplasms male | #8289 |
| patient groups | #8315 |
| 201 | #8324 |
| estradiol | #8325 |
| risk cancer | #8327 |
| triazines | #8331 |
| wellbeing | #8341 |
| sertraline | #8344 |
| concern | #8345 |
| cell lung | #8349 |
| pubmed | #8352 |
| patient treatment | #8362 |
| year follow | #8372 |
| pharmacogenetics | #8372 |
| calcium | #8389 |
| clinical activity | #8395 |
| choose | #8397 |
| 6 cycles | #8403 |
| predisposing | #8405 |
| costly | #8417 |
| preparations | #8422 |
| undergoing | #8422 |
| neck neoplasms | #8435 |
| expense | #8447 |
| married | #8448 |
| detecting | #8460 |
| testing | #8465 |
| underestimate | #8466 |
| composition body | #8478 |
| 3 trial | #8482 |
| 37 | #8482 |
| eruptions | #8486 |
| oncologic | #8488 |
| neuromuscular | #8489 |
| clinical experience | #8509 |
| 39 patients | #8527 |
| respond | #8553 |
| cyclophosphamide | #8562 |
| 253 | #8570 |
| average | #8576 |
| 020 | #8587 |
| stratified | #8596 |
| exists | #8598 |
| ttp | #8610 |
| standard therapy | #8620 |
| 81 | #8624 |
| 015 | #8629 |
| estrogen receptors | #8637 |
| morphine | #8637 |
| cancer female | #8639 |
| remain | #8643 |
| fda | #8646 |
| legs | #8657 |
| initial | #8658 |
| relative risks | #8659 |
| practitioners | #8676 |
| functional status | #8679 |
| syndrome patients | #8684 |
| 6 months | #8685 |
| egfr | #8692 |
| grip | #8695 |
| notable | #8700 |
| single nucleotide polymorphisms | #8700 |
| threatening | #8705 |
| molecular markers | #8705 |
| loss | #8714 |
| aged 80 | #8715 |
| selfreports | #8722 |
| leptin | #8728 |
| 32 patients | #8731 |
| colorectal cancer | #8743 |
| drug | #8748 |
| perspectives | #8751 |
| majority | #8756 |
| illustrates | #8757 |
| inhibitors | #8764 |
| repeated | #8765 |
| 123 | #8769 |
| 2001 | #8774 |
| survivorship | #8779 |
| 066 | #8786 |
| aged models | #8792 |
| mouth | #8800 |
| real | #8800 |
| prospective randomized | #8808 |
| providers | #8813 |
| question | #8814 |
| advanced stage | #8823 |
| accumulating | #8842 |
| groups patients | #8847 |
| ferric | #8858 |
| uremic | #8865 |
| concomitant | #8886 |
| highrisk | #8893 |
| enteral nutrition | #8908 |
| publication aged aged | #8919 |
| predefined | #8929 |
| supplemental | #8938 |
| negatively | #8961 |
| 017 | #8966 |
| 145 | #8971 |
| ovaries | #8984 |
| demographics | #8989 |
| ribose | #8990 |
| 28 patients | #8996 |
| 2 study | #9000 |
| acceptability | #9006 |
| dna neoplasm | #9008 |
| 304 | #9013 |
| lung neoplasms | #9014 |
| analyses | #9017 |
| bivariate | #9019 |
| favored | #9020 |
| longer | #9020 |
| 300 | #9035 |
| 18 | #9037 |
| literature | #9043 |
| 223 | #9060 |
| vagina | #9062 |
| analgesics | #9073 |
| women risk | #9074 |
| 116 | #9084 |
| venous | #9089 |
| 275 | #9107 |
| consisted | #9112 |
| medical treatment | #9114 |
| 70 | #9117 |
| instability | #9124 |
| oral anticoagulants | #9131 |
| referred | #9132 |
| 286 | #9133 |
| gene expression profiling | #9135 |
| rated | #9162 |
| 232 | #9167 |
| 1987 | #9170 |
| 103 | #9180 |
| germ cell | #9183 |
| erbb receptors | #9195 |
| feeling | #9196 |
| moderate | #9197 |
| embryonal | #9202 |
| erythropoiesis | #9216 |
| 12 patients | #9228 |
| predict | #9230 |
| approaches | #9232 |
| 320 | #9249 |
| psycinfo | #9250 |
| update | #9253 |
| incidence | #9265 |
| eighteen | #9277 |
| stimulate | #9281 |
| manifestation | #9291 |
| primary | #9292 |
| administrative | #9293 |
| greater risk | #9301 |
| favorable | #9308 |
| hypnotics | #9310 |
| systematic literature | #9317 |
| 94 | #9317 |
| possess | #9332 |
| 15 | #9332 |
| participant | #9336 |
| grip strength | #9341 |
| metastatic | #9361 |
| lives | #9367 |
| cycles | #9371 |
| mechanisms action | #9383 |
| acceptable | #9383 |
| ambulatory | #9385 |
| drug female | #9385 |
| postulated | #9389 |
| 177 | #9431 |
| 82 | #9435 |
| 28 | #9436 |
| consisting | #9437 |
| neurologic | #9443 |
| definitive | #9454 |
| partial response | #9454 |
| abdomen | #9468 |
| 3 groups | #9499 |
| death patients | #9509 |
| ophthalmic | #9514 |
| recurrence patients | #9518 |
| serving | #9539 |
| cancer crc | #9542 |
| 500 | #9542 |
| 006 | #9545 |
| 065 | #9547 |
| jaw | #9565 |
| decisionmaking | #9568 |
| imbalance | #9575 |
| melphalan | #9579 |
| similarities | #9580 |
| add | #9583 |
| sentinel lymph | #9619 |
| 68 | #9624 |
| progesterone receptor | #9627 |
| addressed | #9641 |
| oral cavity | #9657 |
| prednisone | #9662 |
| electroacupuncture | #9668 |
| publications | #9669 |
| referrals | #9677 |
| items | #9695 |
| p0004 | #9696 |
| fell | #9698 |
| 149 | #9702 |
| nerve injury | #9707 |
| adenocarcinoma aged | #9733 |
| logistic regression analysis | #9737 |
| smokers | #9746 |
| cope | #9749 |
| erbb | #9762 |
| experts | #9767 |
| carcinoma patients | #9777 |
| sleep disorders | #9784 |
| food intake | #9785 |
| priority | #9791 |
| monoclonal humanized | #9791 |
| 0002 | #9797 |
| remission induction | #9812 |
| exercise female | #9831 |
| trends | #9835 |
| 7 | #9836 |
| patient age | #9855 |
| saponins | #9856 |
| palliation | #9857 |
| neuroprotective agents | #9871 |
| avoid | #9872 |
| clinical outcomes patients | #9872 |
| 95ci | #9875 |
| goals | #9882 |
| bleeding | #9884 |
| axonal | #9897 |
| illness | #9909 |
| 89 | #9921 |
| injections | #9941 |
| zinc | #9942 |
| mitigate | #9952 |
| provision | #9954 |
| variety | #9963 |
| telephone | #9968 |
| recurrence rates | #9969 |
| education topic | #9980 |
| 88 | #9985 |
| behavioral therapy | #9988 |
| ethics | #9991 |
| 400 | #9997 |
| growing | #9999 |
| square | #10005 |
| prescribing | #10007 |
| reactions female | #10007 |
| advanced disease | #10009 |
| dosedependent manner | #10013 |
| exist | #10016 |
| art | #10020 |
| bone resorption | #10023 |
| progressed | #10053 |
| women health | #10061 |
| autonomic | #10070 |
| ortho | #10071 |
| reason | #10076 |
| percentages | #10095 |
| candidates | #10096 |
| exceptions | #10097 |
| 76 | #10099 |
| node dissection | #10100 |
| il1β | #10101 |
| criterion | #10109 |
| disease adult | #10113 |
| 56 | #10120 |
| predictive factors | #10154 |
| preference | #10168 |
| micronutrients | #10188 |
| categorized | #10215 |
| measures | #10218 |
| monoamine | #10221 |
| 12 | #10224 |
| 40 patients | #10233 |
| demonstrate | #10251 |
| lack | #10261 |
| curve | #10266 |
| guideline adherence | #10267 |
| 256 | #10271 |
| developed | #10274 |
| achieving | #10279 |
| caused | #10317 |
| higher incidence | #10325 |
| sarcomas | #10341 |
| epidermal | #10345 |
| variables | #10354 |
| bone mineral density | #10369 |
| anemia | #10385 |
| cell transplant | #10386 |
| morning | #10392 |
| changed | #10400 |
| survival dfs | #10400 |
| 3 5 | #10407 |
| 142 | #10413 |
| 141 | #10436 |
| smoking cessation | #10437 |
| chart | #10440 |
| 041 | #10450 |
| revised | #10485 |
| 24 hours | #10489 |
| lvef | #10497 |
| masked | #10500 |
| syndromes | #10508 |
| mineral density | #10522 |
| longitudinal studies | #10522 |
| effort | #10550 |
| instruments | #10555 |
| 154 | #10558 |
| define | #10560 |
| 650 | #10565 |
| surveillance | #10571 |
| persisted | #10581 |
| elucidate | #10582 |
| informed | #10584 |
| trend | #10585 |
| months 95 | #10586 |
| encountered | #10600 |
| 667 | #10608 |
| fewer | #10613 |
| doxorubicin | #10617 |
| counselling | #10617 |
| academic | #10623 |
| include | #10636 |
| concert | #10640 |
| european society | #10663 |
| histories | #10672 |
| curative intent | #10673 |
| upper extremity | #10688 |
| vitamins | #10697 |
| examinations | #10703 |
| treatment chronic | #10721 |
| prognostic significance | #10733 |
| median followup | #10743 |
| tests | #10751 |
| edema | #10753 |
| anticoagulants | #10757 |
| enter | #10757 |
| fat mass | #10763 |
| median duration | #10779 |
| iiia | #10779 |
| patients response | #10788 |
| induction chemotherapy | #10795 |
| 60 years | #10802 |
| clinic | #10803 |
| 182 | #10803 |
| columbia | #10805 |
| 73 | #10812 |
| insufficient | #10814 |
| rcts | #10818 |
| internal consistency | #10826 |
| 21 | #10828 |
| advisory | #10839 |
| noradrenaline | #10843 |
| recurrent | #10863 |
| randomised controlled | #10873 |
| determine | #10873 |
| hydroxy | #10874 |
| neck cancer | #10884 |
| clinicaltrialsgov | #10885 |
| nighttime | #10888 |
| felt | #10892 |
| held | #10899 |
| 1 patient | #10911 |
| 9 patients | #10922 |
| limited | #10928 |
| occurring | #10934 |
| supplements | #10937 |
| kits | #10950 |
| head neck cancer | #10956 |
| cognition disorders | #10958 |
| start | #10961 |
| retrospective review | #10966 |
| failure | #10978 |
| needed | #10981 |
| squamous cell carcinoma | #10982 |
| registry | #10999 |
| physiology | #11017 |
| 155 | #11028 |
| 030 | #11031 |
| agents drug | #11051 |
| rationale | #11080 |
| ascertained | #11084 |
| interventions | #11094 |
| soft tissue | #11097 |
| international society | #11105 |
| smoking | #11105 |
| 3 years | #11121 |
| 043 | #11122 |
| editorial | #11123 |
| years diagnosis | #11128 |
| sleep wake | #11133 |
| practice guidelines | #11135 |
| sick | #11135 |
| 091 | #11146 |
| decrease | #11150 |
| extensive | #11160 |
| head neck | #11164 |
| reduces | #11166 |
| 127 | #11168 |
| subclinical | #11185 |
| decreases | #11199 |
| progesterone | #11207 |
| facilitate | #11216 |
| gamma | #11222 |
| 2004 | #11246 |
| secondary outcome | #11250 |
| anticoagulation | #11251 |
| 1983 | #11257 |
| survival | #11259 |
| prostate | #11267 |
| contributed | #11278 |
| cognitive behavioral | #11279 |
| diploid | #11281 |
| therapy neoplasm | #11287 |
| snps | #11295 |
| closer | #11307 |
| reviews | #11329 |
| benzimidazoles | #11334 |
| vincristine | #11361 |
| 168 | #11373 |
| thrombocytopenia | #11377 |
| 129 | #11387 |
| affect | #11397 |
| radiation therapy | #11423 |
| subgroup analyses | #11428 |
| clinical signs | #11439 |
| apparent | #11439 |
| point | #11449 |
| rating scale | #11457 |
| 78 | #11468 |
| 092 | #11469 |
| label | #11482 |
| 2 trial | #11486 |
| patients patient | #11493 |
| multidimensional | #11498 |
| alive | #11501 |
| caregivers | #11509 |
| 235 | #11509 |
| recombinant human | #11530 |
| 6 | #11541 |
| 130 | #11548 |
| lymphatic metastasis | #11549 |
| 040 | #11553 |
| helps | #11582 |
| computerized | #11583 |
| 109 | #11585 |
| enhancing | #11586 |
| 20 patients | #11588 |
| analgesic | #11591 |
| humans mass | #11616 |
| incontinence | #11617 |
| opioid | #11645 |
| benefits | #11651 |
| pulmonary embolism | #11652 |
| minimal | #11660 |
| peritoneal | #11670 |
| 028 | #11674 |
| gefitinib | #11675 |
| adenocarcinoma adult | #11688 |
| camptothecin | #11691 |
| body image | #11717 |
| docetaxel | #11732 |
| sarcopenia | #11745 |
| lumbar | #11751 |
| small cell | #11764 |
| rheumatic | #11765 |
| comparisons | #11767 |
| nerves | #11789 |
| reduction | #11791 |
| oxidative damage | #11822 |
| aged postoperative | #11823 |
| 128 | #11825 |
| resultsthe | #11835 |
| risk recurrence | #11837 |
| 024 | #11855 |
| definite | #11855 |
| neoplasms cell | #11862 |
| interim | #11864 |
| hematologic | #11897 |
| investigation | #11910 |
| testicular | #11913 |
| cured | #11926 |
| haloperidol | #11938 |
| pelvis | #11956 |
| thirteen | #11969 |
| humanized | #11970 |
| ≥3 | #11995 |
| 1998 | #11997 |
| referral | #11997 |
| involving | #11999 |
| 90 patients | #12014 |
| 24 patients | #12015 |
| humans | #12017 |
| negative breast | #12030 |
| effectively | #12047 |
| thirds | #12053 |
| single nucleotide | #12063 |
| muscarinic | #12067 |
| triphosphate | #12068 |
| committee | #12069 |
| rating | #12071 |
| bone mineral | #12074 |
| − | #12078 |
| toxic | #12079 |
| cumulative incidence | #12103 |
| greater | #12144 |
| expectancy | #12147 |
| dosage | #12148 |
| rectal cancer | #12163 |
| 119 | #12183 |
| 104 | #12187 |
| unadjusted | #12191 |
| validity | #12205 |
| aspirin | #12207 |
| deoxycytidine | #12226 |
| alternatively | #12248 |
| believed | #12251 |
| malignant | #12268 |
| peri | #12270 |
| sodium channel | #12270 |
| 2 weeks | #12279 |
| disease specific | #12302 |
| igf | #12308 |
| compliance | #12317 |
| categories | #12322 |
| cognitive | #12338 |
| terms | #12340 |
| grading | #12342 |
| classic | #12345 |
| tolerability | #12360 |
| sexual | #12361 |
| psychometrics | #12376 |
| 27 | #12378 |
| adjuvants | #12396 |
| falls | #12402 |
| searched | #12414 |
| relapse | #12415 |
| qualitative study | #12416 |
| sentinel | #12421 |
| p21ras | #12426 |
| 1 2 | #12446 |
| anticancer drugs | #12449 |
| science | #12462 |
| drug humans | #12482 |
| 90 | #12485 |
| predictive | #12492 |
| 194 | #12495 |
| embase | #12496 |
| transfusion | #12502 |
| consistency | #12511 |
| reasons | #12523 |
| prognostic factor | #12536 |
| mitomycin | #12540 |
| 010 | #12573 |
| predictors | #12577 |
| bladder cancer | #12581 |
| explored | #12591 |
| bioavailability | #12611 |
| sleep | #12615 |
| attempts | #12621 |
| test | #12626 |
| psychometric | #12641 |
| therapeutic approaches | #12642 |
| supports | #12643 |
| fourteen | #12657 |
| rank test | #12657 |
| recommendations | #12691 |
| problem | #12710 |
| 2013 | #12714 |
| patient outcome | #12719 |
| reliability | #12747 |
| translated | #12749 |
| stiffness | #12752 |
| crc | #12777 |
| missed | #12783 |
| develop | #12817 |
| 023 | #12853 |
| segmental | #12865 |
| cancer nsclc | #12868 |
| patients surgery | #12874 |
| statistics | #12876 |
| subject | #12882 |
| ice | #12886 |
| normal tissue | #12931 |
| interviewed | #12944 |
| inform | #12945 |
| irreversible | #12946 |
| poorer | #12947 |
| coded | #12950 |
| 184 | #12952 |
| single agent | #12954 |
| scale | #12961 |
| univariate | #12983 |
| monoclonal antibodies monoclonal | #13009 |
| 193 | #13020 |
| n4 | #13025 |
| defining | #13026 |
| cancers | #13041 |
| ovariectomy | #13045 |
| paired | #13049 |
| humans logistic | #13082 |
| future | #13082 |
| suggests | #13099 |
| longterm followup | #13101 |
| pharmacotherapy | #13121 |
| trial comparing | #13126 |
| gains | #13129 |
| alter | #13132 |
| aged neoadjuvant | #13151 |
| inflammatory cytokines | #13153 |
| demographic | #13159 |
| originally | #13160 |
| cox regression | #13163 |
| responsiveness | #13183 |
| 44 | #13192 |
| tpa | #13230 |
| multiple myeloma | #13238 |
| epidemiologic | #13262 |
| humans lymphatic | #13262 |
| 21 patients | #13267 |
| longitudinal data | #13270 |
| myeloma | #13286 |
| racial | #13299 |
| requiring | #13322 |
| outpatient | #13334 |
| symptomatic | #13346 |
| cognitive function | #13351 |
| hours | #13376 |
| steroidal | #13380 |
| pg | #13393 |
| measure | #13408 |
| formal | #13409 |
| therapeutic potential | #13414 |
| intermediate | #13433 |
| muscle mass | #13492 |
| ductal | #13505 |
| eventually | #13506 |
| randomised trial | #13513 |
| attending | #13528 |
| psychometric properties | #13563 |
| discriminate | #13564 |
| pharmacological | #13578 |
| typically | #13588 |
| diminished | #13609 |
| improves | #13630 |
| agonists | #13630 |
| 196 | #13634 |
| skin cancer | #13649 |
| tended | #13650 |
| frequency | #13652 |
| participants | #13674 |
| infective | #13701 |
| hypothesis | #13703 |
| tested | #13723 |
| attempted | #13739 |
| initiation | #13758 |
| distress | #13778 |
| foods | #13785 |
| severe | #13795 |
| 192 | #13800 |
| clinical manifestations | #13803 |
| 18 years | #13813 |
| marked | #13813 |
| conditional | #13831 |
| 018 | #13858 |
| colonic | #13890 |
| solid tumors | #13891 |
| negative patients | #13900 |
| march | #13918 |
| lymphatic | #13928 |
| sleep quality | #13935 |
| mechanisms underlying | #13938 |
| 102 | #13944 |
| p00001 | #13946 |
| focus | #13988 |
| aged muscle | #13991 |
| conducting | #13996 |
| estimate male | #13999 |
| igf1 | #14032 |
| calcitonin | #14038 |
| head | #14056 |
| eastern | #14057 |
| lung cancer | #14080 |
| substances | #14080 |
| 0001 | #14090 |
| respondents | #14106 |
| skin | #14109 |
| 169 | #14117 |
| breast cancer cells | #14121 |
| physiologic | #14122 |
| antagonist | #14137 |
| led | #14139 |
| risk death | #14180 |
| her2 | #14186 |
| modality | #14195 |
| protective | #14195 |
| risk developing | #14199 |
| etiology | #14201 |
| 189 | #14202 |
| cytotoxic | #14234 |
| demonstrating | #14236 |
| 124 | #14251 |
| life style | #14259 |
| suboptimal | #14279 |
| careful | #14282 |
| states aged | #14282 |
| cetuximab | #14293 |
| hypothesize | #14318 |
| efficacy safety | #14319 |
| 32 | #14329 |
| recurrence risk | #14331 |
| analysis performed | #14341 |
| instance | #14341 |
| virtually | #14371 |
| 188 | #14375 |
| clinical impact | #14379 |
| cessation | #14403 |
| alpha2 | #14412 |
| produces | #14420 |
| 144 | #14420 |
| 4 patients | #14436 |
| extremity | #14440 |
| nodal | #14440 |
| transitional | #14454 |
| stat | #14456 |
| 178 | #14484 |
| 1997 | #14487 |
| distant metastases | #14504 |
| trial registration | #14517 |
| 2008 | #14518 |
| 8 | #14521 |
| univariate multivariate | #14524 |
| nsclc | #14525 |
| erbb2 | #14544 |
| gm | #14553 |
| 035 | #14567 |
| year survival | #14570 |
| heavily | #14577 |
| iron | #14583 |
| 34 | #14587 |
| prospectively | #14607 |
| 09 | #14626 |
| episodes | #14626 |
| 007 | #14634 |
| tumor response | #14639 |
| hypothetical | #14647 |
| additional | #14648 |
| initial diagnosis | #14674 |
| estrogen receptor | #14679 |
| prophylaxis | #14686 |
| 5 year | #14689 |
| dermal | #14710 |
| adult | #14729 |
| 008 | #14729 |
| menstrual | #14740 |
| examine | #14743 |
| practice | #14751 |
| reflecting | #14758 |
| neoplasm | #14762 |
| 15 years | #14762 |
| neoplasm staging | #14774 |
| interferons | #14781 |
| clarify | #14785 |
| health professionals | #14804 |
| erlotinib | #14821 |
| asian | #14838 |
| relevant | #14863 |
| peer | #14921 |
| 1990 | #14930 |
| cancer cases | #14942 |
| incorporate | #14956 |
| emerged | #14959 |
| cancer diagnosis | #14977 |
| median | #15008 |
| colorectal carcinoma | #15030 |
| cognitive decline | #15047 |
| 07 | #15052 |
| premature | #15064 |
| overexpressing | #15067 |
| expected | #15111 |
| september | #15115 |
| proportions | #15119 |
| 011 | #15123 |
| medical | #15125 |
| 2 | #15153 |
| clear | #15163 |
| p004 | #15169 |
| assessments | #15187 |
| colonoscopy | #15187 |
| odds ratios | #15193 |
| replacement | #15198 |
| ganglia | #15220 |
| specific | #15227 |
| portion | #15240 |
| intervals | #15241 |
| acute | #15247 |
| agreed | #15266 |
| subjective | #15290 |
| area | #15293 |
| subgroups | #15325 |
| achieved | #15344 |
| proliferative | #15352 |
| routine | #15362 |
| releasing hormone | #15390 |
| 197 | #15404 |
| 131 | #15404 |
| 072 | #15431 |
| 070 | #15436 |
| december | #15459 |
| investigate | #15464 |
| reports | #15470 |
| 51 | #15487 |
| race | #15509 |
| education | #15510 |
| 1 | #15515 |
| medication | #15554 |
| basis | #15598 |
| standard | #15614 |
| life expectancy | #15626 |
| ranging | #15639 |
| safely | #15648 |
| estimate | #15652 |
| male | #15673 |
| survival benefit | #15674 |
| 24 months | #15681 |
| criteria | #15693 |
| 502 | #15702 |
| measuring | #15712 |
| animals antineoplastic | #15714 |
| individual | #15716 |
| offered | #15728 |
| option | #15749 |
| updated | #15749 |
| colon | #15751 |
| period | #15756 |
| nutrition | #15780 |
| antagonists | #15789 |
| globulin | #15792 |
| quartile | #15810 |
| nonparametric | #15815 |
| kappa | #15831 |
| rate treatment | #15867 |
| societies medical | #15873 |
| glandular | #15882 |
| local | #15882 |
| 87 | #15905 |
| focused | #15931 |
| pharmacokinetics | #15932 |
| longitudinally | #15937 |
| dfs | #15988 |
| phenomenon | #16013 |
| usa | #16013 |
| roughly | #16039 |
| distant metastasis | #16044 |
| squared | #16045 |
| improvement | #16107 |
| 118 | #16114 |
| 079 | #16120 |
| february | #16127 |
| naïve | #16154 |
| decision | #16179 |
| 95 patients | #16188 |
| 161 | #16209 |
| analysis survival | #16209 |
| drug interactions | #16211 |
| lung | #16212 |
| 081 | #16213 |
| neoadjuvant | #16222 |
| supported | #16222 |
| 162 | #16223 |
| serotonin | #16242 |
| cold | #16243 |
| cation | #16245 |
| cochrane library | #16265 |
| 93 | #16278 |
| alternatives | #16284 |
| exceeded | #16313 |
| colleagues | #16319 |
| detection cancer | #16320 |
| neurotransmitter | #16320 |
| channel blockers | #16348 |
| supplemented | #16355 |
| papillomavirus | #16362 |
| 14 patients | #16380 |
| excision | #16385 |
| releasing | #16393 |
| kras | #16396 |
| neoplasm grading | #16407 |
| progressively | #16413 |
| 0006 | #16416 |
| diagnostic imaging | #16418 |
| improvements | #16418 |
| osteonecrosis | #16452 |
| scales | #16460 |
| 30 | #16525 |
| protect | #16536 |
| declined | #16537 |
| ranged | #16562 |
| black | #16565 |
| support | #16576 |
| population surveillance | #16580 |
| improving | #16587 |
| 13 patients | #16588 |
| condition | #16625 |
| systematic review metaanalysis | #16649 |
| radiation | #16657 |
| male neoplasm | #16705 |
| understand | #16705 |
| tumor size | #16709 |
| treat | #16715 |
| mucosa | #16717 |
| broader | #16719 |
| broadly | #16748 |
| 082 | #16750 |
| 106 | #16760 |
| 10 years | #16780 |
| post operative | #16791 |
| mimic | #16818 |
| studying | #16832 |
| demonstrated | #16842 |
| bayes | #16878 |
| safety | #16885 |
| major | #16886 |
| rarely | #16886 |
| maintained | #16890 |
| inpatient | #16921 |
| aware | #16924 |
| drugs | #16939 |
| 67 | #16962 |
| depletion | #16977 |
| sex | #16982 |
| hormone | #16988 |
| confer | #16998 |
| hemoglobin | #17005 |
| 125 | #17019 |
| maximum | #17031 |
| muscles | #17039 |
| investigating | #17045 |
| issues | #17053 |
| neoadjuvant therapy | #17063 |
| genotype humans | #17068 |
| publication adaptation | #17073 |
| 84 | #17091 |
| directed | #17099 |
| diseasefree survival | #17162 |
| iron deficiency | #17162 |
| disseminated | #17164 |
| utilize | #17166 |
| feasible | #17197 |
| energy intake | #17217 |
| inconsistent | #17247 |
| mineral | #17315 |
| 088 | #17335 |
| valid | #17344 |
| tnfα | #17364 |
| percentage | #17396 |
| interleukin6 | #17416 |
| raf | #17421 |
| describing | #17520 |
| centered | #17529 |
| neck | #17557 |
| functioning | #17582 |
| locally | #17585 |
| physical activity | #17586 |
| survival outcomes | #17596 |
| traditional | #17602 |
| fact | #17609 |
| original | #17648 |
| 080 | #17655 |
| 2019 | #17720 |
| current evidence | #17735 |
| log | #17761 |
| adding | #17766 |
| unrelated | #17776 |
| carcinogenesis | #17789 |
| lactic | #17816 |
| impairment | #17825 |
| assayed | #17837 |
| decreased | #17874 |
| confirms | #17879 |
| 094 | #17886 |
| examination | #17892 |
| graded | #17909 |
| meta | #17936 |
| monoclonal antibodies | #17955 |
| 200 | #17981 |
| minimum | #18048 |
| clinical presentation | #18052 |
| structured | #18083 |
| primary prevention | #18124 |
| 48 | #18131 |
| primary tumors | #18132 |
| formulated | #18148 |
| il6 | #18159 |
| metastasis male | #18162 |
| bone | #18174 |
| medline | #18185 |
| uncommon | #18193 |
| mass screening | #18244 |
| 80 biomarkers | #18256 |
| critically | #18295 |
| assessing | #18322 |
| retinoic | #18359 |
| hazards models | #18394 |
| reporting | #18396 |
| healthrelated quality | #18416 |
| relationships | #18418 |
| respective | #18423 |
| carry | #18439 |
| humans intestinal | #18447 |
| 096 | #18450 |
| 83 | #18485 |
| staging prognosis | #18489 |
| consistently | #18499 |
| akt | #18504 |
| adjustment | #18519 |
| equal | #18526 |
| 2 years | #18534 |
| maintain | #18583 |
| negligible | #18617 |
| nutritional | #18643 |
| 003 | #18655 |
| address | #18711 |
| raised | #18739 |
| 3 patients | #18741 |
| meier estimate | #18762 |
| kaplan meier | #18769 |
| mucosal | #18825 |
| promising | #18832 |
| highlighted | #18856 |
| includes | #18858 |
| 098 | #18862 |
| chronic diseases | #18875 |
| poor | #18878 |
| hormones | #18887 |
| tailored | #18923 |
| status | #18942 |
| united states | #18948 |
| pyridines | #18950 |
| serum | #18956 |
| orr | #18990 |
| histologic | #19009 |
| stimulating | #19056 |
| dysfunction | #19111 |
| meier | #19125 |
| cohort | #19137 |
| mood | #19177 |
| inhibitor | #19177 |
| ≥ | #19195 |
| excessive | #19215 |
| irinotecan | #19250 |
| agents apoptosis | #19258 |
| consensus | #19281 |
| accepted | #19282 |
| candidate | #19292 |
| recombinant proteins | #19298 |
| recorded | #19302 |
| ovarian | #19337 |
| metaanalysis | #19377 |
| newly | #19381 |
| staging | #19391 |
| global | #19431 |
| evidenced | #19433 |
| fats | #19483 |
| inflammatory agents | #19496 |
| proportional hazards | #19507 |
| prone | #19520 |
| asymptomatic | #19544 |
| surgically | #19614 |
| hospitalized | #19617 |
| pretreated | #19680 |
| degree | #19687 |
| predicted | #19728 |
| adaptation psychological | #19769 |
| emotional | #19779 |
| making | #19782 |
| humans kaplan | #19803 |
| scored | #19840 |
| kaplan | #19866 |
| neoplasms carcinoma | #19874 |
| 3 year | #19944 |
| 1995 | #19991 |
| procedures | #20019 |
| 2002 | #20057 |
| cervical | #20082 |
| tumor necrosis factor | #20104 |
| observational studies | #20128 |
| randomised | #20168 |
| mediator | #20189 |
| beneficial | #20254 |
| 24 | #20258 |
| patients risk | #20262 |
| maximal | #20273 |
| log rank | #20282 |
| small | #20300 |
| endocrine | #20301 |
| rates | #20333 |
| involves | #20398 |
| allcause mortality | #20422 |
| exploring | #20500 |
| assess | #20503 |
| adjusting | #20553 |
| successful | #20677 |
| usual | #20690 |
| women aged | #20722 |
| 95 confidence interval | #20729 |
| invasiveness neoplasm | #20747 |
| addressing | #20782 |
| 19 | #20821 |
| concluded | #20831 |
| july | #20847 |
| node | #20854 |
| finding | #21019 |
| remaining | #21031 |
| relationship | #21070 |
| collected | #21085 |
| male mass | #21107 |
| reliable | #21137 |
| year | #21139 |
| january | #21202 |
| statistical | #21265 |
| 1999 | #21287 |
| absence | #21319 |
| mri | #21400 |
| comparison | #21403 |
| extended | #21420 |
| proportional | #21490 |
| feasibility | #21521 |
| rectal | #21541 |
| prognosis | #21551 |
| gradually | #21576 |
| implementing | #21589 |
| models male | #21936 |
| improved | #21939 |
| death | #21941 |
| apply | #21969 |
| morbidity | #22004 |
| intervention | #22038 |
| insulin growth | #22054 |
| verbal | #22139 |
| 10 patients | #22157 |
| urinary | #22186 |
| combination | #22213 |
| authors | #22223 |
| 2005 | #22223 |
| alterations | #22302 |
| aimed | #22386 |
| predictive tests | #22416 |
| event | #22426 |
| fibroblast | #22446 |
| reviewed | #22573 |
| status humans | #22597 |
| elevated | #22633 |
| frequent | #22673 |
| setting | #22759 |
| cox proportional | #22797 |
| malignancies | #22798 |
| allocated | #22808 |
| 95 | #22862 |
| imaging mri | #23033 |
| diverse | #23033 |
| superior | #23111 |
| post | #23144 |
| selected | #23153 |
| june | #23240 |
| surgical resection | #23266 |
| aged neoplasm | #23452 |
| persistent | #23460 |
| term | #23463 |
| represent | #23526 |
| antibodies monoclonal | #23543 |
| comprehensive | #23553 |
| continuously | #23560 |
| remained | #23674 |
| classified | #23739 |
| body | #23757 |
| strong | #23813 |
| monoclonal | #23861 |
| physical | #23883 |
| gastrointestinal | #23900 |
| exclude | #23924 |
| 2011 | #23997 |
| 2017 | #23997 |
| severely | #24141 |
| median follow | #24342 |
| partial | #24353 |
| abnormal | #24383 |
| systemic | #24466 |
| recruited | #24477 |
| general | #24560 |
| dietary | #24683 |
| 1996 | #24713 |
| carcinoma | #24787 |
| susceptible | #24878 |
| providing | #25068 |
| acids | #25078 |
| consistent | #25119 |
| implemented | #25293 |
| attributed | #25373 |
| 17 | #25476 |
| early | #25506 |
| markedly | #25526 |
| inhibition | #25536 |
| free | #25571 |
| lymph | #25627 |
| international | #25729 |
| regional | #25737 |
| sought | #25746 |
| selective | #25748 |
| 0003 | #25751 |
| single | #25859 |
| mechanism | #26084 |
| unclear | #26339 |
| putative | #26419 |
| surgery | #26438 |
| 13 | #26589 |
| unknown | #26785 |
| electronic | #26810 |
| predisposition disease | #26997 |
| accompanied | #26998 |
| multiple | #27050 |
| follow studies | #27065 |
| polymorphism single | #27142 |
| united | #27151 |
| histologically | #27323 |
| inherited | #27404 |
| neoplasm proteins | #27717 |
| prognosis retrospective | #27768 |
| systematic | #27775 |
| functional | #27808 |
| 0005 | #28001 |
| predisposition | #28007 |
| preoperative | #28036 |
| skeletal | #28185 |
| longitudinal | #28189 |
| estimated | #28229 |
| leads | #28238 |
| missing | #28264 |
| acid | #28356 |
| anti inflammatory | #28360 |
| correlate | #28365 |
| larger | #28581 |
| sex factors | #28629 |
| causing | #28688 |
| sensitivity | #28740 |
| vary | #28851 |
| 11 | #28869 |
| matched | #28979 |
| represents | #29258 |
| detection | #29343 |
| active | #29413 |
| differentiate | #29510 |
| objectives | #29543 |
| completely | #29721 |
| factual | #29750 |
| databases factual | #29793 |
| varied | #30036 |
| excluded | #30077 |
| quantified | #30091 |
| occurs | #30143 |
| adjusted | #30189 |
| logistic | #30241 |
| underlying | #30508 |
| allowed | #30520 |
| national | #30765 |
| odds | #30909 |
| 001 | #30996 |
| regression | #31005 |
| unchanged | #31053 |
| separately | #31068 |
| characterize | #31283 |
| recombinant | #31415 |
| adolescent | #31473 |
| dose dependent | #31787 |
| age | #31875 |
| lacking | #31939 |
| attenuated | #31971 |
| lower | #32078 |
| correlated | #32273 |
| postoperative | #32309 |
| negative | #32666 |
| growth factor | #33089 |
| positive | #33861 |
| understood | #33957 |
| confirmed | #33982 |
| reduced | #34048 |
| implicated | #34054 |
| confidence | #34153 |
| defined | #34517 |
| occur | #34659 |
| requires | #35112 |
| directly | #35347 |
| followup | #36532 |
| diagnosed | #36787 |
| suggesting | #37604 |
| remains | #37899 |
| multivariate | #38132 |
| independent | #38886 |
| measured | #38991 |
| proto oncogene | #39186 |
| proto | #39814 |
| biomarkers tumor | #39899 |
| examined | #40295 |
| retrospective studies | #42973 |
| underwent | #43365 |
| 95 confidence | #44196 |
レポートを実行します | |
Prominent publications by Charles L Loprinzi
KOL-Index: 16482
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.
Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.
Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United ...
| で知られている Zoledronic Acid | Bone Metastases | 2 Years | Patients Breast Cancer | Skeletal Events |
KOL-Index: 16399
Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized ...
| で知られている Postmenopausal Women | Bone Loss | Zoledronic Acid | Breast Cancer | Versus Delayed |
KOL-Index: 13693
PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer.
PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the ...
| で知られている Bone Loss | Premenopausal Women | Breast Cancer | 1 Year | Bmd Baseline |
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
[ PUBLICATION ]
BACKGROUND: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have ...
| で知られている Trpv1 Trpa1 | Transient Receptor | Cisplatin Oxaliplatin | Mechanical Allodynia | Treated Mice |
KOL-Index: 13187
PURPOSE: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA.
PATIENTS AND METHODS: This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received ...
| で知られている Oral Iron | Darbepoetin Alfa | Erythropoietic Response | Phase Iii | Ferric Gluconate |
KOL-Index: 12870
To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a ...
| で知られている Cancer Cachexia | International Consensus | Definition Classification | Weight Loss | Reduced Food Intake |
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
[ PUBLICATION ]
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain.
PATIENTS AND METHODS: Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis ...
| で知られている Adjuvant Therapy | Nodal Status | Colon Cancer | Survival Stage | Pooled Analysis |
Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention
[ PUBLICATION ]
OBJECTIVE: To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention.
METHODS: Smokers were randomized to receive a nicotine inhaler, bupropion, or both for 3 months. At 3 months, smoking-abstinent study participants were randomized to their initial medications or placebo. Participants who were smoking at 3 months were randomized to an alternative treatment regimen or placebo. This study was conducted ...
| で知られている Relapse Prevention | Nicotine Inhaler | Bupropion Placebo | Smoking Abstinence | Treatment Phase |
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
[ PUBLICATION ]
BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.
METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of ...
| で知られている Colorectal Adenomas | Patients Aspirin | Observational Studies | Relative Risks | Cancer Adenoma |
KOL-Index: 12619
BACKGROUND: Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting.
OBJECTIVE: To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm).
DESIGN: Blinded, multicenter, cross-sectional study.
SETTING: Communities surrounding 22 participating academic and regional health care systems in the United States.
PARTICIPANTS: 4482 ...
| で知られている Stool Dna | Blood Test | Screen Detection | Colorectal Neoplasia | Humans Specificity |
Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging
[ PUBLICATION ]
PURPOSE: Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN.
PATIENTS AND METHODS: We identified 5,405 patients who underwent surgery between 1997 and 2006. Patients undergoing MRI were identified from a prospective database. Trends in ...
| で知られている Mastectomy Rates | Magnetic Resonance | Patients Mri | Surgery Type | Surgical Year |
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
[ PUBLICATION ]
PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer ...
| で知られている Cancer Anorexia | Megestrol Acetate | Cachexia Patients | Progestational Agents | Corticosteroid Treatment |
KOL-Index: 12321
BACKGROUND: Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of ...
| で知られている Megestrol Acetate | Hot Flashes | Women Breast Cancer | Deprivation Therapy | Weeks Placebo |
のための重要な人々 Hot Flashes
世界のトップコル
検索フレーズを選択します hot flashes , hot flashes women , hot flashes sweats , hot flashes patients , hot flashes hfs
Charles L Loprinzi:専門家の影響
その概念Charles L Loprinzi直接的な影響があります:Hot flashes, Breast cancer, Megestrol acetate, Peripheral neuropathy, Scrambler therapy, Phase iii, Newer antidepressants, Hot flash.
Charles L Loprinzi:KOLインパクト
他の著者の仕事に関連する概念for which Charles L Loprinzi 影響力があります:Breast cancer, Hot flashes, Adjuvant chemotherapy, Quality life, Weight loss, Oral mucositis, Neuropathic pain.
Tools
これはあなたのプロフィールですか？ あなたのプロフィールを主張します URLをコピーします プロフィールへのリンクを埋め込みます |